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Abstract 
This thesis describes the preformulation and formulation studies of a series of novel 
tumour-selective anticancer prodrugs. The increased understanding of the genomics and 
molecular pathology of cancer has shifted the focus of cancer drug development from an 
empirical to a mechanistic viewpoint. The tumour-specific expression of CYPIBI provides 
the opportunity for selective chemotherapy. The suitability for development of lead 
compounds DMU135, DMU212, DMU590, DMU949 and DMU982 was evaluated by 
solubility, pH-solubility profiles, log P, pKa, polymorphism, morphology and cytotoxicity. 
The lead compound DMU212, a non-ionisable stilbene was poorly water soluble, 
lipophilic and thermodynamically stable with no polyrnorphic variants. It was possible to 
formulate DMU212 in oral (capsules containing sorbitol as the diluent) and topical 
preparations (anionic o/w cream), therefore, DMU212 was recommended for further 
development. The ionisable morpholine derivative of DMU212 - DMU590 was 120 times 
more water soluble than DMU212. Thermodynamic evaluation showed DMU590 to exist 
in an amorphous form. DMU590 salt screening studies yielded a phosphate salt. However, 
in vivo studies showed that it is not a candidate for further development. 
The non-ionisable chalcone DMU135 was poorly water soluble, lipophilic and 
thermodynamically stable with no polymorphic variants. However, DMU135 underwent 
photo-isomerization under ambient light conditions and was therefore not a candidate for further development. The non-ionisable pyridone derivative of DMU135 - DMU949 was also poorly water soluble and lipophilic. Thermodynamic evaluation showed DMU949 to have two polymorphs. To overcome the tautomeric nature of DMU949, analogues of DMU949 were designed in a double-prodrug strategy. Metabolic evaluation of these 
analogues showed that the strategy was unsuccessful, since the in vitro re-conversion to DMU949 was not observed. Thus, DMU949 was eliminated as a lead candidate. The ionisable pyridine derivative of DMU135 - DMU982 was poorly water soluble, lipophilic 
and thermodynamically stable with no polymorphic variants. DMU982 salt screening 
studies yielded ten salts, where the maleate was recommended for further development. 
The development challenges associated with non-ionisable chalcones were also 
addressed with the synthesis of novel ionisable chalcones, based on the recently constructed 
CYPIBI pharmacophore model. The 2-imidazole positions were found to be highly 
important in CYPIBI bioactivation compared to the 4-imidazole position. This structure 
activity relationship helped to confirm a necessary hydrogen-bonding interaction near the 
aromatic 'A' ring hydroxylation hotspot for CYPIBI bioactivation. Optimum bioactivity 
was observed with DMU2149, which was thermodynamically stable. DMU2149 salt 
screening studies yielded eleven salts, but due to the lower cytotoxicity of DMU2149 
compared with other lead prodrugs, it was not selected for further development. 
Another strategy implemented in this study to accelerate drug preformulation and 
formulation assessment, was novel use of high-throughput analytical technologies. A high- 
throughput method using a 96-well fluorescent plate reader was successfully used for log P 
quantification. Novel uses were also successfully developed for the 96-well UV plate 
reader firstly in solubility and pKa quantification, and secondly in high-throughput capsule 
formulation screening. Finally, the MTT assay determined formulation effects on active 
drug CYP I enzyme selectivity. 
The current research shows DMU212 and DMU982 have the optimum potency and 
physicochernical properties in a series of lead compounds, and have the greatest potential 
for eventual clinical use. 
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1.1 Cancer 
1.1.1 Cancer epidemiology 
Cancer is a generic term for a group of more than 200 diseases characterized by 
uncontrolled proliferation of abnormal cells that have undergone multiple genetic changes, 
enabling them to negate the homeostatic regulation of normal cell division, invade nearby 
tissues and metastasise to distant sites in the body [1]. 
Cancer is the second leading cause of mortality after heart disease in the United Kingdom, 
contributing to more than a quarter (26%) of all deaths in 2003. Furthermore, one third of 
all individuals in the UK will develop cancer in their lifetime [2]. Lung (22%), colorectal 
(10%), breast (8%) and prostate cancer (7%) are the most prevalent forms of the disease 
accounting for almost half of all mortalities (Figure 1): 
-Lung, 22% 
Other, 30% 
Ovary, Bowel, 10% 
Non-Hodgkin's --ant- 
tymphoma, 3% Breast, 8% 
Bladder, 3%--, 
/ 
Prostate, 7% 
Stomach, 4%_J Pancreas, 5% 
ýOesophagus, 
5% 
All malignant neoplasms - 154,547 
Figure 1. UK mortalities in 2003 from cancer 131. 
Progressions in diagnosis, surgery, radiotherapy and chemotherapy have reduced the 
overall cancer mortality rate over the last 20-50 years [4], nonetheless, death rates remain 
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high and the chemotherapeutic realization is relatively unmet. The main reasons for this 
being the lack of turnour selectivity resulting in systemic toxicity, metastasis; multi-drug 
resistance and the heterogeneity of the disease (5]. A potential strategy to overcome these 
limitations is the rational and mechanistic development of drugs that target the molecular 
circuitry of cancer cells as opposed to normal cells. The intellectual framework provided 
by this phenomenon promises to deliver therapeutic agents which are less toxic and more 
effective than current drugs available on the market. Research from the Human Genome 
project could have a potential input on the effort to identify more turnour specific 
molecules. 
1.1.2 The molecular circuitry of cancer 
A single mutation alone is not enough to cause cancer, for most cancers the transition from 
a normal to cancerous cell is a step-wise evolution requiring over-expression of several 
oncogenes and/or loss of function of turnour suppressor genes (Figure 2) (1,6,7]. The loss 
of function of turnour suppressor genes reduces control over the cell cycle with mutations 
observed in the retinoblastoma protein (RB) and p53 causing evasion of the suicidal 
apoptotic program [1,6,8,9]. Gain of function mutations of oncogenes stimulate over- 
expression of proteins such as EGFP, Ras, Raf, Myc, Fos and Jun that have a crucial role in 
the tyrosine Idnase signalling pathways mediating cell proliferation, division and death 
through a cascade of intracellular biochemical reactions [1,6,9-11]. Both mutations 
ultimately result in escape from normal growth control, evasion of apoptosis, induction of 
angiogenesis and the ability to metastasise and invade healthy tissue [121. 
De Montfort University 3 
Cancer and the Questfor Tumour Selective Chemotherapy Asma Patel 
The molecular circuitry of cancer (Figure 2), encompasses a complex architecture of 
signalling cascades consisting of interacting networks [12], involving multiple steps and 
genetic events. Studies have shown that the initiation of carcinogenesis requires at least 4-6 
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Figure 2. Simplified schematic of the tumour suppressor genes and oncogenes involved in the cell 
signalling cascade adapted from 111,161 and 171. 
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mutations of cancer-associated genes [7,13]. The multiplicity of the disease suggests that 
disruption of only one aberrant enzyme in one particular pathway may be insufficient in 
eliminating malignant transformation. Therefore, the rationale for future 
chernotherapeutics may lie in the development of multi-mechanism drugs targeting 
aberrations in multiple pathways [ 14). 
1.1.3 Current cancer chemotherapy 
Current cancer chemotherapeutics suffer from a lack of tumour selectivity. Most existing 
anticancer agents, in particular those which are 'cytotoxic', target DNA replication of 
dividing cells thus inhibiting tumour cell growth but also inhibiting normal cell growth. 
This causes many undesired and often irreversible effects such as nausea and vomiting, 
alopecia, mucositis, myelosuppression and reproductive sterility, all of which can have 
devastating impacts on a patient's quality of life. Beginning with the first clinical trial for 
nitrogen mustard in 1942 [15] chemotherapy has been used with varying success in the 
treatment of cancer. Traditional cytotoxic anticancer remedies (Table 1) were developed 
empirically with no pre-existing knowledge of the biochemical mode of action [16]. The 
main aim of cancer treatment at that particular time was systemic, non-specific, high-dose 
chemotherapy [17]. The success of these treatments was far-outweighed by the systemic 
toxicity-, furthermore, studies have shown that some chemotherapeutics such as alkylating 
agents are capable of inducing secondary malignancies [ 18,19]. 
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Table 1. Summary of traditional cytotoxic agents, their mode of action and side-effects 118,20,211. 
CLASS OF 
EXAMPLES MODE OF ACTION SIDE EFFECTS DRUG 
Myelosuppression, G1 
Cyclophosphamide Formation of covalent bonds disturbances, hair loss, Alkylating 
Chlorambucil with DNA, thus impeding reduced fertility and agents Melphalan DNA replication increased risk of 
secondary malignancies 
Vincristine Interference with rt-ftrotubule 
Antimitotic Vinblastine assembly of cells, through As for alkylating agents; agents Docctaxel stabilisation or destabilisation 
neurotoxicity Paclitaxel of microtubules, thereby 
blocIdng cell division 
Methotrexate 
Inhibition of metabolic As for alkylating agents; Antimetabolites 5-Flurouracil 
pathways involved in DNA ncphrotoxicity 6-Mercaptopurine 
synthesis 
Doxorubicin As for alkylating agents; Antibiotics 
Mitoxantrone Prevent cell division doxorubicin can cause 
Mitomycin cardiotoxicity 
Topoisomerase 
Podophyllotoxin Inhibition of topoisomerase 
inhibitors 
Etoposide leading to deregulation in the As for alkylating agents 
Irinotecan unwinding of DNA, thereby 
bloclcing DNA synthesis 
Heavy Metal Cisplatin 
As for alkylating agents; 
Derivatives Carboplatin 
As metallating agents nephrotoxicity, 
neurotoxicity and 
potential hearing loss 
Over the past decade the increased understanding of the genomics and molecular pathology 
of cancer [14] has shifted the ethos of cancer drug development from an empirical to a 
mechanism based viewpoint. This has resulted in a new generation of chemotherapeutics 
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that act on specific molecular targets responsible for the malignant phenotype, to 
potentially provide turnour specific therapy (Table 2): 
Table 2. Summary of currently available targeted cancer treatments [17,20,22,231. 
CLASS OF 
DRUG EXAMPLES MODE OF ACTION SIDE EFFECTS 
Blocks estrogen action in breast Endometrial cancer, Tamoxifen 
cancer blood clots, hot flushes 
Hormonal Letrozole Inhibits aromatase, thus blocking the Hot flushes, fatigue, GI 
Therapies Arimidex production of estrogen disturbances 
Blocks androgen action in prostate Bicalutamide Hot flushes, impotence 
cancer 
Imatinib 
Blocks activation of Abl, PDGFR and 
Signalling c-Kit to inhibit cell division in chronic 
Inhibitors myeloid leukaemýia 
Blocks activation of the EGFP, thus 
Gefitinib inhibiting tyrosine kinase activity and 
ultimately cell division 
Rituximab Antibody binds to CD20 antigen on 
lymphocyte derived tumours to induce 
cell death 
Monoclonal Blocks HER2 receptor on breast 
Antibodies Trastuzumab cancer cells, thus preventing 
activation by EGF 
Antibody binds to CD33 antigen on 
Gemtuzumab leukaemic cells and delivers a toxic 
ozogamicin dose of calicheamicin an anti-tumour 
antibody to the leukaemic cell 
Fluid retention, sIdn 
rashes, diarrhoea, GI 
disturbances 
Sldn rashes, diarrhoea, 
GI disturbances 
Allergic response 
Differentiating 
Tretinoin Induces differentiation and death of 
Fever, severe 
Agents 
leukaernic cells 
respiratory distress, 
weight gain 
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Theoretically, use of these putative turnour specific chemotherapeutic agents, whether alone 
or in combination, should lead to an improved clinical response. However, the expression 
of the target proteins is not exclusive to cancer cells alone. The proteins are over-exprcssed 
in cancer cells but also expressed at a lower frequency in normal cells. A potential strategy 
to overcome these limitations and further the quest for tumour selective chemotherapy is 
the use of prodrugs ( 16]. 
1.2 Prodrugs versus active drugs 
The term prodrug was first coined in the 1950s by Albert [24]. Prodrugs are inactive 
derivatives of drug molecules requiring chemical/biological transformation in vivo in order 
to release the active moiety. The prodrug is usually designed to improve an inadequate 
physicochernical property. However, prodrugs can also be designed to achieve target organ 
selectivity through the 'magic bullet' concept i. e. selective action. Most anticancer agents 
in clinical use exert their effects through anti-proliferative action interfering with DNA 
mechanisms; these drugs are not 'magic bullets' and have severe systemic toxic effects. 
Therefore, development of prodrugs has the scope for improving the safety and efficacy of 
chemotherapeutic agents for the treatment of cancer. 
1.21 Design and development of anticancerprodrugs 
In the last century several anticancer prodrug strategies were developed for tumour 
selective chemotherapy [25). The emergence of proteornic and genomic technology has led 
to a better understanding of turnour biology, thereby improving chemotherapeutic 
De Mon#orl UniversitY 8 
Cancer and the Questfor Tumour Selective Chemotherapy Asma Patel 
selectivity. Some of the prodrug activation mechanisms include turnour hypoxia and 
tumour specific exogenous or endogenous enzymie expression. 
I. Z 1.1 Hypoxia selective prodrugs 
Hypoxia is a unique property of cells in solid tumours which have poorly developed 
vasculature and therefore reduced oxygen supply compared to normal tissues. This 
provides a unique envirom-nent which is potentially exploitable in solid-turnour selective 
chemotherapy such as with bioreductive prodrugs (Figure 3). 
Reductase 
Hypoxia 
Bioreductive 
le- 
cytotoxic 
Prodrug Prodrug Agent 
02 02 
Figure 3. The hypoxia-mediated activation of bioreductive drugs to give cytotoxic compounds 1261. 
Bioreductive prodrugs are activated to cytotoxic agents by reductase enzymes to free 
radical intermediates, which are rapidly back-oxidised to the parent prodrug by molecular 
oxygen present in normal cells, therefore restricting prodrug activation to hypoxic cells [ 16, 
26-28]. Currently four classes of such anticancer prodrugs are undergoing clinical or 
preclinical evaluation (Table 3). 
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TWO. Summary of bioreductive prodrugs undergoing clinical and pre-clinical evaluation [16,25-301. 
CLASS 
EXAMPLES MODE OF ACTION 
COMBINATION 
OFDRUG THERAPY 
Nitro- Reduction by DT-diaphorase to a cytotoxic 
ADEPT, GDEPT in 
aromatics 
CB1954 
DNA alkylating agent 
combination with E. 
coli nitroreductase 
Aromatic 
Tirapazamine Reduction by cytochrome P450 reductase to N-oxides 
Cisplatin, 
form nitroxide radicals, which alkylate DNA radiotherapy 
Aliphatic 
AQ4N 
Reduction by CYP3A isoforms to generate Cisplatin, 
N-oxides the cationic diamine AQ4 a potent Cyclophosphamide, 
topoisomerase II inhibitor radiotherapy 
Quinones 
Nlitornycin Reduction by cytochrome P450 reductase Radiotherapy 
Porfiromycin. and DT-diaphorase to fbn'n quinine methide 
intermediates, which alkylate DNA 
Hypoxia induced prodrug transformation has the potential for selective and effective 
chemotherapy, yet there are still some hurdles to overcome before complete selectivity is 
achieved. One of the problems is the ubiquitous expression of the reductase enzymes, 
therefore prodrugs activated by these enzymes may cause side-effects [16]. Another 
problem is the reliance of the treatment on consistently low levels of oxygen in the tumour, 
which will suffer from inter-individual variance, furthermore, solid turnours generally have 
a hypoxia gradient, therefore, potentially a rim of tumour cells in non-hypoxic conditions 
may remain untreated [26,29]. An alternative approach to directly targeting hypoxic 
turnours is to have the appropriate reductive enzyme transcribed or translated by a hyPoxia 
specific-transcription factor such as HIF-la. Iherefore, the expression of that particular 
enzyme would be tumour specific as would the consequent prodrug bioactivation [28,291. 
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1.21.2 Prodrugs activated by tumour targeted exogenous en2ymes 
Tumour specific antigens can be exploited for tumour selective cytotoxicity through 
antibody-directed enzyme prodrug therapy (ADEPT). A monoclonal antibody (mAb) is 
covalently linked to a chosen exogenous enzyme and is administered followed by a prodrug 
which is selectively bioactivated by the enzyme extracellularly at the turnour site (Figure 4) 
[16,25,31,32]. 
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Figure 4. Principles of drug targeting, using ADEPT, GDEPT and VDEPT adapted from 1161 and l3fl. 
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The disadvantages of ADEPT include possible immunogenic response to the enzyme- 
antibody conjugate, scarcity of turnour selective antigens and the extracellular activation of 
drug necessitating difffision into the turnour [31,32]. 
Other turnour-targeted exogenous enzyme approaches include gene-directed enzyme 
prodrug therapy (GDEPT) and virus-directed enzyme prodrug therapy (VDEPT), both of 
which involve incorporation of the exogenous enzyme gene into the turnour genome 
(Figure 4) [16,32,33]. The gene is selectively expressed in turnour cells and the enzyme 
can selectively metabolise the prodrug within the turnour only [30]. The disadvantages of 
GDEPT and VDEPT include possible insertional mutagenesis of the gene and difficulties in 
selective delivery and expression of the gene [16,30]. 
ADEPT, GDEPT and VDEPT have promising futures (Table 4); however, there are certain 
features of the enzyme/prodrug approach which need further improvement such as the 
prodrugs, enzymes and the method of enzymatic delivery to the tumours [33]. 
Table 4. Summary of ADEPT, GDEPT and VDEPT treatments 116,31-35). 
THERAPY PRODRUG (S) ENZYMEIANTI]BODY/ANTIGEN 
ADEPT CMDA 
Carboxypeptidase G2 linked to a murine mAb A5B7, raised 
against a carcinoembryonic antigen 
GDEPT Cyclophosphan-dde, CYP2B I and p450 reductase cDNA 
Ifosfarnide 
VDEPT CB1954 
E. coli nitroreductase cDNA 
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1.21.3 Prodrugs activated b tumour specific endogenous enzymes Y 
Endogenous turnour specific enzymes have been exploited in prodrug design to achieve 
selective bioactivation within the tumour resulting in selective cytotoxicity. Some of the 
enzymes used include oxidoreductases, transferases, hydrolases and lyases [ 16,25]: 
Table 5. Summary of prodrugs activated by endogenous enzymes [16,36,371. 
CLASS ENZYNIE PRODRUG MODE OF ACTION 
DT-diaphorase CB1954 DNA alkylation/hypoxia 
Cytochrome P450 
Tirapazamine DNA alkylatiorL/hypoxia 
reductase 
Oxidoreductases 
Transferases 
Hydrolases 
I. Yases 
Dihydropyrimidine 5-Ethynyl-2(IH)- 
dehydrogenase pyrimidinone 
Tyrosinase 
Thymidine 
phosphorylase 
Glutathione S- 
transferase 
Phenyl mustards 
Inhibitor of DPD preventing the 
rapid breakdown of the 
antimetabolite 5-Fluorouracil 
DNA alkylation 
Capecitabine 
Bioactivation to the 
antimetabolite 5-Fluorouracil 
TER286 
Bioactivation to an aziridinium 
DNA alkylating agent 
Carboxylesterase 
P-Glucuronidase 
Cysteine conjugate 
Irinotecan Topoisomerasc I inhibitor 
Paclitaxel Bioactivation to paclitaxel a 
glucuronide potent antimitotic agent 
qf.. rvq ennillonte.. Q 
Apoptosis inducer and cancer 
P-lyase __ -. 1 -- -Ili preventative 
Oxidoreductase enzymes such as dihydropyrimidine dehydrogenase, P450 reductase, DT- 
diaphorase and tyrosinase catalyse the oxidation or reduction of xenobiotic substrates. A 
major problem with dihydropyrimidine dehydrogenase is its ubiquitous expression and as 
such it is not an ideal target enzyme for prodrug selectivity. P450 reductase and DT- 
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diaphorase activate bioreductive prodrugs (Section 1.2.1.1). These enzymes are also 
widely distributed; however, prodrug activation requires both enzymatic reduction and 
hypoxic conditions, which are unique to solid tumours. Finally, tyrosinase is localised in 
melanoma cells and the degree of enzyme expression has been correlated with malignancy, 
maldng this enzyme a viable target for chemotherapeutic prodrug design [ 16]. 
Transferase enzymes such as thymidine phosphorylase (TP) and glutathione S-transferase 
(GST) are over-expressed in turnours relative to the host cell. However, TP is widely 
expressed in intestinal tissue; therefore, chernotherapeutics activated by this enzyme may 
instigate gastrointestinal toxicity. GST is also widely distributed in normal tissue; 
however, the GST polymorph GSTn 1 -1 is over-expressed in turnours indicating the clinical 
potential of this enzyme in turnour selective therapy [ 16,3 6,3 7]. 
Hydrolytic enzymes such as carboxylesterase and P-glucuronidase are ubiquitous [25) and 
as such these enzymes cannot be used to activate prodrugs locally, except when targeted to 
tumours by ADEPT, GDEPT or VDEPT strategies [16]. Finally, lyase enzymes such as 
cysteine conjugate P-lyase are over-expressed in renal carcinoma tissue compared to 
normal tissue, thereby indicating their potential in kidney-tumour selective therapy ( 16]. 
Theoretically, exploitation of these tumour specific enzymes should amount to non-toxic 
prodrugs. However, inconsistent patterns of enzyme expression have limited the attempts 
to develop endogenous enzyme activated prodrugs so far [28]. Nevertheless, the 
cytochrome P450 (CYP) enzymes which are responsible for the majority of phase I drug 
(chemotherapeutic) metabolism may provide an alternative prodrug design strategy [38, 
39]. 
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LZI. 3.1 Prodrugs activated by CYPs 
Cytochrome P450 (CYP) comprises a superfamily of constitutive and inducible enzymes 
involved in the oxidative metabolism of xenobiotic and endogenous substrates [40]. The 
turnour specific over-expression of individual CYP isozymes increases the potential for 
tuniour selective chemotherapeutic metabolism, resulting in either detoxification or 
bioactivation of chemotherapeutics [41,42]. 
CYP mediated detoxification of anticancer prodrugs involves clearance of cytotoxics from 
the body [39]. The antimitotic agent taxol undergoes detoxification catalysed by CYP2C8, 
generating the metabolite 6-hydroxytaxol, which is 30 times less active than taxol [43]. 
Several clinical trials are investigating the co-administration of taxol with P450 inhibitors 
to alleviate drug inactivation [44]. In separate studies clearance of the anticancer prodrug 
irinotecan was considerably reduced when co-administered with CYP3A4 inhibitors 
ketoconazole or cyclosporin A [39,44]. 
Some anticancer prodrugs are metabolically activated by CYPs. In particular the alkylating 
agents cyclophosphamide and ifosfamide are activated by CYP2B6 and CYP3A4 to yield 
the 4-hydroxy metabolites which undergo spontaneous degradation to generate the ultimate 
cytotoxins, phosphoramide mustard and acrolein [16,45]. The antiestrogentamoxifen also 
undergoes 4-hydroxylation induced by CYP3A4, CYP2D6, and CYP2C9 to trans-4- 
hydroxytarnoxifen, which is 100 times more potent as an estrogen inhibitor than tarnoxifen 
[451. These prodrugs were not actually designed as prodrugs but are serendipitously 
bioactivated by CYPs and as such the bioactivation is mostly systemic and non-specific 
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[39]. Conversely, the next generation of CYP activated anticancer prodrugs have been 
intentionally designed to undergo turnour specific bioactivation. 
Phortress is a novel benzothiazole derivative capable of inducing CYP isozymes that 
mediate its bioactivation [46,47]. It is a potent agonist of the ligand activated transcription 
factor aryl hydrocarbon receptor (AhR), which forms a heterodimer with the AhR nuclear 
translocator (ARNT) to induce CYPIAI and CYPIBI expression resulting in intraturnoural. 
bioactivation of Phortress and thus initiating DNA-adduct mediated cytotoxicity [39,41, 
45,48]. Phase I clinical trials are currently underway for Phortress [49]. 
AQ4N is a bioreductive prodrug which is metabolised by CYP3A4, CYPIAl and CYP2B6 
in hypoxic tumour environments [45,50,51] to the cytotoxic metabolite AQ4 a DNA 
binding agent and topoisomerase 11 inhibitor. Moreover, AQ4 elicits a 'bystander' killing 
effect in surrounding tumour tissue [45] and is 1000 times more cytotoxic compared with 
AQ4N. AQ4N is the first CYP-activated bioreductive prodrug to enter clinical trials, 
although promising as a first line agent, exploitation as radio and chemo-enhancer has 
ftu-ther clinical potential [39,48]. 
Many conventional anticancer prodrugs undergo CYP mediated liver metabolism resulting 
in both reduced drug efficacy and toxicity. CYP-based GDEPT strategies have been 
developed to overcome these limitations by targeting prodrug-activating CYP genes to 
tumour cclls, resulting in localised intraturnoural prodrug activation [52]. These constructs 
were initially explored to overcome cyclophosphamide resistance to brain tumours resulting 
from hepatic CYP over-expression [16,41]. Historically this strategy used rat CYP2131 to 
chernosensitive turnours to cyclophosphamide. However, the immunological response to 
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rat CYP2BI incorporation into human patients [35,41], has resulted in the creation of 
constructs utilising human CYP2B6. MetYja, a novel retroviral vector encoding the human 
CYP2B6 gene in combination with cyclophosphamide, has recently borne fruit in phase I/H 
clinical trials in advanced breast cancer demonstrating both safety and efficacy (35]. 
The tumour-specific locafisation of CYPs can also be exploited in immune-based therapy, 
which involves stimulation of the cancer patient's immune response against the tumour 
[48]. CYPIBI is the only CYP isozyme to date found to be significantly over-expressed in 
turnours and as such represents an ideal target for immunotherapy [41,53]. The novel 
anticancer vaccine ZYC300 is an encapsulated plasmid DNA encoding for CYPIBI 
antigen. Administration of ZYC300 elicits a specific T-cell response to target and destroy 
CYPIBI-expressing turnours [39,41,48,54]. Phase 1/11 clinical trials using ZYC300 are 
currently underway. 
The ability to rationally target CYPs with prodrugs, clinical inhibitors and immunotherapy 
highlights the importance of these enzymes in the quest for tumour selective chemotherapy. 
Consequently, the Cancer Drug Discovery Group (CDDG) at De Montfort University have 
utilised the tumour specific expression of CYPIBI (Table 6) to design a series of novel 
prodrugs that are intended to be activated by CYPIBI only within the turnour. This 
groundbreaking; approach has the potential for improving the safety and efficacy of 
chemotherapy to revolutionise the methods of cancer treatment. 
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1.3 CYPlBl and cancer 
CYPIBI is the most recently cloned dioxin-inducible isozyme of the CYPI family [55]; 
showing 40% sequence homology with both CYPIAI and CYPlA2, and has also been 
shown to be involved in metabolism of xenobiotics and bioactivation of procarcmogens 
[56]. There is a general consensus that CYPlBI is primarily expressed in extrahepatic 
tissue, however, there are inconsistent reports concerning CYPIB1 expression in normal 
human tissue. Several studies have shown the expression to be tumour specific, whereas 
others have reported expression in both malignant and non-malignant tissue. 
The majority of studies evaluating the expression of CYPIBI have concentrated on the 
expression of CYP IBI mRNA. CYP IBI mRNA expression has been reported in a range 
of extrahepatic normal tissue (57-59] including kidney [60], lung [61], brain [62], breast 
[63], prostate, testes [58] and foctal [64]. However, CYPIBI mRNA expression does not 
correlate to the presence of CYPlB I protein and several studies [65,66] have demonstrated 
the absence of CYPIBI protein but expression of CYPlB1 mRNA suggesting that 
regulation of CYPIBI is predominantly post-transcriptional [45,67]. In direct conflict 
with these findings studies by Mushkhelishvili et al reported the expression of both 
CYPIBI mRNA and protein in a range of non-malignant tissue including brain, kidney, 
prostate, breast, cervix, uterus, ovary, lymph nodes and liver [59]. 
The discordance in the literature concerning non-malignant CYPIBI expression may 
principally be due to the erroneous comparison of molecular techniques used in detecting 
CYPlBI expression. CYPlBI mRNA detection is based on PCR techniques which 
amplify the mRNA levels, which may generate misleading results [45]. Further confusion 
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is generated in the immunohistochemical. techniques used in CYPIBI protein detection 
[39]. The immunological similarity between isozymes in the CYPI family may result in 
non-discriminate detection of CYPI isozymes [45]. This is true for CYPIBI; the original 
discovery by Sutter et al [55] was a serendipitous breakthrough where a polyclonal 
antibody raised against CYPIAI was shown to cross-react with a related CYP isozyme 
designated later as CYP I B1 [55]. Further studies using this antibody cannot be given much 
credence since the broad spectrum detection in non-malignant tissue cannot be assigned to 
CYPIBI alone. Importantly, the report by Mushkhelishvili et al of CYP1B1 protein 
expression in nonnal human tissue used this particular antibody and as such doubts are cast 
on the validity of the reported data [59]. In summary, CYPIBI protein has not been 
detected in normal tissue. 
CYPlBI protein expression has also been investigated in a range of cancers, utilising a 
variety of methods [68]. These studies have generally demonstrated absent or low level of 
CYP expression. However, recent immunohistochemical studies [42,60,68-74] have 
demonstrated the over-expression of CYP IBI protein in tumour cells in a range of turnours 
such as bladder, brain, breast, colon, connective tissues, oesophagus, kidney, lung, lymph 
node, ovary, skin, stomach, testis and uterus. CYP IBI expression was detected in all but 5 
of 127 tumours investigated, but not in the corresponding normal tissue (Table 6). In 
contrast to previous studies Murray et al [68] have used validated and well characterised 
polyclonal. and monoclonal antibodies that target a unique CYPlBl peptide sequence [75], 
thereby eliminating cross-reactivity. 
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Table 6. Expression of CYPIB1 in different types of malignant tumours and normal tissue [681. 
TISSUE NORMAL (NO. POSITIVE/ 
NO. TESTED) 
TUMOUR (NO. POSITIVE/ 
NO. TESTED) 
Bladder 0/8 8/8 
Brain 0/12 11/12 
Breast 0/10 12/12 
Colon 0/10 11/12 
Connective tissue 0/9 8/9 
Esophagus 0/8 8/8 
Kidney 0/11 11/11 
Liver 0/8 Not tested 
Lung 0/8 7/8 
Lymph node 015 9/9 
Ovary 015 7/7 
Sldn 0/6 6/6 
Small intestine 015 Not tested 
Stomach 0/10 9/10 
Testis 0/8 8/8 
Uterus 0/7 7/7 
Total 0/130 122/127 
Interestingly, over-expression of the CYPIBI protein has also been detected in pre- 
malignant tissue, which suggests that CYP IBI has a role in turnour development. Studies 
by Stanley el al [76,77] have demonstrated CYPIBI over-expression in colon turnours, 
weak-expression in dysplastic tissue and no expression in normal tissue. A similar study 
conducted by Gibson et al [72] also demonstrated over-expression of CYP1131 in colon 
cancer, with concomitant expression in turnour-associated vasculature. The intensity of 
expression was reduced with distance from the turnour. Studies by Carnell et al [741 give 
further credence to this theory, CYP IBI over-expression was found in prostate cancer and 
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not in the corresponding nonnal tissue. However, over-expression was also detected in the 
associated pre-malignant and hyperplastic tissue. All of these studies implicate a possible 
link in malignant progression and CYP IBI up-regulation and as such CYP IBI could be 
used as a prognostic tumour marker and therapeutic target. 
The endogenous function of CYPIBI, as yet, remains unknown. Recently, CYPIBI 
deficient mice have been used to demonstrate its importance in modulating hypoxia- 
induced neovascularisation [78]. The up-regulation of CYPIBI in vasculature surrounding 
colon tumours has also been described [72]. These studies implicate that CYPlBl is up- 
regulated during tumour development and may be involved in angiogenesis particularly 
under hypoxic conditions. Interestingly, studies have indicated that the AhR pathway (the 
up-regulation of CYPlAl and CYPlB1 can be induced via this pathway (Section 
1.2.1.3.1)) is capable of cross-talking with the hypoxia inducible pathway [79]. In fact the 
ARNT can also forni a heterodimer with the hypoxia-specific transcription factor HIF-la 
to induce the expression of CYPI family isozymes. This indicates that during tumour 
development, hypoxic conditions may induce the expression of CYP IBI and other CYP I 
family isozymes as an endogenous rescue mechanism to prevent tumour gTowth. 
Controversially, the tumour-specific expression of CYPIBI has been linked to 
carcinogenesis itself, due to the CYPIBI-mediated bioactivation of procarcinogens, into 
carcinogenic metabolites [37,80]. However, the formation of toxic metabolites in cancer 
cells can hardly be considered an issue when the cells are already cancerous. In fact 
exposure of cytotoxic metabolites to turnour cells would be advantageous in that these 
metabolites may cause mutagenic damage resulting in cancer cell death, which is actually 
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the goal of tumour selective chemotherapy [81]. In direct conflict with the carcinogenic 
theory, Potter et al see CYPIBI not as the cause of cancer, but as tumour specific rescue 
enzyme that selectively eliminates cancer cells via metabolic activation of natural dietary 
components into compounds with anticancer properties (Section 1.3.2) [81). This theory 
would also explain the over-expression of CYPIBI in a range of cancers irrespective of 
oncogenic origin [68]. To assign CYPIBI as the perpetrator of cancer, principally because 
it is present in tumours may be short-sighted, when its true nature may be as an endogenous 
rescue mechanism up-regulated after the cells have already undergone a malignant 
transformation. 
Another CYP isozyme of interest for chemotherapeutic intervention is CYPIAL CYPIAI 
is an inducible CYP expressed primarily in extrahepatic tissues [82]. The expression of 
CYPIAI has been extensively characterised in tumour tissue; however most studies have 
again focused on the mRNA expression. CYPIAI protein expression has been less well 
characterised (Table 7) [83-85]: 
Table 7. Protein expression of CYPs In specift tumour types (percentage of turnours staining positive by 
immunohistochemistry using antibodies specific to these families and isozymes as appropriate [45]). 
TUMOUR TYPE CYPIA CYPlB1 
Bladder 68 100 
Breast 40 80 
Colon 75 87 
Ovary Not detected 80 
Kidney 100 100 
Esophagus 64 100 
Prostate 63 90 
Sarcoma 70 90 
Stomach 60 90 
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The CYPIAl-mediated activation of polycyclic aromatic hydrocarbons (PAH) such as 
those found in tobacco smoke [86,87] and the over-expression of CYPIAl. in tumour 
tissue has also erroneously led to the belief that CYPlA1 is a carcinogenesis inducer [80]. 
Studies by Antilla et al [85-87] detected CYPIAI protein over-expression in normal lung 
tissue from smokers compared to non-smokers, these results led them to speculate that 
CYPIAI was responsible for the bioactivation of tobacco smoke carcinogens resulting in 
malignant transformation. An opposing viewpoint is to consider the tumoural CYPIAI 
over-expression as a rescue mechanism up-regulated in response to the cellular dysfunction 
already caused by exposure to tobacco smoke carcinogens in an attempt to restore the status 
quo [88]. 
The tumour specific over-expression of CYPI isozymes especially CYPIBI and less-so 
CYPIAI, together with their proposed role as an endogenous rescue mechanism has a 
number of far reaching implications. Firstly they provide a putative therapeutic anticancer 
drug target for development of non-toxic prodrugs which can be selectively metabolised or 
activated within the tumour only, to form highly potent protein tyrosine kinase (PTK) 
inhibitors and antimitotic agents [89,90]. The extrahepatic nature of the enzymes also 
helps to overcome hepatic CYP metabolism which may result in drug toxicity or decreased 
bioavailability. Secondly it provides an alternative strategy to overcome some drug 
resistance caused by CYP metabolism in tumours (e. g. taxol), through inhibition of CYP I 
isozymes [43,54,91,92]. However, inhibition may be futile as the role of these enzymes 
may be to inhibit malignant growth by acting as tumour suppressor 'rescue' enzymes, 
therefore, enzyme inhibition may paradoxically lead to further malignant propogation. 
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1.3.1 CYPIBI and estradiol 
17P Estradiol (E2) is the only currently known endogenous substrate of CYPlB1 and has 
been widely implicated with carcinogenicity, possibly as a result of E2 metabolism 
generating 4-hydroxyestradiol (4-OHE2) and 2-hydroxyestradiol (2-OHE2) [93). 2-OHE2 
has little or no carcinogenicity and is mainly formed in the liver by CYP3A4 [94]. 
However 4-OHE2 is formed mainly in extrahepatic tissues and has been shown to be highly 
carcinogenic in hamster kidney, showing the selective induction of carcinogenesis [93-96]: 
CH3 OH CH3 OH 
CYP1B1 
211 
HO 4 
HO 
65 
OH 
Nß Estradiol (E2) 4-Hydroxyestradiol +OHE2) 
Figure 5. CYP1131 activated 4-hydroxylation of E2 to the carcinogenic metabolite 4-OHE2- 
4-OHE2 can cause DNA, protein and lipid damage through CYP mediated redox. cycling to 
serniquinone and quinone forms [97]. The selective 4-hydroxylation of E2 by CYP IBI has 
been ftu-ther demonstrated by Hayes et al in human breast cell lines; kinetic experiments 
demonstrated CYP IBI catalysed E2 hydroxylation. at the 4-position preferentially to the 2- 
position [98]. The fact that E2 is selectively activated by CYPIBI to form the carcinogenic 
metabolite 4-OHE2, suggests the use of the E2 molecular skeleton as a template for novel 
CYP IBI activated anticancer prodrugs. 
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1.3.2 Rationalefor CYPIBI activated anticancer prodrugs 
Although the expression level of CYPI isozymes differs between turnour and 
corresponding nonnal tissue, CYP IBI is the only CYP I isozyme that is significantly over- 
expressed in turnours [39], thereby providing a rational target for anticancer drug 
development. Furthermore, the selective 4-hydroxylation of E2 by CYP IBI permits the use 
of the E2 pharmacophore in providing a framework for rational and mechanistic 
development of CYPIBI activated anticancer prodrugs. Potter and McCague initially 
pioneered this type of steroidal mapping in drug design [99]. The synthetic estrogen 
stilbestrol was mapped onto the E2 pharmacophore with the two para hydroxyl goups of 
the A and B ring mapping onto the E2-3 and 17p-positions respectively: 
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This type of estrogenic mapping was used to explain the potency of the estrogenic 
metabolite trans-4-hydroxytamoxifen, which is 100 times more potent as an estrogen 
inhibitor than the parent compound tamoxifen [45,99]. Furthermore, this led to the rational 
design of the tamoxifen derivative idoxifene for the treatment of metastatic breast cancer 
[ 100]. 
Phytoestrogens can also act as substrates for CYPIBI given that the core structure is 
similar to that of E2. This may result in aromatic hydroxylation corresponding to that of 4- 
OHE2, to generate toxic species within CYP IBI -expressing tumours only. This hypothesis 
was partially confirmed using resveratrol; a naturally occurring anticancer agent found in 
red wine, broccoli and peanuts [101]. Resveratrol is a stilbene and is classified as a 
phytoestrogen because of its structural similarity to E2 and plant derivation. The molecular 
structure of resveratrol can be mapped onto the E2 framework: 
OH 
5: ý" Resveratrol 
OH 
170 Estradiol 
HO 
Hydroxylation by CYP IBI 
Figure 7. Mapping resveratrol onto the pharmacophore of E2- 
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This relationship enabled Potter and colleagues [81] to hypothesiZe that resveratrol would 
undergo 3-hydroxylation catalysed. by CYPIBI corresponding to that of 4-OHE2, to 
generate piceatannol, a known PTK inhibitor (MAPK) [102] with antileukaen& properties. 
OH OH 
CYP1B1 
1 OH 1 OH 
HO"*' HO 
OH 
Resveratrol Piceatannol 
Figure 8. CYPIB1 activated 3-hydroxylation of resveratrol to the anticancer agent piceatannol. 
The study demonstrated bioactivation. of resveratrol to piceatannol by CYP IBI, therefore, 
piceatannol formation maybe shown to be turnour specific [103]. From these findings the 
CDDG have proposed the molecular function of CYPIBI to be a tumour suppressor 
64rescue" enzyme, wherein CYPIBI catalyses the bioactivation of natural prodrugs to 
growth inhibitor substances localised in turnour tissue [81]. Consequently, the CDDG have 
designed a series of novel anticancer agents based on the E2 pharmacophore. The stilbene, 
chalcone pyridone and pyridine non-toxic prodrugs are hydroxylated only within the 
tumour, thereby reducing any potential side-effects, to form highly cytotoxic antimitotic 
and PTK inhibitors in situ in a multi-mechanism approach [ 14,90]: 
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Figure 9. Rationale for prodrug design using the tumour specific expression of CYPI BI. 
1.3.21 Mapping of lead compounds onto the estradiolframework 
The potential lead hydroxylation-activated anticancer prodrugs selected to undergo 
preclinical evaluation are DMU135, DMU212, DMU590, DMU949 and DMU982. The 
steroidal mapping of stilbenes and phytoestrogens onto the E2 framework was similarly 
implemented for mapping these prodrugs (except for DMU590, see Section 1.3.2.3). The 
use of this rationale facilitated the prediction of toxic metabolites generated by CYPIBI- 
mediated hydroxylation, corresponding to the 4-hydroxylation of E2 generating the 
carcinogenic metabolite 4-OHE2: 
Tumour cells 
die but 
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Figure 10. Mapping of the novel stilbene (DMU212), chalcone (DMU135), pyridone (DMU949) and 
pyridine (DM U982) anticancer prodrugs onto the pharmacophore of E2- 
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1.3. Z2 Intratumoural CYPIBI generation of tyrosine kinase inhibitors 
The ubiquitous expression of PTK can present a potential problem in chemotherapeutic 
intervention using PTK inhibitors. The approach used by the CDDG in CYP IBI activated 
prodrugs overcomes this problem via the intraturnoural generation of tyrosine kinase 
inhibitors targeting multiple aberrations in several pathways in a multi-mechanistic 
modality. 
The potential for intratumoural CYPlBl generation of PTK inhibitors was rationalised 
from the mapping of the synthetic stilbene derivative stilbestrol onto the E2 framework 
(Figure 6). These stilbene derivatives not only mimic E2 but are structurally similar to the 
tyrphostins which were developed as analogues of the natural PTK inhibitor erbstatin [104]. 
In a structure activity relationship for the tyrphostins Gazit and colleagues found the 
introduction of the 3-hydroxy functionality and the catechol motif to be highly important in 
enhancing potency of the PTK inhibitors. Interestingly the para-methoxy analogue 
tyrphostin Al was almost completely inactive with an IC50 value of more than 12501AM, 
whereas the 3,4-dihydroxy analogue tyiphostin A23 was an active PTK inhibitor (EGFR 
and MAPK) with an IC50 value of 35liM: 
MeO 
Z',., 
-f"ý 
YCN CN CN 
HO"" 
CN 
OH 
Tyrphostin Al - Inactive PTK inhibitor Tyrphostin A23 - Active PFK inhibitor 
Figure 11. Structures of the PTK Inhibitors tyrphostin Al and A23 11041. 
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Crucially this 3-hydoxy motif corresponds to the CYPIBI-mediated enzymatic 
introduction of the 4-hydroxy group of E2 (Figure 5). Therefore, it was realised that a 
CYP IBI activated prodrug could be designed that contained only a para-hydoxy (similar to 
resveratrol (Figure 8)), para-methoxy (DMU212) or methylenedioxy group (DMU135, 
DMU949 and DMU982), which could be activated by CYPIBI-mediated meta aromatic 
hydroxylation resulting in intraturnoural PTK inhibition [90]. 
1.3. Z3 Intratuntoural CYPIBI generation of antimitotic agents 
Antimitotic agents have been used in chemotherapy with limited success due to the severe 
systernic toxicity resulting from microtubule and consequent cell division inhibition of both 
normal and tumour cells. The approach used by the CDDG in CYP IBI activated prodrugs 
overcomes this problem via the intratumoural generation of antimitotic agents through 
CYPIBI-mediated aromatic hydroxylation, in a similar fashion to that proposed for 
intratumoural generation of PTK inhibitors. 
Intriguingly the importance of the 3-hydroxy motif in enhancing the potency of PTK 
inhibitors is mirrored with known antimitotic agents such as Combretastatin A-4 (CA-4), a 
highly potent cis-stilbene isolated from bark of a South African willow tree Combretum 
caffrum [105-107]. CA-4 has been shown to be a potent inhibitor of cancer cell growth 
[108], angiogenesis (1061, and tubulin assembly [109]. In a structure activity relationship 
for these stilbenes Cushman and colleagues found the introduction of the 4-methoxy/3- 
hydroxy motif on the B-ring to be highly important in enhancing cytotoxicity. The 
trimethoxybenzene Functionality observed in a 3,4,5 configuration on the A-ring of other 
anfimitotic agents such as colchicine, podophyllotoxin and steganacin was also important 
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for the activity of these compounds [ 105,110,111 ]. Additionally, the CA-4 cis-isomer 
exhibited superior cytotoxicity with an ICSO value of 0.00 1 gM, whereas the trans-isomer 
was less cytotoxic with an IC50 value of 0.0 1 gM [ 105,111 ]. However, the cis-isomer of 
CA-4 does not map well onto the E2 framework (Figure 12), whereas the trans-isomer of 
CA-4 maps on very well to E2: 
ome 
MeO 
cis-CA4 
MeO 
I OH 17P Estradiol 
MeO 
OH 
OMe trans-CA-4 
OMe HO 
OMe 
MeO 
H 
Figure 12. Mapping of the stilbenes trans- and cis-CA4 onto the E2 framework. 
Even though the cis-isomer of CA-4 is the most potent, the trans-isomer still showed 
favourable potency and some of the trans-CDDG prodrugs are bioactivated to the cis- 
stilbene in situ [81]. Furthermore, studies by Cushman and colleagues demonstrated the 
requirement for the 3-hydroxy substituent in the B-ring for maximal antimitotic activity 
regardless of geometric conformation [105]. Therefore, firstly based on the structure of 
trans-CA-4, DMU212 [90,112] was synthesised with the intention that the active 3- 
hydroxy fimctionality is introduced in situ by tumours to generate the PTK inhibitor and 
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antimitotic metabolite DMU214 or trans-CA-4, thus moderating any potential side-effects 
compared to that of CA-4 (Figure 13). Secondly, an analogue of cis-CA4 i. e. DMU590 
was designed to potentially overcome the solubility problems associated with the parent 
compound [107]: 
OMe 
MeO OMe 
cis-CA4 trans-CA4 
MeO OMe 
0 me 
1: 
OH MeO 
OM6 OH omý 
meo ome 
DMU590 DMU212 
0 N,,,,, -ýo OMe 
OMe 
MeO 
ome 
Figure 13. Mapping of the stilbenes DMU212 and DMUS90 onto the trans- and cis-CA4 framework. 
Studies by Ducki et al [113-115] have also used the CA4 pharmacophore in the design of 
antimitotic chalcones. A series of analogues were prepared and the most potent agents 
were found to be those possessing the 4-methoxy/3-hydroxy motif on the B-ring and the 
3,4,5-trimethoxy functionality on the A-ring as with CA-4 [113,116]. Optimum activity 
was found with the cc-methyl chalcone (Figure 14), which had comparable and in some 
cases superior activity compared to CA-4 [115]. This potency is thought to arise from 
geometric considerations [107,117]. The cc-methyl chalcone can adopt an s-trans; 
conformation, structurally similar to CA-4, whereas with a lack of steric hindrance from the 
methyl substitution, the chalcone prefers to adopt a less potent s-cis conformation. 
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Accordingly, the CDDG have designed a library of novel antirnitotic chalcones based on 
the structure of trans-CA-4 [118], which upon CYPlBl-mediated hydroxylation. result in 
intraturnoural antimitotic activity. The most potent chalcone was identified as DMU135 
[118,119] which was predicted to undergo CYPIBI-mediated hydroxylation of the 
methylenedioxy group to generate the catechol metabolite DMUI 17 (Figure 14): 
OMe 
trans-CA4 
OMe 
OH 17P Estradiol 
MeO 
. "' 1 01,11" DMU135 
HO OMe 
OM'e,, 
ome 0 
DNW117 
OMe 0 
OMe 
ome 
HOJ 
OH 
II 
Figure 14. Mapping of the stilbene trans-CA4 and the chalcones DMU135 and DMU117 (the 
hydroxylated form of DMIJ135) onto the E2 framework. 
Prediction of this metabolic activation was facilitated by the CYPlBl-mediated aromatic 
hydroxylation of E2 to generate the catechol. 4-OHE2 (Figure 5) as well as the CYPIBI- 
mediated metabolism of phytoestrogens such as resveratrol to generate the catechol 
metabolite piceatannol (Figure 8). 
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Interestingly a striking similarity was noted between functionalities present in antimitotic 
agents and PTK inhibitors. The CYPIBI metabolites of DMU212 and DMU135 i. e. 
DMU214 and DMUI 17 can both be mapped onto the tyrphostins (Figure 11) and CA-4 
(Figures 13 and 14) both of which require the 3-hydroxy motif in the A-ring for maximal 
PTK inhibition and antimitotic, activity. This relationship leads to the speculation that the 
CDDG prodrugs may function in a multi-mechanistic fashion once intraturnourally 
metabolised by CYP IB1, wherein antimitotic activity may be linked to PTK inhibition. 
1.4 Prodrugs: Preclinical drug development impasse? 
Recent advances in proteornic and genomic technology have generated a host of high- 
throughput technologies enabling the identification of specific biological targets [1201. 
Combinatorial chemistry has been utilised to rapidly generate libraries of compounds, 
which can be screened rapidly through in vitro high-throughput assays to generate a 
multitude of 'hits'. This high-throughput approach was expected to accelerate the 
identification of lead compounds and to shorten the time to the market, ironically, high 
attrition rates in the later stages of drug development, have been attributed to the birth of 
high-throughput technology itself [ 12 11. 
One of the reasons behind the high attrition rates is the almost exclusive focus on drug 
potency and selectivity, with insufficient focus on the pharmacokinetic and pharmaceutical 
properties of the drug [122,123]. Many of these compounds exhibit physicochemical 
properties presenting difficulties in development, including high molecular-weight, high 
lipophilicity and poor aqueous solubility; all of which are a major source of failure in early 
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development [121]. This is corroborated by the design of CDDG prodrugs DMU135 and 
DMU212, which are lipophilic and have no derivatisable functional group to enable 
manipulation of physicochemical properties, since the active moiety is introduced in situ. 
Another reason for disconnect between discovery and pre-clinical development is the lack 
of available high-throughput technologies at a pre-clinical level to deal with increased 
output of compounds downstream of discovery [120,123]. As such, effective tumour 
specific prodrugs have yet to meet the chemotherapeutic realisation despite showing 
preclinical promise [25]. 
Limitations with pre-clinical high-throughput technologies raise signficant hurdles for 
advancement of compounds into the clinic and therefore, preclinical. development is rapidly 
becoming a bottleneck in drug development [123]. The key to coordinating drug discovery 
and development, and thereby improving efficiency and reducing attrition may lie in the 
development of high-throughput technologies for the preformulation. programme, to 
identify potential physicochernical problems (solubility, log P) at an carly drug 
development stage [122,124-127]; thus providing an earlier estimation of the drug 
pharmaceutical properties [120]. This concept will be implemented in the body of this 
work in novel miniaturisation of analytical assays for preformulation and formulation 
analysis. 
Moreover, parallel optimisation of potency and pharmaceutical properties will be 
considered in the design and consequent synthesis of novel CYP IBI activated prodrugs. A 
similar strategy was implemented by Pettit et al in the design of CA-4 analogues [1281. 
Although CA-4 has'shown to be a highly potent antimitotic agent in vitro, the in vivo 
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efficacy was poor in comparison partly due to its very limited aqueous solubility and high 
lipophilicity [107]. Subsequently, a water-soluble disodium phosphate prodrug CA4P was 
developed [128], with improved pharmacokinetic properties thereby allowing much easier 
in vivo administration [110]. CA4P is rapidly dephosphorylated in the plasma releasing the 
parent compound CA-4 [107,110] and as such is currently undergoing phase I/H clinical 
trials. Taking the lead from Pettit and colleagues a series of novel CYPIBI activated 
prodrugs will be rationally designed as completely new entities or as analogues of existing 
compounds, all provided with derivatisable functional groups to potentially favour both 
drug potency and pharmaceutical properties in ultimately furthering the quest for tumour 
selective chemotherapy. 
1.5 Project aims 
In this thesis, the pharmaceutical development and formulation of novel anticancer 
prodrugs developed by the CDDG in the Leicester School of Pharmacy is presented. The 
development of prodrugs will include synthesis of novel entities and analogues of existing 
compounds, to facilitate the development of prodrugs with better pharmaceutical properties. 
The preformulation of lead CDDG prodrugs will quantify physicochemical properties 
which may influence formulation design, drug manufacture and pharmacokinetics. 
Formulation of lead prodrugs will enable the transition from a preclinical, discovery stage 
into formulated dosage forms appropriate for clinical trials. Finally, miniaturisation of 
assays during preformulation and formulation will also be conducted to enable efficient and 
high-throughput drug development. In summary the aims of this thesis were: 
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e To conduct preformulation studies for a series of novel lipophilic lead prodrugs 
synthesised by the CDDG (DMU135, DMU212, DMU590, DMU949 and DMU982). 
This involved the investigation of solubility, log P, pKa, scanning electron micrograph 
imaging and differential scanning calorimetry. 
o To develop orally available capsule and topical forraulations for a novel lipophilic lead 
prodrug DMU212 and subsequently demonstrate the in vitro activity and bioavailability 
of the formulated prodrugs in model systems, to be used as pre-clinical data in support 
of subsequent phase I clinical trials. 
9 To identify and characterise salt forras of DMU590 and DMU982 with the desired 
physicochemical properties i. e. aqueous solubility and to enable its formulation into 
solid dosage fonns. 
* To synthesise a series of novel imidazole and thiazole CYPIB1 activated prodrugs with 
desirable biological and physicochernical properties for subsequent salt selection and 
formulation. 
9 To synthesise novel analogues of DMU949 with desirable physicochemical. properties 
for subsequent metabolic evaluation in a double-prodrug strategy. This will involve the 
investigation of CYPIAI, CYPIBI and liver microsome mediated metabolism and 
identification of the metabolites fonncd. 
* To develop novel high-throughput analytical quantification methods for log P, pKa and 
solubility determination, and measurement of dissolution samples. 
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2.1 Introduction 
2 1.1 Discovery of a novel stilbene prodrug 
Stilbenes are found extensively in nature and as synthetic biologically active compounds, 
both of which are reported to exhibit a variety of therapeutic functions including 
antibacterial, antifungal, antioxidant, anti-inflammatory, anticancer and anti-malarial (129]. 
The anticancer activity in particular has garnered attention in the design of synthetic 
stilbenes, most notably in hormone based therapies and particularly in estrogenic cancer 
treatments, since the core stilbene structure can be mapped onto the E2 framework: 
Stilbene 
17P Estradiol 
Figure 15. Mapping of the core stilbene structure onto the E2 framework. 
The antiestrogens stilbestrol and tamoxifen, used in the treatment of breast cancer, can also 
be mapped onto the E2 framework (Figure 6), which would explain the potency of their 
respective estrogenic metabolites [99]. 
Interest in the use of stilbenes as anticancer agents stems from the discovery of the ability 
of many such natural products to act as antimitotic and antileukaemic: agents [1051. The 
most potent natural antimitotic stilbene to date is Combretastatin A4 (CA4), a cis-stilbene 
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isolated from bark of the South African willow tree Combretum caffrum (Section 1.3.2.3) 
[105-107]. The CA-4 cytoskeleton has drawn wide attention in the design of novel 
synthetic stilbene analogues as has the phytoestrogen resveratrol. 
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a naturally occurring stilbene generated in 
response to environmental stress in grapes, peanuts and other Legurninosae family plants 
[101]. The chernopreventative activity of resveratrol has recently attracted interest because 
of its inhibitory activity on multiple cellular events associated with carcinogenesis 
(initiation, promotion and progression) (101] and its potent growth inhibitory effects on a 
variety of cancer cells [130]. In view of the pharmacological potential of resveratrol, the 
polyhydroxystilbene scaffold has served as a useful chemical platform for developing more 
potent and selective chemotherapeutic agents. 
Accordingly, the CDDG have implemented the molecular framework provided by both 
combretastatin and resveratrol in the design of novel CYPlBI activated cis and trans 
stilbene prodrugs. The cytotoxicity of the compounds synthesised was investigated using 
an in-house human breast cell-line screen with well characterised CYP1 expression. The 
panel consisted of MCF7, MDA-MB468 and MCFIOA cell-lines. The estrogen receptor 
positive cell-line MCF7 originates from the pleural cavity of a Caucasian female with 
malignant breast disease, when induced with 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) 
MCF7 cells express CYPIA1 and CYPIBI. (131], where mainly CYPIAl is functional. 
The estrogen receptor negative cell-line MDA-MB468, originates from the pleural 
effusion of a Black female with metastatic adenocarcinoma of the breast. This cell-line is 
isolated from a more aggressive tumour [ 132], which constitutively expresses CYP IB1 and 
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CYPIAI, where mainly CYPIBI is functional. Finally, MCFIOA was used in this assay 
for comparison with tumorigenic CYPI expressing cell lines. MCFIOA cells are 
immortalized from cultures of normal breast epithelial. cells; they retain epithelial. 
morphology, are non-tumorigenic and do not express any CYPs [ 133]. 
A standard MTT in vitro assay (see Section 3.2.6) [134] employing these cell-lines was 
used to study differential cytotoxicity between MCF10A and MDA-MB-468 and MCF7 
with and without TCDD to identify compounds which preferentially inhibit cancer cell 
growth without affecting normal cell growth i. e. CYPIBI activated compounds. The 0- 
mcthylated analogue of resvcratrol, DMU212 (trans-3,4,5,4'-tctramcthoxystilbcnc) 
emerged as one of the strongest candidates for anticancer therapy. 
Table 8. Summary of DMU212 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
HUMAN MCF7 MCF7 
ACTIVATION MDA- 
TUMOUR 
BREAST VMUOUT WITH 
FACTOR 
MCF10A 
NIB468 
SELECTIVE 
CELL-LINE TCDD TCDD FACTOR 
IC50 
VALUES 2.6 0.12 22 4.3 0.001 4300 
(MM) 
DMU212 was found to potently inhibit the growth of MDA-MB468 and TCDD induced 
MCF7 cancer cells, compared to the non-CYP expressing MCF I OA and na7fve MCF7 cells 
(Table 8). Furthermore, studies by Lu et al have demonstrated the potent apoptotic activity 
of DMU212 with preferential inhibition of virally transformed human lung-derived cells 
(W138VA) and little or no inhibition of the untransformed counterparts (W138) [135]. 
DMU212 was also reported to be 50- to 100- fold more potent than resveratrol in inhibiting 
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the growth of these transformed cells [136]. Studies by Sale et al also demonstrated 
superior DMU212 cytotoxicity compared with resveratrol, where DMU212 was 4 times 
more potent as an inhibitor of the growth of human-derived HCA-7 colon cancer cells [137, 
138]. DMU212 also exhibited higher bioavailability in mouse small intestine, colon and 
brain compared to resveratrol [137,138] and oral administration of DMU212 in Apc'ýfln/+ 
mouse models retarded the gastrointestinal adenoma formation by 24% [138]. Crucially, 
studies by Wilsher of the CDDG have recently demonstrated the selective bioactivation of 
DMU212 in human breast tumour clinical samples [103], indicating the clinical potential 
for DMU212 in turnour selective chemotherapy. In light of these findings DMU212 has 
recently been the subject of a successful patent application by the CDDG [901 and is about 
to enter phase I clinical trials in USA and as such will undergo preliminary pre-clinical 
evaluation within the body of this work. 
Z 1.2 Discovery of a novel chalcone prodrug 
Chalcones are the biogenetic precursors of flavonoids found extensively in nature from 
ferns to higher plants [139] and they display a wide variety of biological effects including 
estrogenic, antibacterial, antifimgal, antiviral, anti-inflammatory and anticancer activities 
[116,140]. The chalcone cytoskeleton. can be mapped onto the E2 framework (Figure 16) 
as well as other steroidal pharmacophores; this propensity has recently borne fruit in the 
design of aromatase and 170-hydroxysteroid dehydrogenase inhibitors in the treatment of 
hormone dependant cancers [140]. 
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Figure 16. Mapping of the core chalcone structure onto the E2 framework. 
Chalcone derivatives have also shown cytotoxicity in the design of novel antin-titotic agents 
possessing some of the structural functionalities present in CA-4 (Section 1.3.2.3) [113- 
115]. Accordingly, the CDDG have designed a library of novel synthetic chalcones based 
on the structure of CA-4 (Figure 14) and the hydrocarbon backbone of E2 [118]. The 
cytotoxicity of these chalcones was screened in the MTT in vitro assay, as described in 
section 2.1.1, wherein the 3,4-methylenedioxy chalcone DMU135 exhibited optimum 
anticancer activity [118,119]: 
Table 9. Summary of DMU135 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
HU'MAN MCF7 MCF7 TUMOUR 
ACTIVATION MDA- 
BREAST WITHOUT V= MCF10A SELECTIVE 
FACTOR MB-468 
CELL-LM TCDD TCDD FACTOR 
IC50 
VALUES 7.0 0.08 90 2.3 0.006 380 
(jiM) 
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DMU135 was found to be potently cytotoxic in MDA-MB-468 and TCDD induced MCF7 
cancer cells with appreciably reduced cytotoxicity in MCFIOA and na7fve MCF7 cells 
(Table 9). Upon CYPI-mediated metabolism DMU135 is activated in the turnour to the 
potent tyrosine Idnase inhibitor DMUI 17 (Figure 14). The catechol metabolite DMUI 17 is 
a potent broad spectrum tyrosine Idnase inhibitor, which diminishes more than 30% of the 
total cellular tyrosine kinase activity [119]. The in vivo activity of DMU135 has also been 
investigated in xenograft models of human cancer (MDA-MB-468) in nude mice [141]. 
DMU135 was found to be well tolerated with a maximum tolerated dose of 200mg/kg. 
Dosing at this concentration DMU135 rapidly reached both the liver (15-170pM) and 
xenograft (20-75pM) 15 minutes after administration, with drug concentrations in 
xenografts remaining up to I OgM over the period of investigation. These results buttressed 
the advancement of DMU135 to pre-clinical animal studies, whereby, oral administration 
of DMU135 in Apcminl+ mouse models retarded the gastrointestinal adenoma formation by 
46% [142]. In light of these findings DMU135 has recently been the subject of another 
successful patent application by the CDDG (118] and as such warrants further scrutiny in 
the preformulation of novel CYP I activated anticancer prodrugs. 
2.1.3 Preformulation of novel anticancer prodrugs 
Preformulation programmes provide fundamental physicochemical characterisation for new 
chemical entities (NCEs), to indicate strategies for future development through 
identification of factors that may influence formulation design, drug manufacture, 
biopharmaceutics and pharmacoldnetics, thereby creating an optimum drug delivery system 
[143,144]. Of particular importance are the aqueous solubility and lipophilicity [145], 
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which influence the drug's dissolution, distribution, adsorption and bioavailability; 
followed by solid state properties such as crystallinity, particle size and morphology which 
affect drug processing and in vivo behaviour. 
The impact of these physicochemical. properties on the development (Section 1.4) of NCEs 
provides an impetus for in-depth preformulation at an earlier drug development stage, to 
minimise extensive and expensive testing of NCEs that possess unsatisfactory 
pharmaceutical properties, thereby reducing attrition rates in the later stages of drug 
development [146]. The evolution of proteomic, genomic and combinatorial synthetic 
technologies has enabled the rapid generation of NCEs in short periods of time and has 
subsequently prompted the quest for parallel high-throughput prcformulation technology. 
In this study the following physicochernical properties of the non-ionisable prodrugs 
DMU135 and DMU212 were determined; solubility, partition coefficient, scanning electron 
micrograph (SEM) imaging and differential scanning calorimetry (DSQ. High-throughput 
analytical methods were also developed for solubility and 'partition coefficient 
determination. 
ZL3.1 Solubility 
Solubility is defted as the concentration of solute dissolved in a solvent when equilibrium 
has been established between the two (i. e. a saturated solution) [147]. The aqueous 
solubility determines the concentration of drug in the solution (e. g. the intestinal fluid) from 
which the drug will be absorbed. Low aqueous solubility can lead to failure of NCEs 
during drug development and arises because of lipophilic substituents or strong 
intramolecular crystal lattice forces (124]. Drug solubility is an important physicochernical 
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property influencing drug bioavailability, rate of release into the dissolution medium and 
therapeutic efficacy. Many drugs are poorly soluble in water; therefore, measurement of 
drug solubility in various solvents is paramount for development of parenteral 
formulations. The solvents chosen for these preformulation studies were water to 
determine solubility in the intestinal fluids, ethanol 10% v/v, isopropyl alcohol (IPA), 
glycerol, propylene glycol, polyethylene glycol (PEG) and N-methyl pyrrolidone (NMP). 
NMP is a stable and safe solubilizer of hydrophobic drugs and solubility in NMP is 
comparable to dimethylsulfoxide (DMSO) but without the associated in vivo toxicity [148]. 
Several patents have elucidated improvements in drug solubility with NMP [148]. 
Solubility experiments are often described using the terms "kinetic solubility" and 
"thermodynamic solubility" [127]. For kinetic solubility measurements, the compounds are 
pre-dissolved in DMSO, or another suitable solvent and the solubility is measured as the 
concentration at which the sample precipitates from the aqueous medium [149]., For 
thermodynamic solubility measurements, the shake-flask method is used which measures 
the solubility at equilibriurn. Usually the concentration at equilibrium is determined by 
adding excess drug into a medium, stirring the suspension for a defined time, 
filtering/centrifuging the suspension 'and quantifying the drug concentration in the 
supersaturated solutions [150]. 
Kinetic solubility measurements do not give a true measure of the drug solubility but rather 
an apparent solubility because crystal lattice effects are negated when the compound is 
dissolved in DMSO. Thus, any effects on solubility due to polymorphic variants cannot be 
investigated [ 15 1 ]. However, in the early stages of discovery, when many compounds are 
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synthesised in small quantities, high-throughput kinetic solubility measurements can 
provide an early indication of compounds that will present developmental challenges. 
Kinetic solubility measurements are also more amenable to automated methods, require 
minimal sarnple size and preparation, and are more appropriate in the discovery stage not 
only from an optimization perspective but also because most screens are run using 
compounds in DMSO medium [149]. 
Several kinetic solubility methods have been described in literature, using turbidimetry 
(151], nephelometry [152] and direct UV [153]. Lipinski et al [151] described a method to 
measure solubility by adding a DMSO stock solution dropwise to pH 7 phosphate buffer in 
a cuvette and using turbidity to detect precipitation. The solution turbidity was measured 
by light scattering in the 620-820 nm range with a UV detector. A high-throughput 
variation of this method using nephelometry was developed by Bevan et al [152], where 
DMSO stock solutions were added to phosphate buffer and serially diluted across a 96-well 
plate. The degree of light scattering of the dilutions was measured using a nephelometric 
plate reader and the concentration at which particulates appeared was used to estimate the 
upper limit of solubility. A high-throughput direct UV method has also been developed by 
Avdeef et al [153]. In this method DMSO stock solutions were robotically added to buffer 
in a 96-well plate and after an 18 hour period of equilibration,, the filtered solution was 
analysed using a UV plate reader [1531. 
The drawbacks with kinetic solubility measurements are that they may be time-dependant 
and are most likely to use compounds pre-dissolved in DMSO [154]. The use of DMSO 
may increase the solubility to an unpredictable extent, since DMSO dilutions can easily 
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form supersaturated solutions [150,155]. Consequently, the influence of crystal lattice 
energy and polymorphic variants are also completely masked in the DMSO dissolution 
process [151]. For compounds that are insoluble due to high crystallinity, the kinetic 
solubility will most likely differ significantly from the thermodynamic solubility [154]. 
And for compounds that exist as polymorphic variants, the precipitating form of the drug 
may not necessarily be the most stable one, which is a problem since polymorphs can differ 
greatly in solubilities [150]. 
For discovery scientists, solubility is used to assist in the rational selection of hits for 
further consideration; therefore, kinetic solubility measurements are acceptable. On the 
other hand, development scientists need to select amongst salt or crystalline forms, evaluate 
formulation excipients and determine minimum absorbable dose [155]. Therefore, 
development scientists generally measure the intrinsic solubility i. e. thermodynamic 
solubility of a compound. Traditional thermodynamic solubility measurements (shake- 
flask) are not feasible at an early drug discovery stage because of the large sample 
requirement, low throughput, and labour intensive sample preparation [1491. However, 
with the advances in automation, high-throughput variations of this method have also been 
developed. Glomme et al [150] have developed a miniaturised shake-flask method where 
the compound was weighed into a Whatman UniPrep filter chamber, buffer was added and 
the chamber was closed with the plunger, which has a filtration membrane on one end and a 
pre-attached cap on the other. The sample vials were placed in a HPLC autosampler-vial 
block and stirred for 24 hours, after which the block was placed in a Whatman. processor 
that simultaneously depressed the plunger of all the devices, forcing the filtrate into the 
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reservoir of the plunger. HPLC was used to measure the filtrate concentration. This 
technique reduces the time for sample preparation for thermodynamic solubility 
measurement, because all of the operations are conducted in one device, and the filtration 
and analysis steps are automated [125]. 
Roy et al detailed the development of a 96-well plate assay, where the drug was initially 
introduced into the wells dissolved in acetonitrile, which was subsequently evaporated. 
Water was then added to the wells and the suspensions stirred for 24 hours followed by 
simultaneous filtration of suspensions contained in the wells and quantification on a UV 
plate reader [156]. The overall aim of both the high-throughput thermodynamic solubility 
methods discussed is to reduce the number of time-consuming steps in the shake-flask 
technique to improve its efficiency. This strategy was adopted within the scope of this 
thesis, where the traditional shake-flask method was used for sample equilibration followed 
by novel high-throughput assay on a LTV plate reader. DMU135 and DMU212 solubility 
were determined and the novel technique was validated using conventional compounds 
(indomethacin) and a conventional assay (LJV spectrophotometer). 
ZL3.2 Partition coe dents 
The partition coefficient of a NCE provides a thermodynanlic measure of its hydrophilic- 
lipophilic balance. Lipophilicity reflects the ability of the NCE to permeate biological lipid 
membranes in order to be absorbed, distributed into organs and tissues, and finally 
eliminated, so is important for pharmacokinetic properties. The relative affinity of the 
NCEs for aqueous and lipid environments determines the ease of solute permeation through 
the lipid membranes and is often represented by the octanol-watcr partition coefficient 
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[157]. A relationship exists between log P and aqueous solubility, highly lipophilic drugs 
often have poor aqueous solubility and vice-versa. A certain degree of lipophilicity is 
required for drug permeation of lipid membranes. However, solubility in the intestinal 
fluids is also a prerequisite for drug absorption from oral dosage forms. Therefore, NCE 
with a balance between the two parameters promise to result in optimum bioavailability. 
The partition coefficient (P) for a non-ionisable drug is the ratio of concentrations (C) 
between two immiscible phases, e. g. organic (C,, ) and aqueous (C,, ), at equilibrium [1581: 
log P= log[-EC.. ", -] (2.1) 
Log P can be calculated experimentally using the shake-flask method to assess drug- 
portioning between organic (usually n-octanol) and aqueous phase. Drawbacks of this 
technique include time and relatively large quantities of drug needed. High-throughput log 
P methods have been developed through miniaturisation of the equilibration method in 96- 
well plates using robotic sample preparation combined with automated separation and 
analysis by reverse phase HPLC [159]. Wang et al have developed a modifled shake-flask 
method, where partitioning is conducted in sealed vials and samples are quantified using 
LC/MS. Other high-throughput techniques include capillary electrophoresis in a 96-array 
format coupled with micellar electrokinetic chromatography [146] and reverse phase HPLC 
where test compounds partition between the polar mobile phase and the stationary non- 
polar phase (usually octadecane bonded to silica or polymer) [125]. The approach used in 
this thesis was to combine the usual shake-flask method with high-throughput analytical 
quantiflcation. 
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Octanol. is the most commonly used model for biological phospholipid membranes; because 
of its frequent application (i. e. convention is as important as any supposed biological 
relevance [160]). Considering the membrane complexities a simple isotropic solvent has 
served well as a model for predicting drug lipophilicity. This may be facilitated by the 
amphiphilic octanol structure containing eight hydrophobic C-atoms and a hydrophilic OH 
group, which is reflected in the octanol solubility parameter (8=10.24) central to the range 
of most drugs [1441. Octanol is also able to donate hydrogen bonds and accept them almost 
as well as water in keeping with many biological macromolecules. Moreover, the use of 
alternative solvents with higher or lower polarities than octanol, may distort the measured 
log P [144]. Such that within a homologous drug series, solvents less polar than octanol 
e. g. hexane may be hyperdiscriminatory and exaggerate the differences in compound 
lipophilicity. On the other hand, solvents more polar than octanol e. g. butanol may be 
hypodiscriminatory resulting in log P values which are too close together [ 144]. 
This study details the novel application for a fluorescent plate reader (FPR) in high- 
throughput assay of log P samples which have been previously equilibrated using the 
traditional shake-flask method. The development of this method using DMU135 and 
DMU212 and the consequent validation of the novel' application using conventional 
compounds (17p-estradiol and hydrocortisone) and a conventional assay (UV 
spcctrophotometer) is also reported. 
ZL3.3 Thermodynamic evaluation 
Thermal analytical methods such as DSC can be used to investigate thermal stability, glass 
transitions, polymorphism and solvation of NCE [161]. DSC measures the amount of 
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exothermic or endothermic energy (i. e. heat flow) required to keep the sample at the same 
temperature as the reference, as samples are heated or cooled at a constant rate [144]. 
Samples are encapsulated in aluminium. pans and heated at rates of 1-400 'C/min to 
generate plots of sample heat flow vs. temperature: 
Melting point 
enclotheffn 
End 
Glass of heating 
transition 
Enclothermic ACP 
0 
Isothermal Isothermal 
cu 
Crystallization 
Beginning exotherm 
of heating AH, Melting point 
Exothermic and range 
Temperature (*C) 
Figure 17. Schematic thermogram. Following a period of isothermal equilibration, the temperature is 
Increased at a constant rate and the heat flow output is plotted vs. temperature [1441. 
These measurements provide information on glass transitions (i. e. T. half extrapolated, 
which is the temperature extrapolated to the middle point of the glass transition and the 
change in heat capacity at a glass transition ACp), crystallization (i. e. enthalpy of 
crystallization AI-Q, stability and melting points (i. e. the enthalpy of fusion MO. In 
particular DSC is a useful tool for studying polymorphism or solvation. [144,161]. 
2. L3.4 Morphological evaluation 
The morphology of a drug is defmed by both its structure and habit [147] and can impact 
both bioavailability and manufacturability. The internal structure of a crystal can exist in 
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cubic, tetragonal, orthorhombic, monoclinic, triclinic and hexagonal fonns. The habit 
describes the external structure of the crystal and includes needle, columnar, blade, plate 
and tabular types (Figure 18) [147,162]. The habits acquired depend on the crystallization 
conditions such as solvent, temperature and impurity concentration [15 8]. 
50 ý;;; ý \=. =ý Equant Tablet Plate 
Plake Columnar Rod 
z1r, 
t:: 
ý. \. I. 
ýIlw 
Blade Ribbon Needle 
"0% 
Fibrous 
Figure 18. Illustration of crystal habit descriptions 11621. 
The SEM is ideal for morphological evaluation. In this technique the interrogating electron 
beam lies above the sample and is focused through a series of lenses to construct an image 
with scattered electromagnetic radiation. Samples are usually gold-coated to minimise the 
detrimental effects of surface charging [161]. SEM is a useful tool for distinguishing 
between different crystal habits with optimum bioavailability and manufacturability. 
2.2 Materials and methods 
Reagents were used as received from Sigma-Aldrich Chemical Company (Dorset, UK). 
General analytical grade ethanol, IPA, DMSO, HPLC grade water and 96-well Nunc(& 
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plates were obtained from Fisher Scientific (Loughborough, UK). Anticancer prodrugs 
DMU135 and DMU212 were supplied by K. Ruparelia of the CDDG. 
ZZI Determination of solubility 
DMU135 and DMU212 drug solubility were measured in water, ethanol, IPA, NMP, 
glycerol, propylene glycol and PEG 400. The solubility of DMU135, DMU212 and 
indomethacin were determined by the shake-flask method. Excess amounts of drug (milled 
in a pestle and mortar beforehand) were added to test-tubes containing I OmL of different 
solvents. The drug suspensions were stirred continuously at 22"C 20C for 24 hours to 
attain solubility equilibrium. The suspensions were then centrifuged in 96 deep-well plates 
at 3500rpm (Jouan bench-top centrifuge, model CR4i, Thermo Electron Corporation, 
Massachusetts, USA) for 15 minutes at 22"C to remove any particulate matter and assayed 
on the HeXios 0 UV spectrophotometer (Unicam, Cambridge, UK) and Spectramax M5 UV 
plate reader (Molecular Devices, California, USA) at the pre-determined wavelength. 
Appropriate calibration curves were conducted for all solvent-drug systems and dilutions 
were conducted if necessary. All experiments were conducted in triplicate. 
ZZ2 Determination of log P 
The log P values of DMU135, DMU212,17p-estradiol and hydrocortisone were 
determined using the shake-flask method. The log P was determined at 220C ± 211C by 
preparing a 100 gg/mL drug stock solution in octanol and mixing it with an equal volume 
of water in lOmL test-tubes (the octanol and water were pre-saturated with each other 
beforehand). The two immiscible phases were stirred together for 24 hours at 22'C ± 20C 
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to allow the solute to reach partition equilibrium. After allowing the mixture to stand for 
24 hours, the samples were centrifuged in 96 deep-well plates for 15 minutes at 35OOrpm 
(Jouan bench-top centrifuge) after which the two phases were separated. Aliquots of the 
samples were assayed either on a HeMos UV spectrophotometer at the corresponding 
maximum wavelength or plated out into 96-well plates and measured on the SpectraMax 
M5 fluorescent plate reader (Molecular Devices, California, USA) at the corresponding 
emission and excitation wavelengths. 
Drug concentration in each phase was quantified through construction of calibration curves 
prepared in 96-deep well plates and log P was calculated using equation 2.1. Lipophilic 
calibration curves were prepared from a 100 pghnL drug-octanol stock to give 
concentrations in the range 10-100 gg/mL and hydrophilic calibration curves were prepared 
from a5 pg/mL drug-water stock to give concentrations in the range 0.5-5 pg/mL. All 
experiments were conducted in triplicate. 
ZZ3 Differential scanning calorimetry 
The swnples, (1-6mg) were placed in sealed aluminium. pans, model number 0219-0062 
(PerkinElmer) for solid samples. For oily samples (chapter S) aluminium pans with a pin- 
holed lid, model number B0169317 (PerkinElmer) were used. Experiments were run in a 
PerkinElmer Diamond DSC (Massachusetts, USA) supplied with nitrogen and helium gas 
and connected to a PerkinElmercryofill. A heating rate of 400OC/min was used over a -100 
to 300'C range, immediately after heating samples were rapidly cooled to the initial 
temperature of -100*C using liquid nitrogen and re-heated to determine the stability of the 
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compounds. An empty pan served as the reference and Indium was used to calibrate the 
temperature. Data analysis was conducted with Pyris software. 
Z24 Scanning electron microscopy 
Samples (1-5mg) were mounted onto SEM alun-iinium stubs, using double-sided sticking 
tape (Agar Scientific Ltd., Essex, UK) and coated with gold for 60 seconds under argon 
using an Edwards SB150 sputter coater (Sussex, LTK) in a high vacuum evaporator 
equipped with an onmi-rotary stage. The morphologies of the samples were investigated 
using a Leica S430 SEM (London, UK) at 5KV with a probe current of 150 picoamps, a 
working distance of 25mm and magnification ranging from 25 to 950OX. The samples 
were analysed using Leica electron optics software version V. 02.04B. 
ZZ5 Statistical analysis 
The data obtained in this study were subjected to statistical analysis using Microsoft Excel 
Software, for a one-way analysis of variance (ANOVA). A p-value of less than 0.05 was 
considered evidence of a significant difference. 
2.3 Results 
Z3.1 Solubility determination 
Both DMU135 and DMU212 are slightly soluble in water; however, they were more 
soluble in organic solvents such as IPA and NMP. Overall, DMU135 (Table 10) was more 
soluble in all solvents compared to DMU212 (Table 11) and solubility values measured on 
the UV plate reader were comparable with those measured on the UV spectrophotometer: 
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Table 10. Average solubility of DMU135 In various solvents measured at 22: L 2'C. 
AVERAGE SOLUBILITY OF AVERAGE SOLUBILITY OF 
DMU135 MEASURED ON DMU135 MEASURED ON THE 
SOLVENT 
THE UV PLATE READER UV SPECTROPHOTOM[ETER 
(mg/mL) (n--3) (mg/mL) (n--3) 
Water 0.001 -L 0.0001 0.00 1±0.000 1 
10% v/v aqueous ethanol 0.003 ± 0.0005 0.003 0.0005 
Isopropyl alcohol 1.510± 0.085 1.642 0.070 
N-Methyl Pyrrolidone 388.863 14.004 367.569 ± 4.286 
Glycerol 0.039 ± 0.010 0.045 ± 0.012 
Propylene Glycol 1.356 0.005 1.282 0.019 
Polyethylene Glycol 400 39.880 5.727 41.685 1.505 
Table 11. Average solubility of DMU212 in various solvents measured at 224: 20C 
AVERAGE SOLUBILITY OF AVERAGE SOLUBILITY OF 
DMU212 N[EASURED ON DMU212 MEASURED ON THE 
SOLVENT 
THE UV PLATE READER UV SPECTROPHOTOMETER 
(mg/mL) (n=3) (mg/mL) (n=3) 
Water 0.001 ± 0.0001 0.001 ± 0.0001 
10% v/v aqueous ethanol 0.001 ± 0.0001 0.001 ± 0.0002 
Isopropyl alcohol 0.585: h 0.025 0.656± 0.013 
N-Methyl Pyrrolidone 150.573: 1: 6.886 152.727 ± 10.496 
Glycerol 0.016: 1: 0.001 0.018 ± 0.002 
Propylene Glycol 0.451 ± 0.133 0.492: L 0.027 
Polyethylene Glycol 400 13.508 -h 1.612 14.281 :ý0.033 
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In a further test of this method's validity the aqueous solubility of indomethacin was 
determined on both the UV spectrophotometer and plate reader and corresponded to that 
stated in literature of 0.0 15 mg/mL [ 163]. 
Table 12. Average solubility of indomethacin in water measured at 22 -+ 2*C 
AVERAGE SOLUBILITY OF AVERAGE SOLUBILITY OF 
INDOMETHACIN MEASURED ON INDOMETHACIN MEASURED ON 
SOLVENT 
THE UV PLATE READER (mg/mL) THE LTV SPECTROPHOTOMETER. 
(n--3) (mg/mL) (n=3) 
Water 0.010 ±0.001 0.010 ± 0.001 
Z3.2 Log P determination 
Log P experimental values determined suggest that DMU135 (Table 13) is a more 
favourable candidate for preclinical evaluation than DMU212 (Table 14), which has a 
higher log P value and therefore is more lipophilic, presenting greater barriers to 
formulation and drug aqueous solubility. 
Table 13. Concentration of DMU135 In different phases and log P, measured on UV 
spectrophotometer. 
MEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(jig/mL) (n--6) (ptg/mL) (n=6) 
0.25 79.65 2.50 
2 0.25 80.62 2.51 
3 0.26 79.17 2.48 
MEAN log P 2.49+-0.01 
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Table 14. Concentration of DMU212 in different phases and log P, measured on UV 
spectrophotometer. 
MEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(gg/niL) (n=6) (gg/mL) (n=6) 
0.127 95.57 2.87 
2 0.109 97.27 2.95 
0.102 93.58 2.96 
MEAN log P 2.93 d: 0.05 
Z3. Z1 Fluorescentplate reader method 
The log P values for DMU135 and DMU212 determined on the fluorescent plate reader 
were comparable with those determined on the UV spectrophotometer, thereby confirming 
the usefulness of the high-throughput method: 
Table 15. Concentration of DMU135 In different phases and log P, measured on the fluorescent plate 
reader. 
WAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE LogP 
(Vg/mL) (n--6) (VghnL) (n=6) 
0.27 71.45 2.42 
2 0.29 75.56 2.41 
3 0.25 73.11 2.47 
MEAN log P 2.44 ± 0.03 
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Table 16. Concentration of DMU212 In different phases and log P, measured on the fluorescent plate 
reader. 
MEAN CONCENTRATION OF IýIEAN CONCENTRATION OF 
SANTLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(gg/mL) (n=6) (jig/mL) (n--6) 
1 0.07 
2 0.08 
3 0.09 
98.99 3.12 
103.38 3.12 
100.90 3.05 
MEAN Iog P 3.10± 0.04 
2.3. ZLI Comparison with I 7. gestradiol and hydrocortisone 
In a further test of the high-throughput method validity the log P of 17p-estradiol and 
hydrocortisone determined on the UV spectrophotometer were comparable to those 
determined on the fluorescent plate reader- 
Table 17. Concentration of 17p-estradiol in different phases and log P, measured on UV 
spectrophotometer. 
MEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE LogP 
(jig/mL) (n--6) (gg/mL) (n=6) 
1 0.15 89.86 2.78 
2 0.52 
0.22 
90.81 2.24 
91.43 2.61 
MEAN log P 2.54± 0.28 
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Table 18. Concentration of 17p-estradiol in different phases and log P, measured on fluorescent plate 
reader. 
NEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SANTLE, DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(jigtmL) (n7-6) (ýLglmL) (n7-6) 
1 0.18 98.01 2.73 
2 0.21 95.39 2.65 
3 0.20 95.12 2.67 
MEAN log P 2.68 ± 0.04 
Table 19. Concentration of hydrocortisone In different phases and log P, measured on UV 
spectrophotometer. 
IýIEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SANTLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(pg/mL) (n--6) (gg/mL) (n=6) 
1 1.83 90.61 1.70 
2 1.90 90.55 1.68 
3 1.93 89.99 1.67 
MEAN log P 1.68± 0.01 
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Table 20. Concentration of hydrGcortisone in different phases and log P, measured on fluorescent plate 
reader. 
MEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(gg/mL) (n=6) (ýLg/mL) (n=6) 
1 2.54 89.65 1.55 
2 1.97 81.42 1.62 
3 2.36 92.77 1.59 
MEAN log P 1.59 ± 0.04 
Furthermore, the log P values for 17P-estradiol and hydrocortisone determined on both the 
fluorescent plate reader and UV spectrophotometer corresponded to values stated in 
literature [164], as shown by Figure 19: 
Figure 19. Correlation bet-Aeen experimental log P values measured versus values from literature for 
hydrocortisone and 17ft-estradiol. (1) Hydrocortisone log P measured on the UV spectrophotometer; (2) 
hydrocortisone log P from literature; (3) hydrocortisone log P measured on the fluorescent plate reader; (4) 
170-estradiol log P measured on the UV spectrophotometer ; (5) 17p-estradiol log P from literature; (4) 17p- 
estradiol log P measured on the fluorescent plate reader. 
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23.3 Differential scanning calorimetry 
DSC measurements for DMU135 and DMU212 do not show the presence of polymorphs, 
solvates and impurities, since both prodrug scans exhibited a single endotherm peak: 
Table 21. DSC of DMU135 and DMU212 - initial heating from -100-3000C at 400*C/min. 
MELTING POINT ENDOTHERM 
DRUG ONSET PEAK ENTHALPY OF 
TEMPERATURE ('C) TEMPERATURE (OC) FUSION AH (J/g) 
DMU 135 138.27 148.43 83.79 
DMU212 164.96 173.49 107.27 
131.3 
Peak = 148A3 OC 
120 
110 
10 0 
90 Area = 219 538 mJ 
Delta H= 83.7929 JIg 
80 
ui 1 70 
U. I so Onset 138.27 'C 
x 
so 
40 
30 
22.87 
-5124 0 so 00 150 200 250 291 Tomerature 
Figure 20. IDSC thermogram of DMU135. 
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Figure 21. DSC thermogram of DMU212. 
Immediately after the initial scan the samples were rapidly cooled and reheated to 
deterrnine if any recrystallization was apparent. The second DSC for DMU212 showed no 
immediate re-crystallization, whereas DMU135 exhibited a small amount of re- 
crystallization: 
Table 22. DSC of DMU135 and DMU212 - immediate re-heat from -100-3000C at 400OC/min 
Tg MELTING POINT ENDOTHERM 
DRUG 
ONSET T. HALF 
AC 
ONSET PEAK ENTHALPY 
TEMP EXTRAPOLATED TENT TEMP OF FUSION 
(OC) (OC) ,- (OC) (OC) AH (J/g) 
DMU135 25.60 32.91 0.46 138.48 147.08 1.42 
DMU212 3.93 12.06 0.47 --- 
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Z3.4 Scanning electron microscopy 
A sma Patel 
SEM imaging of DMU135 showed the crystals to exist as big agglomerated blades, 
whereas, DMU212 crystals had large particles with a smaller surface area, in the form of 
columnar crystals: 
Table 23. SEM imaging of DMU135 and DMU212. 
DRUG CRYSTAL SHAPE SEM IMAGE 
Trichnic, 
DW212 
columnar 
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2.4 Discussion 
DMU135 exhibited a slightly better solubility profile in all solvents compared with 
DMU212. However, both DMU135 and DMU212 exhibited poor aqueous solubility at 
0.001 mg/mL. The lipophilicity of these prodrugs stems from the non-ionisable groups on 
the stilbene and chalcone backbones, the presence of the lipophilic methyl groups on both 
prodrugs is important for potency, however, the opposite effect is true for the drug 
pharmaceutical properties [151]. DMU135 contains three methyl groups as well as six 
hydrogen bond acceptor groups and DMU212 contains four of each, which is reflected in 
their relative solubilites as the presence of two extra polar oxygen groups and one less 
methyl group in DMU135 slightly increases its polarity. 
Maximum solubility for both prodrugs was exhibited in NMP, probably resulting from the 
chemical reactions on the NMP pyrrolidone ring including hydrogen bonding and polar 
interactions. DMU135 NMP solubility of 388.863 ± 4.004 mg/mL on the UV plate reader 
and 367.569 ± 4.286 mg/mL on the LJV spectrophotometer and DMU212 NMP solubility 
of 150.573 ± 6.886 mghnL on the UV plate reader and 152.727 ± 10.496 on the UV 
spectrophotometer suggests that this may be the solvent/co-solvent of choice for future 
parenteral formulation and pharmacokinetic studies possibly combined with PEG 400, 
propylene glycol or IPA, which were the next best prodrug solubilizing agents respectively. 
The solubility values determined on the UV plate reader were comparable to those 
determined on the UV spectrophotometer with maximum difference between the two 
techniques being approximately 10%. In a further test of this method's validity the aqueous 
solubility of indomethacin determined by both the LTV plate reader and spectrophotometer 
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was 0.010 mghnL and corresponded with that stated in literature of 0.015 mg/mL [163]. 
To determine whether the differences in solubility were a factor of the drug concentration, 
the solubility values for all compounds measured with both techniques were statistically 
compared with ANOVA (Section 2.2.5): 
Table 24. Statistical comparison between DMU135, DMU212 and indomethacin solubility values as 
measured on the UV plate reader and spectrophotometer. 
SOLVENT DMU135 p VALUE DMU212 p VALUE 
INDONETHACIN 
p VALUE 
Water 0.594 0.809 0.999 
10% v/v aqueous ethanol 0.682 0.716 
Isopropyl alcohol 0.105 0.012 
N-Methyl Pyrrolidone 0.003 0.781 
Glycerol 0.629 0.501 
Propylene Glycol 0.031 0.716 
Polyethylene Glycol 400 0.708 0.568 
The majority of solubility measurements between the two assay techniques were not found 
to be significantly different (p>0.05). However, DMU135 solubility measurements in 
NMp and propylene glycol and DMU212 solubility measurements in IPA were found to be 
sigrifficantly different (p<0.05). The solubility values obtained in these instances were with 
the higher drug concentrations, however, in most cases even at these concentrations a 
significant difference was not observed between the UV plate reader and LJV 
spectrophotometer methods. On the whole, these results indicate that the 96-well UV plate 
reader can be successfully implemented for high-throughput, miniaturised and valid 
solubility quantification. 
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Both DMU135 and DMU212 log P data suggest that the prodrugs are lipophilic, DMU135 
exhibited the more favourable (i. e. less lipophilic) log P (2.49) compared with DMU212 
(2.93) which is more lipophilic presenting greater barriers to drug aqueous solubility and 
adsorption. The log P of DMU135 determined by the UV spectrophotorneter was 2.49 ± 
0.01, compared to that determined on the fluorescent plate reader at 2.44 ± 0.03 and the log 
P of DMU212 determined by the UV spectrophotometer was 2.93 ± 0.05, comparable to 
the value determined on the fluorescent plate reader at 3.10 ±- 0.04, thereby confirming the 
usefulness of the high-throughput method. In a further test of this method's validity, the 
log P of 17P-estradiol determined by the UV spectrophotometer was 2.54 ± 0.28 compared 
with the value of 2.68 ± 0.04 obtained with the fluorescent plate reader, corresponding well 
with that stated in literature of 2.69 [164]. The log P of hydrocortisone determined by the 
UV spectrophotometer was 1.68 ± 0.01 and with the fluorescent plate reader was 1.59 1 
0.04, again both corresponding with that stated in literature of 1.53. Figure 19 illustrates 
the correspondence between log P values stated in literature to those determined 
experimentally with both techniques. Overall, the results as determined on the fluorescent 
plate reader were closer to the published log P values, compared to those determined by the 
UV spectrophotometer. 
DMU135 has better aqueous solubility compared with DMU212 as reflected in the 
respective log P values. This arises because DMU212 contains more lipophilic substituents 
and less hydrogen-bond acceptor groups compared with DMU135. DMU135 can therefore 
form stronger polar interactions with water through van der Waal forces compared with 
DMU212, resulting in increased DMU212 lipophilicity through a stronger affinity for 
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octanol, which may impair permeability across phospholipid membranes, since aqueous 
solubility in the intestinal fluids is a prerequisite for oral drug absorption. 
The effect of the different substituents on the log P of both DMU135 and DMU212 can be 
ftu-ther analysed by considering the log Pas an additive-constitutive property [160]. Infact 
several methods for calculating log P are based on the theory first proposed by Hansch and 
Fujita [157], that molecules can be broken down into predefined fragments and their 
corresponding contributions summed up to obtain the final log P[ 160]. The most widely 
used method for calculating log P is the CLOGP method developed by Hansch and Leo 
[165,166]. Using this method different fragments are assigned log P contribution values. 
The fragments of interest within the context of this study were the methyl with a fragment 
contribution of 0.876; aliphatic oxygen with a fragment contribution of -1.820 and aromatic 
oxygen with a fragment contribution of -0.610. DMU135 contains three methyl 
substituents, as well as four aliphatic and two aromatic oxygen substituents, whereas 
DMU212 contains four methyl and four aliphatic oxygen substituents. Therefore, 
theoretically the summing up of these fragment contributions, to obtain the final calculated 
log P of the core molecule, would mean that DMU212 is the more lipophilic prodrug, 
which is corroborated by the measured log P. Overall, the results indicate that the 96-well 
fluorescent plate reader can be successfully implemented for high-throughput, miniaturised 
and valid log P quantification. 
DSC measurements for DMU135 and DMU212 do not show the presence of polymorphs, 
solvates and impurities, since both prodrug scans exhibited a single melting point 
endothenri. The onset temperature for DMU135 was 138.270C and for DMU212 was 
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164.961C. The AH for DMU135 and DMU212 was 83.79 and 107.27 J/g respectively. 
These values correlate with the overall solubility of the two drugs; DMU135 requires less 
energy to overcome the intermolecular crystal lattice forces (i. e. AH) and as such was more 
soluble in all solvents compared with DMU212. Immediately after the initial scan the 
samples were rapidly cooled and reheated to determine if recrystallization was apparent and 
subsequently to determine the solid-state stability of the prodrugs. In the second DSC scan 
the melting point endotherm for DMU212 was absent and the onset of a glass transition 
temperature (To was observed at 3.930C, suggesting that the crystals were in an amorphous 
state and no immediate recrystallization was apparent. With DMU135 a T. was observed at 
25.60"C, however, a small melting point endotherm was also observed at 138.480C with a 
AH of 1.42 J/g. This indicates that upon inunediate reheat DMU135 crystals were mostly 
in an amorphous state, however, a small proportion of recrystallization was apparent. The 
fact that DMU135 exhibited recrystallization. suggests that the solid-state stability of 
DMU135 is superior to that of DMU212. 
SEM imaging of DMU135 showed the crystals system was orthorhombic with big 
agglomerated blades, whereas, DMU212 crystals had very large particles with a small 
surface area and existed as triclinic columnar crystals. The particle size of DMU135 is 
difficult to assess as the aggregates have both loosely and tightly bound particles [ 162] and 
DMU212 particle size was relatively large at >Imm. The degree of agglomeration and the 
relatively small surface area of both drugs would account for their poor aqueous solubility. 
The physicochemical properties of DMU135 and DMU212 have been evaluated and the 
core fmdings are summarised in Table 25: 
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Table 25. Comparison of some of the physicochemical properties of DMU135 and DMU212. 
DRUG 
Ty 
DMU135 DMU212 I ROPER r%7 ý 
Activation Factor 90 22 
Turnour Selective Factor 380 4300 
Appearance Pale yellow, crystalline Yellow, crystalline 
Molecular Weight 342 300 
Melting Point (T) 138.27 164.96 
Enthalpy of fusion AH (J/g) 83.79 107.27 
Orthorhombic, aggregated Crystal System Triclinic, columnar blades 
Polymorphism No evidence of polymorphs No evidence of polymorphs 
Hydrogen Bond Acceptor Groups 6 4 
Aqueous solubility (mg/mL) 0.001 ± 0.0001 0.001 4- 0.0001 
Solubility in NMP (mg/mL) 367.569 ± 4.286 152.727 ± 10.496 
Log P 2.49 ±- 0.01 2.93 ± 0.05 
Generally, both DMU135 and DMU212 were found to be lipophilic, poorly soluble in 
water and greatly soluble in organic solvents such as NMP- The high crystallinity of both 
compounds significantly contributes to their non-polarity. The preformulation study 
conducted suggests that DMU135 has better development prospects compared to DMU212 
with optimum solubility, log P and thermodynamic stability. On the other hand DMU212 
is eleven times more potent as a CYPIBI activated prodrug compared to DMU135. 
Furthermore, studies within the CDDG have found DMU135 to be unstable in-vitro, 
whereas DNW212 was relatively stable. Chalcones such as DMU135 are synthesised by 
Claisen-Schmidt aldol condensation reactions between acetophenone and benzaldehydes 
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with elimination of a water molecule to generate a (x, p-unsaturated ketone. This structure 
is vulnerable in aqueous conditions to retro-aldol condensation reactions, where the 
presence of water reverses the reaction to liberate the starting materials; benzaldehyde and 
acetophenone. Moreover, DMU135 was also shown to undergo photo-isomerization under 
ambient light from the trans to the cis isomer (unpublished results, D. Ankrett, CDDG). As 
isomerisation can be extremely fast (seconds), the biological evaluation of chalcones can be 
fairly complicated, in that the potency and stability may differ significantly between the 
trans and cis isomers [ 167]. 
Overall, both DMU135 and DMU212 had the same aqueous solubility, with closely related 
solubilites in various organic solvents. The log P values were also relatively similar. 
DMU135 had the better thermodynamic solubility but in-house studies have shown 
DMU212 to have better solution stability. Accrued with the cytotoxic data these 
physicochemical studies buttress the advancement of DMU212 to further drug development 
studies. Novel high-throughput screening methods using 96-well fluorescent and UV plate 
readers have also been successfully implemented and validated for log P and solubility 
determination. High-throughput analytical technology can potentially accelerate the 
acquisition of physicochemical data for a NCE at an early stage in the drug development 
pipeline and miniaturisation of sample quantities can also be a benefit during 
preformulation where drug supplies can be limited. On the whole, 96-well plate high- 
throughput quantification may find use in pharmaceutics, to potentially reduce drug 
development times, resource requirements and the number of in vivo experiments. 
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3.1 Introduction 
Synthesis of CYPIBI non-toxic prodrugs is fimitless without the transfer of these NCEs 
from a preclinical, discovery stage into formulated dosage forms appropriate for clinical 
trials. These can vary from simple solutions through to complex drug delivery systems 
using numerous additives and excipients (147]. Before a NCE can be successfully 
formulated into a dosage form three factors are taken into consideration. These are the 
physicochemical properties of the drug; biopharmaceutical considerations, including factors 
affecting the rate and extent of drug absorption from different routes of administration and 
finally therapeutic considerations of the clinical indication to be treated [ 147]. 
However, the increasing adoption of high-throughput screens and combinatorial chemistry 
in the pharmaceutic 
I 
al industry has prompted the quest for the development of parallel 
technology in formulation [121] and more importantly fuelled the development of drugs 
which almost exclusively focus on drug potency and selectivity whilst compromising on 
pharmaceutical properties, thereby creating higher attrition rates in formulation [122,123]. 
The anticancer prodrug DMU212 was designed in this manner with non-ionisable O-methyl 
groups which are important for potency but provide no capability for salt selection, since 
the active moiety is introduced in situ. Consequently DMU212 exhibits both lipophilicity 
and poor aqueous solubility which may present challenges during formulation studies. 
3.1.1 Oralformulation of novel anticancer prodrugs 
Oral dosage fonns are one of the most frequently used for drug administration because of 
their convenience, simplicity and cost-effective manufacturing processes (147]. Orally 
De Montfort UniversitY 75 
Oral Formulation ofNon-lonisable Prodrugs Asma Patel 
administered anticancer drugs have become increasingly abundant in chemotherapeutics, 
corroborated by the profusion of orally formulated agents currently in development [168]. 
Moreover, several new oral analogues or oral formulations Of conventional cytotoxic agents 
such as etoposide, cyclophosphamide and 5-FU have recently been developed [169). Oral 
chemotherapy is to be preferred in the first place for its convenience and its potential to 
improve patient quality of life. In addition, the need for infusions and consequent 
hospitalisation are eliminated, therefore, making this route of administration more patient 
compliant, practical and economically viable. Finally, the oral route also facilitates the use 
of more chronic treatment regimens, which result in prolonged exposure to 
chemotherapeutic agents [169]. 
3. LL1 Hardgelatine capsules 
Capsules are one of the most popular of oral dosage forms and generally the bioavailability 
is better or equal to that of a tablet and unlike a tablet, no complex formulations, or 
techniques are needed, allowing quicker submission of the NCE for clinical trials as fewer 
development problems are encountered [170,1711. There are many factors influencing 
release of drugs from capsules such as capsule shell disintegration and dissolution of the 
encapsulated product. Dissolution rate may be the most important limitation in rate of drug 
absorption compared with phospholipid membrane permeation, and is influenced by the 
capsule formulation and local conditions in the gastrointestinal tract. Therefore, 
formulation is an important factor in determining the release rate and bioavailability of the 
encapsulated product [ 147]. 
De Montrorl UniversitY 76 
Oral Formulation ofNon-Ionisable Prodrugs Asma Patel 
The major constituents of the powder mixture investigated for DMU212 capsule 
formulation were the drug and hydrophilic diluents; (e. g. lactose and sorbitol) generally 
added to increase powder bulk; however, addition of hydrophilic diluents can also improve 
the solubility of poorly soluble drugs by improving the drug-water affinity, through 
optin-dsation of effective drug surface area (172]. Cyclodextrins were also used as diluents 
to potentially improve the solubility of DMU212 through formation of inclusion 
complexes, acting as drug carriers by masking drug hydrophobicity [173]. Incorporation of 
surfactants as wetting agents e. g. sodium lauryl sulphate (SLS) was also studied for 
possible dissolution enhancement, through reduction of interfacial tension between the drug 
and mediun-L Glidants/lubricants such as magnesium stearate were also incorporated to 
improve powder flow in high-speed capsule filling machinery, however, as the capsules 
will initially be produced by hand, such materials will not be needed in the immediate 
future [ 147,174]. 
3. LI. 2 In vitro release of drugsfrom capsules 
Formulation efficacy was determined using the BP paddle dissolution method [175], a 
simple in vitro test, which has been well standardised and is a regulatory requirement 
submitted for pre-clinical data and used to ensure batch to batch uniformity. Before a drug 
is absorbed into the gastrointestinal tract it has to be released and dissolved first. These 
variables are evaluated with the in vitro dissolution test which quantifies the rate of active 
drug release into the dissolution medium and consequently the effects of excipient 
variability can be assessed. 
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The basic principles underlying the dissolution process can be identified by the Noyes- 
Whitney equation [176]: 
dC 
= 
DA(Cs - C) 
dt h 
(3.1) 
Where dCldt is the rate of dissolution of the drug particles, D is the diffusion coefficient of 
the drug, A represents the effective surface area, h is the thickness of the boundary layer 
adjacent to the dissolving surface, CS is the saturation solubility of the drug in the 
dissolution medium and C is the drug concentration in the bulk of the dissolving medium 
[147]. There are many physicochemical and experimental factors which can influence 
Equation 3.1 and therefore the dissolution rate. Physicochemical factors include the 
particle size, dispersibility and porosity of the drug particles [147]. 
The experimental factors that can influence the dissolution rate are the composition and 
volume of dissolution media, type of apparatus and the temperature and agitation of the 
media [147]. The degree of media agitation dictates the thickness of the boundary layer 
(h), where an increase in agitation can reduce the thickness of the stagnant film surrounding 
the capsule to result in an increased dissolution rate [177]. The drug saturation solubility in 
the dissolution medium (Cs) can also influence the dissolution rate. If the concentration of 
drug dissolved in the dissolution medium (C) does not exceed 10% of the drug saturation 
concentration, then 'sink conditions' are said to exist. Under sink conditions saturation 
solubility is mostly responsible for determining the drug concentration gradient across the 
boundary layer, which is the driving force behind dissolution. The standard methods of 
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controlling the saturation solubility are to alter the dissolution media volume or to change 
the media composition [177]. 
Most studies use water, buffers, acids or alkalis as dissolution media [178]. However, for 
poorly soluble drugs dissolution in the aforementioned media may be challenging 
especially if they are lipophilic and non-ionisable like DMU212. In developing a 
dissolution test for poorly soluble drugs such as DMU212, a variety of media have been 
used to increase drug solubility such as alcohols or other organic solvents, these media have 
no physiological relevance and as such may result in poor in vivo-in vitro correlations 
[179]. Consequently, potential solubility improvements in aqueous media may be 
facilitated through inclusion of surfactants in the dissolution medium. Poorly soluble drugs 
can be solubilized in the body by endogenous surfactants e. g. bile and lecithin, therefore, 
inclusion of natural surfactants in the dissolution media simulates the gastrointestinal fluid 
milieu [1801, thereby exhibiting test conditions more useful in evaluating drug quality. 
However, the expense of natural surfactant media has led to the employment of synthetic 
ionic and non-ionic surfactants such as SLS, cetyltrimethylammonium bromide (CTAB) 
and the polysorbates (or Tweens) [177,179-181], all of which are more cost-effective. 
Moreover, the physiological relevance of synthetic surfactants has been approved by the 
FDA for sparingly water-soluble drug dissolution methods [ 178]. 
Within the scope of this thesis DMU212 capsule formulations were developed and 
subsequently evaluated using the BP paddle dissolution method [175]. A high-throughput 
assay on a UV plate reader was also developed for dissolution sample measurement and the 
novel technique was validated using indomethacin and UV spectrophotometry, A novel 
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application for the standard MTT in vitro assay [134] was also used to demonstrate the 
retention of DMU212 CYP I enzyme selectivity after capsule formulation, and to detennine 
whether the excipients had any effect on the drug's cytotoxicity. 
3.2 Materials and methods 
Reagents were used as received from Sigrna-Aldrich Chemical Company (Dorset, UK) or 
Alfa Aesar (Lancashire, UK). Tween 80 was obtained from Thornton and Ross Ltd. 
(Huddersfield, UK) and size 2 hard gelatine capsule shells were purchased from Davcaps 
(Hertfordshire, UK). TCDD (2,3,7,8 tetrachlorodibenzo-p-dioxin) was obtained from 
British Greyhound Chromatography (Birkenhead, UK). HPLC grade water, 2.5mL 
eppendorf tubes, 96-well Nunc(& plates, 96 deep square well polypropylene plates and SLS 
were obtained from Fisher Scientific (Loughborough, UK). Human breast cell lines were 
obtained from the American Type Culture Collection and DMU212 was supplied by K. 
Ruparelia of the CDDG. 
3. Z1 Dissolution media preparation 
All dissolution media were prepared using the following reagents: HPLC grade water, 
hydrochloric acid (HCI), sodium hydroxide (NaOH), potassium phosphate (KH2PO4). 
disodium hydrogen orthophosphate (Na2HP04), Tween 80 and SLS. All media were 
degassed by sonication before use. Buffer solutions were prepared as described in the 
British Pharmacopoeia 2003 (Volume IV, Appendix ID, A130). Depending on the initial 
pH, either IM NaOH or HCl was used to adjust the pH appropriately using a SevenEasyTm 
benchtop pH meter (Mettler-Toledo Inc., Ohio, USA). 
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A-T - -- 3.2.2 Capsuleformulations 
Powder blends containing DMU212 or indomethacin and the chosen excipients were 
prepared by trituration in a pestle and mortar. The formulations were manually packed into 
size 2 hard gelatine capsule shells using bench scale capsule filling equipment. The effect 
of particle size on DMU212 dissolution was also studied with capl/50D, where samples 
were passed through a series of sieves with different aperture sizes (Endecotts Ltd., 
London, UK). The following particle size fractions were collected and encapsulated: 
<150gM, 150-250liM and 250-500ýM. The following capsules were prepared for other 
dissolution studies: 
Table 26. Summary of DMU212 capsule formulations: 
INGREDEENT CC- P- 
DMU212 Sorbitol Lactose SLS Magnesium Cyclo_ Cyclo_ 
CAPSUL (mg) (mg) (mg) (mg) Stearate dextrin dextrin 
FORMULATIO (mg) ATIO (mg) (mg) 
Capl/50D so 
Cap2/50D/L 50 ISO 
Cap3/SOD/S 50 150 
Cap4/50D/MS/L 50 140 10 
Cap5/5OD/MS/S 50 140 10 
Cap6/50D/SLS/L 50 140 10 
Cap7/50D/SLS/S 50 140 10 - 
Cap8/5OD/SLS/L 50 50 100 
Cap9/50D/SLS/S 50 50 100 
CapIO/lOOD 100 
CapI 1/10OD/L 100 100 
Capl2/IOOD/S 100 100 
Cap13/50D/ACYC 50 150 
Capl4/50D/BCYC 50 150 
De Monffiort UniversitY 81 
Oral Formulation ofNon-lonisable Prodrugs Asma Patel 
Table 27. Summary of Indomethacin capsule formulations: 
INGREDEENT 
Indomethacin Sorbitol Lactose 
CAPSULE (Mg) (Mg) (Mg) 
FORMULAJIONý 
CapI/lOOD 100 
Cap2/lOOD/L 100 100 
Cap3/lOOD/S 100 100 
3-Z3 Determination ofsaturation concentration 
It is higWy important to determine the saturation concentration of the drug in the 
dissolution medium to ensure that sink conditions are maintained. The saturation 
concentration of DMU212 was determined in 1% w/v SLS (i. e. optimum dissolution 
conditions) by adding excess drug to 900mL of dissolution medium, which was stirred 
using a paddle stirrer at 100 rpm over 24 hours at 37.50C (±0.5'C) (section 3.2.4). 
Afterwards, I mL of the suspension was centrifuged for 1 minute at 13,000 rpm and assayed 
for DMU212 using the UV spectrophotometer and UV plate reader at kmax of 326nm. 
3.24 In vitro dissolution studies 
T'he BP paddle dissolution test was used for all in vitro dissolution studies (2003, Volume 
IV, Appendix X MID, A249). Experiments were carried out using a manual Erweka 
Dissolution System (Heusenstamm, Germany) equipped with paddle stirrers fixed at depth 
of 23-27mm from the bottom of the dissolution vessel whilst rotating at 50-100 rpm. The 
capsules were placed in steel wire springs to weigh them down and introduced into 900mL 
of the dissolution medium maintained at a temperature of 37.5'C (+-0.5'C) [ 175]: 
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100 rpm 
Flask Sampling Point: 
midway between top 
of blade and top of 
900ml- dissolution medium, no closer 
medium at 37.5*C than 10mm to side 
of flask 
Paddle 
Paddle Position 
23-27mm from 
bottom of vessel Weighted 
Capsule 
Figure 22. Schematic of the BP paddle method used for dissolution studies. 
At specified time intervals ImL of dissolution medium was taken and centrifuged for I 
niinute at 13,000 rpm (the samples were not filtered due to adsorption of drug onto the 
cellulose nitrate membrane filters, which would have been otherwise used). An equal 
volume of fresh dissolution medium was added after each removal to maintain a constant 
volume. The samples were then assayed using the UV spectrophotometer (HeXios P) and 
the UV plate reader (Spectramax M5) at ?, max of 326nm. The method variables evaluated 
were the stirring speed and dissolution medium and after method development a range of 
capsule formulations were evaluated (Tables 26 and 27). 
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3.2.5 Analysis of dissolution samples 
Initial dissolution samples were assayed on a UV spectrophotometer at Xmax of 326nm and 
subsequently on a LJV plate reader at Xmax of 326nm. Calibration curves were constructed 
from the appropriate medium using a 100 gghnL DMU212 stock in DMSO to give 
concentrations in the range 1-100 pg/mL. The concentrations were diluted 5-fold with the 
medium directly in the cuvettes for the UV spectrophotometer and in deep well plates for 
the UV plate reader which were then plated into 96-well microtitre plates for analysis; this 
was to standardize the volume of dissolution sample measured for both analytical 
techniques and to measure a more homogeneous sample. 
The calibration curves were validated through preparation of known concentrations of 
standards within the calibration range, which were then treated as unknowns and their 
concentrations were back calculated from the calibration curves constructed. The 
excipients did not affect drug absorbance, which was demonstrated through comparison of 
standards prepared in neat dissolution media and standards prepared in solutions containing 
the maximum concentration of powder blends in the appropriate dissolution media. 
3.2.5.1 Calculationsfor drug release data 
The equation of the line for corresponding calibration curves were rearranged to convert 
absorbance into apparent drug concentration in the corresponding sample of dissolution 
medium removed at time t: 
(Absorbance 
-y Intercept Apparent Concentration of DMU212 (mg/mL) = ý- (3.2) Slope 
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Corrected concentration of DMU212 was calculated to correct for error caused by 
replacement of ImL samples withdrawn from the dissolution medium Also the volume of 
dissolution medium was constantly 9OOmL, therefore, the equation used for corrected 
concentration of DMU212 was: 
Corrected Concentration = Apparent Concentration +1Z 
of previous apparent )(3.3) 
900 
ý 
concentrations 
at time t (mghiQ at time t 
The total amount (mg) of dissolved drug present in 900mL of dissolution medium at a 
given time of sampling t, was given by-. 
Total Amount of Drug = Corrected concentration (mg/mL) x 900 (3.4) 
Released (mg) of drug released at time t 
The percentage of drug released at a given time of sampling t, was then calculated. 
3. Z6 MTT in vitro cytotoxicity assay 
The MTT assay (Section 2.1.1) performed by P. Butler was employed to demonstrate the 
CYPI enzyme selectivity of DMU212 after capsule formulation, and to determine whether 
the excipients had any effect on cytotoxicity. The human breast cell-lines used included 
MCF7, MDA-MB-468 and MCFIOA. MCF7 cells were cultured in RIPMI 1640 medium, 
MDA-MB-468 cells were cultured in RPMI 1640 medium without phenol red, MCFIOA 
cells were cultured in DMEMNAM's F-12 medium with 10 Pg/mL insulin, 500 ng/mL 
hydrocortisone and 20 ng/mL epidermal growth factor. All media were supplemented with 
glutamine and 10% v/v heat inactivated foetal calf serum. Cells were incubated at 37"C, 
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5% C02f95% air with 100% humidity and passaged at subconfluence using 0.5% 
trypsin/0.2% EDTA. 
The cells cultured in medium were plated out at 2x 104 cells per well in 96-well plates and 
allowed to attach for 4 hours before treatment. MCF7 cells were induced with 100[d of 
medium containing 20AM TCDD or without TCDD (vehicle control, 0.2% v/v DMSO) for 
24 hours to allow CYP expression. The medium was then aspirated and the cells were 
resuspended in 100jiL of fresh medium. Serial dilutions of the test compounds (DMU212, 
cap3/50D/S and sorbitol) were added to the 96-well plates. All test compound 
concentrations (0.0003-IOOpM) were examined in quadruplicate. After a 96 hour 
incubation period 50jiL of MTT at 2 mg/mL in RPMI 1640 without phenol red was added 
to each well followed by incubation for a further 2 hours. All medium was aspirated and 
the formazan product generated by viable cells was solubilized with I 00gl DMSO. Plates 
were vortexed and the absorbance at 540nm determined using a Labsystems, Multiskan MS 
plate reader (Helsinki, Finland). Results were expressed as the percentage of 100% 
(control) proliferation and the IC50 calculated from the linear regression analysis of 
experimental data using GraphPad Prism version 4 software. The activity of the drugs in 
the cell-lines was calculated using the turnour selective factor (Equation 3.5) and the 
activation factor (Equation 3.6): 
Tumour selective factor -- 
(IC50 in MCFIOA) (3.5) 
(IC50 in MDA - MB - 468) 
Activation factor - 
(IC50 in MCF7) (3.6) 
(IC50 in TCDD induced MCF7) 
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3.2 7 Statistical analysis 
See Section 2.2.5. 
3.3 Results 
3.3.1 Dissolution quantification on the UVspectrophotometer 
Initial dissolution studies were conducted with water as the medium: 
1.40 
2 1.20 
1.00 
0.80 
N :)0.60 
:E 
a 
15 0.40 
2 
CO 0.20 
0.00 
capl/50D 
cap2/50D/L 
cap3/50D/S 
Figure 23. Percent DMU212 released with time for a range of capsule formulations in water. 
DMU212 aqueous dissolution was very poor, however, the drug released appeared to be 
oscillating with time. The observed oscillation may be a factor of the drug solubility where 
the drug molecules may be dissolving and crystallizing out of the dissolution medium, until 
the thermodynamic solubility level is reached. To prove or disprove this theory, tighter 
time points were measured in the aqueous dissolution of cap I /50D: 
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Figure 24. Percent DMU212 released with time for capl/50D in water. 
No conclusive solubility oscillation phenomenon was observed; therefore, further 
dissolution studies were conducted in a range of media to screen for the best conditions for 
drug release: 
100 0 . 
80.0- Water 
OAM FICI 
60.0 - 
cm --4*- Phosphate 
C-4 Buffer pH 7.4 :3 40.01 1%w/vSLS 
I% w/v Tween 
200 
CL 
00 
0 50 100 150 200 
Time (mins) 
Figure 25. Percent DMU212 released with time for capl/50D in various media at 100 rpm and 37.51C 
(n=3). 
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C14 
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20.0 
0.0 1% W/V 1%w/v Tween 80 CTAB 
Figure 26. Total percent DMU212 released from capl/50D in various dissolution media over 4 hours 
(n=3). 
The best dissolution conditions were observed with media containing surfactants most 
notably with 1% SLS dissolution medium. To further maximise the sensitivity of the 
test conditions the best rotary speed was determined with 1% w/v SLS and cap 1/50D: 
100.0 
6 80.0 
60.0 A capl/50 rpm 
C4 6 capl/75 rpm 
40.0 --o--capl/100 rpm 
200 - 
CAL 
00 
0 so 00 150 200 
Time (mins) 
Figure 27. Percent DMU212 released with time for capl/50D in 1% w/v SLS dissolution medium at 
different stirring speeds W3). 
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Figure 28. Total percent DMU212 released from capl/50D at different agitation speeds in 1% w/v SLS 
dissolution medium over 4 hours (n=3). 
The highest dissolution rate was observed with a rotary speed of 100 rpm and the lowest 
was with 50 rpm. Prior to formulation screening studies the effect of drug particle size on 
DMU212 dissolution rate was also evaluated using capl/50D: 
100.0 
80.0 
A capl/<l50uM 
60.0 - 
C4 capl/150- 
C4 :3 25OuM 
40.0 - 
-0-capl/250- 
500um 
20.0 
CL 
oo 
0 50 100 150 200 
Time (mins) 
Figure 29. Percent DMU212 released with time for capl/50D at different particle sizes in 1% w/v SILS 
dissolution medium (n=3). 
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Figure 30. Total percent DMU212 released from capl/50D at different particle sizes in 1% w/v SLS 
dissolution medium over 4 hours (n=3). 
The fastest drug release for capl/50D was with drug particle size at <150pM and the 
slowest release was with particle size at 250-500ýM. Overall, the best dissolution test 
conditions determined were with DMU212 particle size <150ýM, a rotary speed of 100 
rpm and I% w/v SLS dissolution medium. To establish whether a lower SLS concentration 
could be used in the dissolution media, formulation screening studies were conducted with 
both 0.5 and 1% w/v SLS media to determine the minimum amount of surfactant required 
for 75-80% drug dissolution within 4 hours: 
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Figure 31. Percent DMU212 released with time for capsule formulations in 0.5% w/v SLS dissolution 
medium (n=3). 
Figure 32. Total percent DMU212 released from different capsule formulations in 0.5% w/v SLS 
dissolution medium over 4 hours (n=3). 
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Figure 33. Percent DMU212 released with time for capsule formulations in 1% w/v SLS dissolution 
medium (n=3). 
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Figure 34. Total percent DMU212 released from different capsule formulations in 1% w/v SLS 
dissolution medium over 4 hours (n=3). 
The highest drug release was observed with cap2/50D/L and cap3/50D/S and the lowest 
was with cap4/50D/MS/L and cap5/50D/MS/S with both 0.5 and 1% w/v SLS media. The 
fastest dissolution was with 1% w/v SLS medium, therefore, to establish if sink conditions 
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were maintained throughout these experiments the saturation concentration of DMU212 in 
1% w/v SLS was determined using the UV spectrophotometer and plate reader: 
Table 28. Average DM U212 solubility in I% w/v SLS. 
AVERAGE SOLUBILITY OF 
AVERAGE SOLUBILITY OF 
SOLVENT DMU212 MEASURED ON THE UV DMU212 MEASURED ON THE LTV 
PLATE READER (mg/niL) (n=3) SPECTROPHOTOMEETER (mg/niL) 
(n=3) 
1% w/v SLS 0.091 ± 0.001 0.095 ± 0.005 
The solubility of DMU212 in 1% w/v SLS measured on both the UV spectrophotometer 
and plate reader is two times the concentration of DMU212 that would be observed if 100% 
dissolution was observed. Overall, the formulation screening studies showed the best 
formulations to be those with drug and diluent only. Capsules containing 10mg SLS in the 
formulation, did not dramatically enhance the dissolution rate compared to those without, 
therefore, further dissolution studies were conducted with an increased SLS formulation 
content of I 00mg: 
100.0 
60 0 
cap8/50D/SLS/L 
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Figure 35. Percent DMU212 released with time for different capsule formulations containing diluent 
and 1 00mg of SLS in I% w/v SLS dissolution medium. 
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However, inclusion of I 00mg SLS in the formulation still did not enhance the drug release 
profile extensively compared to formulations containing drug and diluent only. Therefore, 
another strategy was implemented to potentially improve the dissolution rate using oc- and 
P-cyclodextrins as the diluents: 
Iwo 
mo 
MO 
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N 
2 
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20.0 - 
CL 
0.0 
0 50 100 150 200 
Time (mins) 
Figure 36. Percent DMU212 released with time for different capsule formulations containing 
cyclodextrins as the diluent in I% w/v SLS dissolution medium. 
The use of (x- and P-cyclodextrin as diluents and larger quantities of SLS in the capsule 
formulation did not improve the dissolution rate much compared to capsules containing 
DMU212 and either lactose or sorbitol only (Figure 37): 
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Figure 37. Dissolution rate of different DMU212 capsule formulations in 1% w/v SLS dissolution 
medium. 
Since, capsules containing drug and diluent only were the optimum formulations the 
DMU212 drug load was increased from 50mg to 100mg for these capsule formulations and 
similar results were found: 
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Figure 38. Percent D%IU212 released with time for capsule formulations containing 100mg of drug in 
1% w/v SLS dissolution medium (n=3). 
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3.3.2 Dissolution quantification on the UVplate reader 
The experiment was repeated for cap 10/ 1 OOD, cap II/I OOD/L and cap 12/1 OOD/S where 
dissolution samples were assayed on a 96-well UV plate reader to attempt the construction 
of a high-throughput analysis method to improve assay efficiency: 
Figure 39. Percent DMU212 released with time for capsule formulations in 1% w/v SLS dissolution 
medium measured on a UV plate reader (n=3). 
The order of capsule formulation drug release profiles measured on the LJV plate reader 
was the same as those measured on the UV spectrophotometer. Negligible differences were 
found in the dissolution rates measured, with slightly lower release rates observed on the 
UV plate reader. The novel high-throughput assay method was then challenged with a 
conventional compound such as indomethacin: 
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Figure 40. Percent indomethacin released with time for capsule formulations in phosphate buffer pH 
6.4 dissolution medium measured on a UV plate reader (n=3). 
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Figure 41. Percent indomethacin released with time for capsule formulations in phosphate buffer pH 
6.4 dissolution medium measured on a UV spectrophotometer (n=3). 
The difference in the drug release profiles measured on the UV spectrophotometer and 
plate reader was also apparent with indomethacin; however, the rank order of dissolution 
profiles remained consistent, regardless of the assay method. 
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3.3.3 Biological evaluation of cap3150DIS 
The biological activity of cap3/50D/S was evaluated using the MTT assay and compared 
with the parent compound DMU212 and the excipient sorbitol alone: 
125- 
100- MCF7 DMU212 
EI MCF7 TCDD 
'A 75- 
I 
DMU212 
-H 
:F 
MCF7 cap3/50D/S 
50- MCF7 TCDD 
cap3/50D/S 0 
25 MCF7 sorbitol 
MCF7 TCDD 
sorbitol 011 I'M 
control 
10-4 10-3 10-2 10-1 100 10,102 
concentration (pM) 
Figure 42. Cytotoxicity profile of DNIU212, cap3/50D/S and sorbitol in MCF7 with and without TCDD 
induction. 
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Figure 43. Cytotoxicitv profile of DMU212, cap3/50D/S and sorbitol in MDA-MB468 and MCF10A cell 
lines. 
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Table 29. Biological evaluation of DMU212, cap3150DIS and sorbitol. 
MCF7 
MCF7 MCF10A MDA- TUMOUR 
TCDD ACTIVATION 
DRUG IC50 IC50 MB-468 SELECTIVE 
INDUCED FACTOR 
(9NO (PM IC50 (W) FACTOR 
IC50 (PM 
DMU212 20 0.3 66.7 20 0.05 400 
cap3/50D/S 8.4 0.03 280 20 0.01 2000 
Sorbitol >100 >100 I >100 >100 I 
Cap3/5OD/S appears to enhance the activation factor approximately 4 times more than 
DMU212 in the MCF7 assay. The tumour selectivity factor was also enhanced 5 times 
more than DMU212 in the MDA-MB-468/MCFIOA assay. The excipient sorbitol did not 
have toxic effects in either cell-line. 
3.4 Discussion 
Initial dissolution studies conducted in water appeared to show the drug release uniformly 
oscillating with time possibly around the solubility level (Figure 23). Potter and colleagues 
demonstrated a similar phenomenon in the oscillating crystallization of enantiomers during 
resolution [ 182]; tMs theory was used to explain DMU212 oscillation i. e. initially DMU212 
molecules leave the crystal surface and dissolve until a critical supersaturation Point is 
reached (CS). After this point is reached the DMU212 molecules may be driven back out 
of solution to recrystallize until an unsaturation point is reached (U). This process (i. e. 
oscillation) may continue until solution equilibrium is reached (SE), which is the 
then-nodynamic solubility level: 
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To confirm this observation the dissolution study was repeated in water with capl/50D 
whilst observing tighter time points. However, no substantial continuous oscillation 
patterns were observed (Figure 24), suggesting the perceived oscillations were random 
fluctuations attributed to experimental noise, rather than any theoretical solubility 
configuration. Further studies were conducted with standard dissolution media, including 
0.1 M HCI and pH 7.4 phosphate buffer (Figure 25). However, dissolution studies were not 
possible with these media because of DMU212 lipophilicity coupled with its non-ionisable 
nature and poor aqueous solubility (Table 30). 
Dissolution rates were significantly enhanced in media containing surfactants; this is 
because the surfactant acts to lower the interfacial tension and increase the wetting between 
hydrophobic DMU212 and the aqueous dissolution medium to improve media penetration 
into the capsule mass [172]. In fact it has been suggested that use of surfactant media is 
more representative of in vivo dissolution rates for poorly soluble drugs because of these 
reasons i. e. bile salts and lecithin also act as wetting agents in gastric fluid by lowering the 
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interfacial tension [183]. Table 30 shows the efficiency of the DMU212 dissolution 
process with different media: 
Table 30. Dissolution of capl/501) In various media at 100 rpm (n=3). 
MEDIA 
15 
% DMU212 DISSOLVED IN STATED MINUTES 
30 60 120 180 240 
0.121 0.18 4- 0.18d: 0.27 0.31± 0.36 
Water 
0.04 0.02 0.02 0.01 0.06 0.02 
0.25-+ 0.34 ± 0.53 ± 0.53-+ 1.01 ± 1.01 ± 
OAM HCI 
0.14 0.27 0.27 0.11 0.40 0.67 
Phosphate Buffer 0.10± 0.20 ± 0.28 :b 0.3 1 :h 0.37 ± 0.39 ± 
pH 7.4 0.00 0.08 0.09 0.12 0.21 0.15 
2.03 ± 16.08: 1: 41.16 J: 68.78 79.81 ± 83.88 
I% w/v SLS 1.87 8.14 6.04 2.84 0.75 0.06 
9.97 ± 12.35 ± 15.63: 1: 18.80: L 20.78 ± 23.21 
I% w/v Tween 80 1.58 1.02 0.63 0.40 0.31 0.16 
11.43 19.84 ± 32.68 45.62 62.03 ± 73.60 
I% w/v CTAB 0.30 0.01 1.19 5.51 2.53 0.74 
Dissolution studies conducted in 1% w/v non-ionic Tween. 80 resulted in the lowest 
dissolution rates with regards to surfactant media, followed by 1% w/v cationic CTAB. 
During the first 30 minutes of dissolution fastest release was with 1% w/v CTAB medium, 
thereafter and overall the fastest dissolution for capl/50D was exhibited in 1% w/v SLS 
media. Overall, dissolution efficiency with 1% w/v SLS was more than 200-fold better 
when compared with aqueous media such as water, buffers and acids (p<0.05). This 
improvement in solubility may be attributed to SLS lowering the interfacial tension and 
improving the wettability of DMU212, which in turn increases the drug dissolution rate 
[1841. 
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To further maximise the sensitivity of the test conditions the optimum rotary speed was 
determined with 1% w/v SLS and capl/50D (Figure 27). Generally an increase in agitation 
induces a decrease in thickness of the diff-usion boundary layer at the capsule-media 
interface, as well as providing better mixing to prevent the development of static areas 
where localised drug concentrations may arise. A total of 43.98 ± 3.56%, 71.59 ± 1.71% 
and 83.88 ± 0.06% DMU212 was released using stirring speeds of 50,75, and 100 
respectively (Figure 28) (p<0.05). At a rotor speed of 50 rpm the lowest release was 
observed, probably since the boundary layers at the capsule-media interface were stagnant, 
thereby, providing additional resistance to drug diffusion from the capsule mass, since a 
lower drug concentration gradient exists across the boundary layer i. e. non-sink conditions 
exist (Section 3.1.1.2). Optimum drug release rate was observed with a speed of 100 rpm 
and since the dissolution rate for DMU212 appears to be quite slow this agitation speed was 
implemented to potentially increase the rate for future dissolution studies. 
The effect of particle size on DMU212 dissolution rate was also studied (Figure 29) with 
cap]/50D at 100 rpm in 1% w/v SLS dissolution medium. A total of 83.88 ± 0.06%, 60.87 
± 2.20% and 26.54 ± 4.05% DMU212 was released using particle size fractions of 
<150pM, 150-25OpM and 250-5OOpM respectively (Figure 30) (p<0.05). These results 
demonstrate the discriminatory power of the developed dissolution method, since 
differences in drug characteristics such as particle size exhibited measurable differences. 
DMU212 drug release was shown to be particle size dependent, with greatest drug release 
at <150pM, followed by 150-25OpM and finally 250-5OOgM. These results can be 
explained using the Noyes-Whitney equation (Equation 3.1), in which the dissolution rate 
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is directly proportional to the surface area of the drug. In turn the surface area to volume 
ratio increases with decreasing particle size depending on the amount of drug used and 
providing that the drug particles are intimately wetted by the dissolution medium [147], 
which is applicable for DMU212 dissolution. 
Initial formulation screening studies were conducted in both 0.5 and 1% w/v SLS to 
determine the lowest surfactant concentration necessary for 75-80% dissolution within a 
reasonable period of time. The optimum dissolution rates were observed with 1% w/v SLS 
dissolution medium for all formulations and as such DMU212 saturation concentration in 
this medium was determined. The saturation solubility of DMU212 in 1% w/v SLS at 
0.091 mg/mL measured on the UV plate reader and 0.095 mg/mL on the UV 
spectrophotometer is twice the concentration of DMU212 that would be observed if 100% 
dissolution was observed i. e. 0.056 mg/mL. Although sink conditions state that the 
solubility of drug in the media should be five times the intended dose, studies by Brown el 
al state that non-sink conditions are justifiable if the medium provides sufficient 
discriminatory power and reliable data which can only be obtained with addition of 
surfactants [181], both of which are true for DMU212 dissolution. Furthermore, it is more 
important that the proposed dissolution test closely simulate the gastrointestinal milieu than 
necessarily produce sink conditions. 
Nonetheless, in both SLS media, drug release from capl/50D was much lower compared 
with other capsule formulations, thereby indicating the need for other excipients in 
DMU212 capsule formulation to aid drug release. Inclusion of hydrophilic diluents e. g. 
sorbitol or lactose in the formulation enhanced the dissolution rate (Figures 31-34), since 
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the hydrophilic particles in the capsule mass dissolved first in the dissolution medium to 
leave a porous mass of dispersed hydrophobic drug through which the medium could 
penetrate much more easily compared with clumped capl/50D drug particles [172], thereby 
improving the effective drug surface area and therefore the dissolution rate [147]. The best 
dissolution rate was observed with cap3/5OD/S followed by cap2/5ODIL. 
The addition of SLS to the formulation did not significantly improve the dissolution rate 
compared with capsules containing drug and diluent only (p>0.05), even with 50% w/w 
SLS incorporation (cap8/SOD/SLS/L and cap9/SOD/SLS/S) (p>0.05). Therefore, 
incorporation of such a high SLS formulation concentration, which could potentially cause 
patient side effects (Figure 35) was unjustified. The inclusion of magnesium stearate in the 
formulation reduced the dissolution rate significantly even when compared with capl/50D 
i. e. drug alone (p<0.05). These results suggest that strong interactions are formed between 
DMU212 and magnesium stearate (i. e. magnesium stearate may coat the'DMU212 
particles); such that the hydrophobic nature of the drug is ftirther enhanced by a 
hydrophobic excipient, therefore, incorporation of magnesium stearate in the capsule 
formulations was disregarded. Finally capsules containing cyclodextrins 
(capl3/50D/ACYC and capl4/50D/ACYC) did not exhibit faster (Figure 36) dissolution 
rates compared with capsules containing drug and sorbitol/lactose (Figure 37) (p>0.05). 
Overall, capsules containing sorbitol as the diluent gave the optimum release profile with 
the fastest dissolution rate, validated with a DMU212 dose increase from 50mg to 100mg to 
give the same results with a maximum drug release of 85.74 ± 3.89% (Figure 38). These 
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results also demonstrated the robustness of the dissolution method, since the drug release 
profile was more or less the same independent of drug loading. 
The dissolution samples assayed on the UV plate reader (Figure 39) were comparable to 
those determined on the UV spectrophotometer (Figure 38) with optimum difference 
between the two assay techniques being ±10% (p>0.05): 
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Figure 45. Comparison between dissolution samples measured on the UV spectrophotometer and UV 
plate reader for DNI U212 capsule formulations in I% w/v SLS dissolution medium (n=3). 
Capsules assayed on the 96-well LJV plate reader exhibited slightly lower dissolution rates 
compared to measurements on the UV spectrophotometer. Initial differences were thought 
to arise from miniaturisation of dissolution sample volumes; therefore, sample volumes 
used for both assay methods were standardised, however, the results still indicated a 
difference in sensitivity between the two methods of assay. Regardless of the sensitivity 
differences, the order of capsule formulation drug release profiles measured on the LTV 
plate reader was the same as those measured on the LJV spectrophotometer. This 
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phenomenon was also observed with dissolution studies of a conventional compound such 
as indomethacin: 
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Figure 46. Comparison between dissolution samples measured on the UV spectrophotometer and UV 
plate reader for indomethacin capsule formulations in phosphate buffer pH 6.4 dissolution medium 
(n=3). 
The differences measured between the dissolution profiles on the UV plate reader and 
spectrophotometer were not found to be statistically significantly (p>0.05) for either 
DMU212 or indomethacin capsule formulations. Therefore, it is proposed that the UV 
plate reader method be utilised as a high-throughput capsule formulation screening method, 
from which candidate formulations may be determined as validated by the dissolution and 
consequent assay of the conventional compound indomethacin (Figures 40-41). The 
dissolution rate for these formulations can then be validated through conventional UV 
spectrophotometry. 
Biological evaluation of cap3/50D/S compared to DMU212 (Figures 42-43) showed a 4- 
fold increase in the activation factor with a 2.5-fold toxicity enhancement against non- 
induced MCF7 cells and a considerable 10-fold increase in induced cells. The turnour 
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selective factor was also enhanced 5-fold; MDA-MB-468 cytotoxicity was again enhanced 
5-fold, however in the norrml cell line MCFIOA there was no alterations in toxicity. These 
results all suggest that the capsule formulation increases DMU212 cytotoxicity to tumour 
cells; this is probably since sorbitol as the excipient is a nutrient and is therefore enhancing 
the turnour growth cycle and promoting cell death as a consequence. The excipient sorbitol 
alone with an IC50 of more than I OOgM had no influence on cytotoxicity in any cell line. 
On the whole, a dissolution method was developed with optimum test conditions using an 
agitation speed of 100 rpm and 1% w/v SLS dissolution medium at 37.5"C. DMU212 
dissolution was found to be particle size dependant with fastest drug release using a particle 
size fraction of <150gM. Formulation screening studies assayed on both the UV 
spectrophotometer and plate reader showed capsules containing DNM212 and sorbitol only 
to give the fastest drug release, regardless of the initial drug load. Overall, use of the UV 
plate reader for high-throughput capsule formulation screening was also validated from 
which candidate formulations may be determined and a novel application for the MTT 
assay was developed to determine capsule formulation effect on DMU212 cytotoxicity. 
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4.1 Introduction 
In addition to oral administration, another route for administration of chemotherapeutic 
agents is through topical application. The need for topically administered anticancer agents 
has gathered momentum along with the increasing incidence of s1dn cancer [169]; current 
cytotoxic agents most commonly administcrcd topically include 5-FU [185]. The 
advantages of topical chemotherapy include high local drug concentrations for optimum 
therapeutic efficacy, low systemic toxicity, and avoidance of first pass metabolism [169]. 
The major factors which determine the pharmacological response to topically applied drugs 
are the regional differences in skin permeability, the concentration gradient and the 
partition coefficient, all of which drive the rcleasc of drugs from topical formulations and 
most importantly the topical vehicle which influences skin penetration and topical 
bioavailability [ 169]. 
4. LI Topicalformulation 
Topically applied formulations can be classified into liquid (emulsions, solutions and 
suspensions), solid (powders) or semisolid systems [ 186]. Semisolid formulations are the 
most popular of topically applied preparations and are characterised by their rheological 
behaviour which allows them to reside on the skin for longer periods to allow prolonged 
drug delivery at the application site. Advantages of semisolid formulations are case of 
application and the capacity for topical delivery of a wide variety of drugs [ 187]. 
Semisolids are available as a wide variety of formulation types such as ointments, creams, 
gels and pastes, each having unique characteristics. Ointments are greasy, semisolid 
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preparations intended for external application to the skin, they are often anhydrous and the 
drug may be either dissolved or dispersed in the vehicle [186-189]. Ointment bases can be 
broadly classified into hydrocarbons, absorption and emulsifying bases. Hydrocarbon 
bases mostly consist of paraffins, are lipophilic, anhydrous and form an occlusive layer on 
the skin, thereby malcing them useful for dry scaly conditions. Absorption bases, in 
addition to lipophilic components, contain emulsifiers which allow the formulation to 
incorporate water resulting in the formation of water-in-oil (w/o) emulsions. Emulsifying 
bases are similar to absorption bases but can form oil-in-water (o/w) emulsions which make 
them miscible with water. 
Patients prefer creams to ointments as creams are less greasy and easier to apply, they 
consist of medicaments dissolved or suspended in water soluble or vanishing cream bases 
[186-188]. Creams can be defined as ointments which incorporate an aqueous phase to 
form either o/W or w/o emulsions, if the oil droplets are dispersed in water, then the system 
is described as an o/w emulsion; conversely if the disperse phase is water and the 
continuous phase is oily then a wto emulsion exists. Gels are two-phase systems consisting 
of a continuous liquid phase such as water or ethanol thickened by a disperse phase such as 
carbopol and hydroxypropylmethylcellulose to form a three-dimensional structure that can 
entrap large amounts of solvent [147]. Gels can be either water-based (aqueous gels) or 
organic solvent based (organogels). Pastes are stiff ointments which contain a high 
proportion of powder suspended in a fatty base. Because of their consistency, pastes are 
useful in treating highly localised areas of the body; furthermore, they are less greasy than 
ointments since the powder adsorbs some of the fluid hydrocarbons [ 186,188]. 
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The appropriate choice of semisolid vehicle not only involves delivery of the compound to 
the target tissue but also maximises therapeutic efficacy by considering the aetiology of the 
disease and the mechanism of action of the drug [190]. In this context, the formulation 
clearly influences skin penetration and topical bioavailability, therefore, selection of an 
appropriate vehicle is one of the most important parameters in increasing efficacy of a 
topically applied drug [1911. In order to study the influence of the semisolid vehicle on the 
drug release of DMU212, various hydrophilic and lipophilic: vehicles were evaluated in this 
study. These included anhydrous absorption and anhydrous washable (emulsifying) 
ointments, since ointments are occlusive and so are useful for dry lesions [186]. Anionic, 
cationic and non-ionic o/w creams and a w/o cream were also evaluated, since creams are 
generally preferred by patients. 
4.1.2 In vitro release ofdrugsfrom topicalformulations 
The formulation efficacy was determined using an in vitro release test, which serves to 
ensure batch to batch uniformity, to act as a guide for topical formulation during product 
development and possibly to predict in vivo performance. Before a topically applied 
product can be efficacious, it must release the active moiety from the vehicle in order to 
penetrate the skin and exert its effect; these processes are influenced by the 
physicochemical properties of the drug, the vehicle and the skin [191]. With respect to 
skin/membrane permeation this process is most often described by Fick's first law of 
diffusion [147,186]: 
j= dm = 
DCvK 
dt h 
(4.1) 
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Where J is the steady-state drug flux and dmldt is the cumulative amount of drug, m, 
passing through a unit area of membrane as a function of time t, D is the diffusion 
coefficient of the drug, Cv is the concentration of drug in the topical vehicle (concentration 
in the dissolution medium is assumed to be zero with maintenance of sink conditions), K is 
the partition coefficient of the drug between the membrane and the topical vehicle and h is 
the thickness of the membrane. The steady-state flux J can be estimated from the slope of 
the linear portion of a plot of dmldt against time. 
The scenario in which the transport of a drug within the vehicle is the rate-detennining step 
can be described by Higuchi's equations, which are derived from Fick's law [192,193]. 
Higuchi proposed two equations, one in which the drug exists as a solution in the vehicle: 
2CO Dt (4.2) 
and one in which the drug exists as a suspension in the vehicle: 
ý2-TC-o -CS t (4.3) 
Where Q is the amount of drug released per unit area, D is the diffusion coefficient of the 
drug, CO is the initial drug concentration in the topical vehicle, Cs is the saturation 
concentration of drug in the dissolution medium and t is the elapsed time. Irrespective of 
whether the drug is solubilized or suspended in the vehicle, the release should be 
proportional to the square root of time, if the release is governed by Higuchi kinetics. 
The assumptions made in deriving Higuchi's equations were as follows: (1) the drug 
particles are much smaller in diameter than the thickness of the applied layer such that 
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dissolution of the particles is not rate-limiting, (2) the initial concentration of the drug in the 
topical vehicle Cy or CO is much larger than its saturation concentration Cs, (3) the drug 
solubility in the receptor fluid is rapid enough such that dissolution is not rate-limiting, (4) 
sink conditions are maintained, (5) the diffusion coefficient is invariant with respect to time 
or position within the vehicle and (6) only a single drug is present in the vehicle and only 
the drug molecules diffuse into the receptor fluid [147,191,193]. There are many 
physicochemical and experimental factors which can influence Equations 4.1-4.3 and 
therefore the drug release rate. Physicochernical factors include the solubility, diffusion 
and partition coefficient molecular size and shape and concentration of the drug [147]. 
The experimental factors that can influence the drug release rate are the composition of the 
topical vehicle, temperature, agitation and composition of the dissolution medium and the 
membrane [186,191]. The composition of the topical vehicle will directly influence the 
diffusion, partitioning and solubility of the drug within the vehicle, and therefore the drug 
release rate [1941. For example, studies by Rege et al showed that hydrophobic drugs have 
a higher affinity for oleaginous vehicles and therefore have a slower release rate into 
aqueous media [195]. Another major influence on the drug release rate is the 
thermodynamic activity of the drug in the topical vehicle, whereby the maximum release is 
obtained when the drug is saturated (i. e. suspended) in the topical vehicle [186,1911. Only 
the dissolved drug molecules can penetrate the skin, however, as the drug is released from 
the vehicle the suspended drug particles dissolve to replenish the donor phase and therefore 
maintain the driving force for drug release. For this approach to be successful the 
suspended drug particles have to rapidly dissolve in the topical vehicle, and since the 
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dissolution rate is inversely proportional to the particle size (Noyes-Whitney equation), 
then smaller size particles are more likely to replenish the donor phase without introducing 
a dissolution rate-limiting barrier to drug release [186]. 
The temperature at which the in vitro release studies are conducted can influence the drug 
release rate from formulations by altering the viscosity of the vehicle as well as the 
solubilitylpartition coefficient of the drug all of which may affect the diffusion of the drug 
through the vehicle. The experiments are typically conducted at 32"C to reflect ambient 
skin temperature [196]. The degree of media agitation dictates the thickness of the 
diffusion layer at the interface between the dissolution medium and the membrane, an 
increase in agitation can reduce the thickness of this stagnant film to result in an increased 
drug release rate. Another factor that can influence the drug release rate is the drug 
saturation solubility in the dissolution medium (Cs). If the concentration of drug dissolved 
in the dissolution medium does not exceed 10% of the drug saturation concentration, then 
tsink conditions' are said to exist (Section 3.1.1.2), in which a favourable driving force for 
drug release from the vehicle and through the skin is maintained. The standard methods of 
controlling the saturation solubility are to alter the dissolution medium volume and more 
commonly to change the medium composition [191]. 
Most studies use physiologically relevant media such as water or phosphate buffler, 
however, it is also important that the drug has sufficient solubility in the dissolution 
medium to maintain sink conditions and that the medium has'sufficient partitioning 
characteristics to receive the drug. Therefore, lipophilic drugs such as DMU212 are not 
suitable for measurement in this type of media, since they will not readily dissolve or 
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partition into aqueous media [186,191]. In developing an in vitro release test for such 
compounds, dissolution media containing surfactants, aqueous or organic solvents can be 
used [ 197]. For many studies, the latter option has been the most popular, and a wide range 
of compositions of ethanol/water co-solvent systems has been used. Recently, in vitro 
release from corticosteroid ointments was studied using this co-solvent dissolution medium 
with the addition of isopropyl myristate (IPM) in a mixture consisting of IPWwater/ethanol 
in a ratio of 10: 5: 85 [198]. Several investigators have studied the use of IPM as a 
dissolution medium since it has been recognised as a good model compound representing 
skin lipids [194], therefore, when used in combination with ethanol and water the medium 
is more representative of the skin whilst simultaneously acting as a sink [ 19 1 ]. 
The membrane used for in vitro release studies can also dictate the drug release rate from 
topical vehicles. Commonly, skin (i. e. the stratum corneum) is used as the membrane to 
separate the formulation and dissolution medium. However, the constraints in availability, 
together with the variability associated with animal and human skin has instigated the use 
of synthetic membranes [199]. The synthetic membrane selected should not impede or 
control drug diffusion from the formulation to the dissolution medium, but should only 
provide an inert support. It should be sufficiently permeable to the test drug with minimal 
thickness, and exhibit no binding to offer the lowest diff-usional resistance, such that the 
only rate-limiting factor, and therefore the measurable one is drug release from the 
semisolid [200,201]. Synthetic membranes can be used to compare drug release from 
different vehicles; however, to ultimately determine drug absorption, skin would still need 
to be used. 
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To date no universal apparatus, methods or test conditions for in vitro release from 
semisolid dosage forrns have been described in any relevant Pharmacopoeias [202]. 
However, general guidelines given by the FDA [203] describe a method using an open 
chamber diffusion cell system, fitted usually with a synthetic membrane. The semisolid 
dosage form is placed in the open chamber of the diffusion cell and is separated from the 
dissolution medium by a synthetic membrane. Diffusion of the drug from the topical 
formulation and across the membrane is determined by assay of sequentially collected 
samples of dissolution medium to give a time-dependent release profile. 
Currently the most popular method for conducting in vitro release studies is with the use of 
Franz diffusion cells, which consist of a donor and receptor compartment between which a 
horizontally mounted membrane is clamped. The test formulation is applied to the donor 
side of the compartment and the receptor compartment is maintained at the sidn surface 
temperature of 32"C. The dissolution medium is agitated with a magnetic stirrer and 
samples are withdrawn from a side-arm located on the receptor compartment at regular 
intervals [186). This technique tends be complicated and the method does not lend itself 
easily to full automation [204]. 
An alternative technique is the BP paddle-over-disk dissolution apparatus [175] modified to 
accommodate a release cell, where the release cell rests at the bottom of a dissolution 
vessel, with a paddle stirring the dissolution medium above it. The release cell generally 
consists of a sample reservoir and an open screw-on cap to secure the membrane over the 
sample reservoir. One such device is the newly developed Enhancer celITMcomposed 
entirely of Teflon@ containing an adjustable-capacity sample reservoir, a washer for 
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controlling the exposure of the surface area, and an open screw-on cap to secure the washer 
and the membrane over the sample reservoir [187,195,204]. Crucially, studies by Sanghvi 
et al have demonstrated higher cumulative drug release from ointments and greater ease of 
use with the Enhancer celITMcompared with the Franz diffusion cells [205], furthermore, 
similar results were also found by Fares et al who compared the release from in-house gel 
formulations [206]. This technique lends itself to full automation, whilst generating 
reliable release data and using commercially available apparatus, at a relatively low cost 
with better temperature and stirring control than the Franz diffusion cell technique. 
Within the scope of this thesis the drug release of DNW212 from six topical bases each 
possessing different physicochernical properties was studied using a modified BP paddle- 
over-disk dissolution method [175] with an in-house release cell. The method variables 
evaluated were the composition of dissolution medium, agitation speed and the choice of 
the synthetic membrane. 
4.2 Materials and methods 
Reagents were used as received from Sigma-Aldrich Chemical Company (Dorset, UK) or 
Alfa Aesar (Lancashire, UK). HPLC grade water, ethanol, SLS, white soft paraffin, liquid 
paraffin, hard paraffin and cellulose acetate membrane (44pin. thickness) were obtained 
from Fisher Scientific (Loughborough, UK). Hydrous wool fat BP and wool alcohol BP 
were obtained from I M. Loveridge Ltd. (Hampshire, UK). Silicone membrane (thickness 
300wn) was obtained from Samco Silicone Products Ltd. (Nuneaton, UK). DMU212 was 
supplied by K. Ruparelia of the CDDG. 
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4. Zl Topicalformulations 
All formulations were prepared manually whereby the oily phase of the formulation 
(DMU212 (passed through a 150ýtkl sieve), cetostearyl alcohol, white soft paraffin, liquid 
paraffin, hard paraffin, wool alcohol and hydrous wool fat BP) was melted at 600C in a 
porcelain dish over a steam bath. For cream formulations the appropriate aqueous phase 
(sodium propyl p-hydroxybenzoate, sodium methyl p-hydroxybenzoate, phenoxyethanol, 
emulsifier e. g. SLS, cetrimide or tween 60 and water) was also heated at 60"C in a 
porcelain dish and added to the molten oily phase. The formulation was stirred 
continuously to room temperature and the flinal weight of product was checked and adjusted 
with water if necessary. The following formulations were prepared for in vitro studies: 
Table 31. Summary of DMU212 topical formulations: 
-ý'--ý, 
_FORMULATION 
TOPI TOP2 TOM TOP4 TOP5 TOP6 
ow/w) (%W/W) (%W/W) (o/,, W/W) (o/ow/w) (o/ INGREDIENT W/W) 
DMU212 1 1 1 1 1 
Sodium Propylp-Hydroxybenzoate 0.05 0.05 0.05 0.05 
Sodium Methyl p-Hydroxybenzoate 0.15 0.15 0.15 0.15 
Phenoxyethanol 0.8 0.8 0.8 0.8 
Sodium Lauryl Sulphate 2 2 
Cetrimide 2 
Tween 60 2 
Cetostearyl Alcohol 4 27 9 9 9 
Wool Alcohol 6 
Hard Paraffin 15 
Liquid Paraffin 35 6 6 6 40 
White Soft Paraffin 70 35 15 15 15 8 
Hydrous Wool Fat BP 25 
Purified Water (freshly boiled and 66 66 66 29 
cooled) 
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4. Z2 Dissolution media preparation 
See Section 3.2.1. 
4.23 In vitro dissolution studies 
The modified BP paddle-over-disk dissolution test (2003, Volume IV, Appendix X MID 
A249) [175] with an in-house release cell was used for all in vitro dissolution studies. 
Experiments were carried out using a fully automated Pharmatest dissolution flow-through 
system (PT-DT7, Pharmatest Apparatebau GmbH, Hainburg, Germany), equipped with 
paddle stirrers fixed at distance of 23-27mm from the top of the release cell whilst rotating 
at a known fixed speed in the range of 50-200 rpm: 
Flask 
5MmL dissolution 
medium at 32*C 
Paddle Posdion 
23-27mm from 
membrane 
Paddle 
Automated Sampling 
Tubes 
Cellulose Acetate 
Membrane 
Topical Formulation 
Release Cell 
Figure 47. Schematic of the dissolution apparatus. 
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An 8g sample of the test formulation was placed in the reservoir of the release cell. The 
membrane (previously wetted with the dissolution medium for 10 minutes and then patted 
dry) was mounted over the sample and the screw cap secured in place to give a release area 
of 12.6cm2. Care was taken to ensure that no entrapped air was present at the membrane- 
formulation interface. The loaded cell was then introduced into 5OOmL of the dissolution 
medium maintained at a temperature of 32.0'C (-+0.5'C). At specified time intervals 
samples of the dissolution medium were withdrawn using a peristaltic ptunp (Pharmatest- 
P80), assayed automatically on a UV spectrophotometer (Cecil CE 3021, Cecil Instruments 
Ltd., Cambridge, UK) at Ainax of 326nm and then fed back into the system. The method 
variables controlled were the dissolution media, stirring speed and choice of membrane and 
after method development a range of topical formulations were evaluated (Table 3 1). 
4. Z4 Membrane validation 
The possibility of DMU212 binding to the most suitable synthetic membrane was also 
checked by using a 1% w/v DMU212 solution in DMSO to the release rate profile 
experiment (Section 4.2.3), whereby, the topical vehicle was substituted with the solution 
in the release cell at the s=e drug concentration. 
4.2.5 Analysis of dissolution samples 
Dissolution samples were assayed on a UV spectrophotometer at %max of 326nm. 
Calibration curves were constructed from the appropriate medium using a 200 ýtghnL 
DMU212 stock in DMSO to give concentrations in the range 2-20 gg/niL. The calibration 
curves were validatcd through preparation of known concentrations of standards within the 
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calibration range, which were then treated as unknowns and their concentrations were back 
calculated from the calibration curves constructed. The topical vehicle excipients did not 
contribute to the drug absorbance and therefore the drug release, this was demonstrated 
through release studies with all of tested vehicles (Table 3 1) containing no DMU212. 
4.25.1 Calculationsfor drug release data 
The equation of the line for corresponding calibration curves were rearranged to convert 
absorbance into apparent drug concentration in the corresponding sample of dissolution 
medium removed at time t: 
Apparent Concentration of DMU212 (mg/rnL) = 
(Absorbance 
-y Intercept) (4.3) 
Slope 
'Me total amount of dissolved drug present in 500mL of dissolution medium at a given time 
of sampling t was given by: 
Total Amount of 
)= 
(Apparent concentration (mghnL) x 500 
XlOOQ (4.4) 
Drug Released (Itg of drug released at time t 
The drug release per unit area of the membrane at a given time of sampling t was given by: 
Drug Released per unit area (14cm 2 
Total amount of drug released at time t (4.5) 
12.6cm 2 
The drug release rate (vglcmýrnin) or (Vg/cm2mino*5) was calculated from the slope of the 
graph of drug release per unit area plotted against time or the square root of time, according 
to Fick's and Higuchi's equations respectively (Equation 4.1-4.3). 
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4.2.6 Determination of DMU212 saturation concentration in 
dissolution media 
It is important to determine the saturation concentration of the drug in the dissolution 
medium to ensure that sink conditions are maintained. The saturation concentration of 
DMU212 was determined in ethanol/water/IPM solvent mixtures to ensure favourable 
partitioning of DMU212 from a lipophilic topical vehicle to a lipophilic dissolution 
medium. A ternary phase diagram was constructed for the three-phase solvent mixture, to 
determine the optimum mixture for dissolution studies: 
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go 10 
()u 
70 30 
60 V 40 
ETRANOL IPM 
Q5vo vv\ 50) 
/40/40 
\EO 
30 
v 
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V\/\/ 
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M\/V 
90 
0 \A/V\=- \//ý- 100 100 
90 80 70 60 50 40 30 20 10 0 
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Figure 48. A diagram to show the co-ordinates used when plotting a ternary phase diagram to 
determine the optimum DINIU212 solubility In mixtures of ethanol, water and JPM. 
The saturation concentration of DMU212 at each solvent mixture was determined by the 
shake-flask method (Section 2.2.1). 
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4.2.7 Determination of DMU212 saturation concentration in topical 
formulations 
The formulations were prepared with a definite concentration of DMU212 (0.25-2% w/w), 
after having been left for 3 days at room temperature the formulations were examined for 
the presence of DMU212 crystals using a Leica DMIL microscope (London, UK). The first 
concentration at which crystals were observed was taken as the saturation concentration 
[2071. 
4.28 Determination of emulsion type of cream formulations 
Ile emulsion type was determined by incorporation of a water-soluble dye (methylene 
blue) into the aqueous phase of the cream (TOP3-6); the preparations were examined under 
a Leica DMIL microscope. The dye stained the corresponding aqueous phase of the o/w or 
w/o, cream i. e. disperse or continuous phase. 
0 4.2.9 Statistical analysis 
See Section 2.2-5. 
4.3 Results 
Linear data plots for the in vitro drug release studies were obtained by fitting the 
dissolution data to Fick's law (Equation 4.1). The cumulative amount of drug release per 
unit area (gg/cm) was plotted as a function of time (min). The regression coefficients 
were greater than 0.99 in most cases. Initial drug release studies were conducted using a 
range of media to screen for the optimum conditions for drug release: 
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Figure 49. Release of DMU212 from TOM in various dissolution media at 50 rpm and 3211C. 
Figure 50. Release rate (slope of the release/area vs. time plots) of DMU212 from TOP3 in various 
dissolution media over 4 hours. 
DMU212 drug release was minimal with aqueous media such as phosphate buffer pH 7.4 
and 1% w/v SLS. The highest drug release was observed from organic dissolution media 
i. e. ethanol/water and even then only a total amount of 36.47 ± 3.84l. Lg/CM2 or 0.57 ± 0.06% 
was released. Therefore, to develop a method with favourable sink conditions and 
sufficient partitioning characteristics to receive the drug, the saturation concentration of 
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DMU212 was determined in organic solvent mixtures of ethanol/water/IPM using a ternary 
phase diagram: 
Table 32. Saturation concentration of DMU212 in mixtures of IPM, ethanol and water. 
MIXTURE RATIO 
ETHANOL IPM WATER 
AVERAGE SOLUBILITY OF DMU212 
MEASURED ON A UV 
SPECTROPHOTOMETER (jig/mL) (n--3) 
0 0 100 1.34: L 0.22 
10 0 90 1.42 ± 0.07 
20 0 80 2.21 ± 0.24 
30 0 70 4.96 ± 0.41 
40 0 60 24.14±1.47 
50 0 50 92.90 0.76 
60 0 40 196.32 4.93 
70 0 30 435.17±18.81 
80 0 20 742.32127.67 
90 0 10 1341.63 ± 44.59 
100 0 0 1078.45 ± 62.52 
0 100 0 1477.45 ± 26.38 
10 90 0 1716.96 ± 35.72 
20 80 0 1979.15 ± 24.88 
30 70 0 2530.24± 45.25 
40 60 0 2054.87 ± 80.38 
50 50 0 1981.58186.98 
60 40 0 1939.27± 15.56 
70 30 0 1780.03 ± 69.33 
80 20 0 1707.74 ± 84.57 
80 10 10 1591.14± 61.91 
90 10 0 1103.77-119.54 
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Figure 51. DNI L'212 Saturation concentration in mixtures of I PM, ethanol and water (n=3). 
The highest DMU212 solubility was with ethanol/water/IPM in a ratio of 30: 0: 70 and the 
lowest was with 100% water. There were 22 combinations of miscible solvents; the only 
mixture nuscible with all 3 solvents was ethanol/water/IPM in a ratio of 80: 10: 10 (Figure 
52). Although the optimum solubility was found with a mixture of 30% ethanol in IPM, 
use of this medium for numerous drug release studies would be expensive. However, there 
were numerous solvent combinations with saturation concentrations above 1500 ýLg/mL, 
therefore, the solvent combination chosen was ethanoUwater/IPM in a ratio of 80: 10: 10, 
since all 3 solvents %vere utilised, and previous topical studies with corticosteroids by Shah 
et al [198] used a similar combination of ethanol/water/IPM in a ratio of in a ratio of 
85: 5: 10. 
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Figure 52. A ternary phase diagram to show the mixture of ethanol, water and IPM chosen for 
DNI ['212 topical release studies. 
To further maximise the sensitivity of the test conditions the optimum rotary speed was 
determined using ethanol/water/IPM in a ratio of 80: 10: 10 and TOP3: 
250.0 
200.0 
A 200rprn 
150.0 * 150rpm 
N 100rpm 
100.0 75rpm 
A 50rpm 
* 25rpm 
Lo 50.0 
cm 3 
0.0 
0 50 100 150 200 250 
Time (min) 
Figure 53. Release of DMU212 from TOP3 in EtOH: IPM: H20 180: 10: 101 at different stirring speeds 
(n=3). 
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Figure 54. Average release rate (slope of the release/area vs. time plots) of DMU212 from TOM over a 
range of rotor speeds (n=3). 
At a rotor speed of 25 rpm the lowest drug release was observed, from 50 to 200 rpm the 
drug release rate and total amount of drug released were not significantly different. A rotor 
speed of 50 rpm is recommended by BP standards for the paddle-over disk method for 
semisolid formulations; therefore, this speed was implemented. The effect of membrane 
selection on DMU212 drug release rate was also evaluated using TOP3: 
250.0 
E 
ý5200.0 
150-01 A Cellulose 
Acetate 
100.0, Silicone 
50.0 
0.0 
0 50 100 150 200 2 50 
Time (min) 
Figure 55. Release of DMU212 from TOP3 in EtOH: IPM: H20 180: 10: 101 through different membranes 
(n=3). 
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Figure 56. Average release rate (slope of the release/area vs. time plots) of DMU212 from TOM 
through various artificial membranes (n=3). 
The highest drug release was observed with the cellulose acetate membranes and the lowest 
with the silicone membranes and as such the cellulose acetate membrane was chosen as the 
support membrane. In order to ensure that the drug release observed was a factor of the 
formulation only and that the membrane was not rate-limiting a 1% w/v DMU212 solution 
in DMSO was tested in the in vitro set-up: 
000 0 1 . 
AE 
800.0 
r 00 0 A 1% W/V , . aqueous 
DMU212 
solution 400.0 m TOP3 
2000 
cm ........... 
0.0 
0 50 100 150 200 2 50 
Time (min) 
Figure 57. Release of DMU212 from a 1% w/v aqueous solution and TOP3 in EtOH: IPM: HzO 
180: 10: 101 (n=3). 
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The results indicated that 5 times the amount of DMU212 applied from the 1% w/v solution 
had passed through the cellulose acetate membrane, compared with TOP3. These results 
suggest that DMU212 does not bind to the cellulose acetate membrane and that the release 
is governed almost entirely by the formulation itself Overall, the preferred test conditions 
determined were with a rotary speed of 50 rpm, dissolution medium of ethanol/water/IPM 
in a ratio of 80: 10: 10 and a cellulose acetate support membrane. This release method was 
then used to screen the different topical formulations (Table 31): 
Figure 58. Release of DNIU212 from topical formulations in EtOH: IPM: H20 [80: 10: 101 (n=3). 
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Figure 59. Average release rate (slope of the release/area vs. time plots) of DMU212 from different 
topical formulations (n=3). 
The dissolution data for the various formulations was also plotted according to Higuchi's 
law (Equation 4.3), to determine whether fitting the data to Fick's or Higuchi's law affects 
the rank order for the various formulations. The cumulative amount of drug release per unit 
area (ýLg/cm 2) was plotted as a function of the square root of time (mino . 5): 
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Figure 60. Release of DNIU212 from topical formulations in EtOH: IPM: H20 180: 10: 101, plotted vs. the 
square root of time (n=3). 
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Figure 61. Average release rate (slope of the release/area vs. square root of time plots) of DMU212 from 
different topical formulations (n=3). 
Regardless of the law used the highest drug release was observed from TOP3,4 and 5 and 
the lowest was from TOPI, 2 and 6 respectively. TOP3,4 and 5 have the same formulae 
apart from the emulsifier (SLS for the anionic o/w cream, cetrimide for the cationic o/w 
cream and tween 60 for the non-ionic o/w cream), however the differences in drug release 
varied greatly: 
250.0 
200.0- 
X, 150.0- 
ET 
100.0 
50.0 
0.0 
SLS Cetrimide I ween 60 
Emulsifier Type 
Figure 62. Average DMU212 total drug release per unit area from topical formulations as a function of 
emulsifier type (n=3). 
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The highest drug release was with an anionic emulsifier (SLS), followed by a non-ionic 
emulsifier (tween 60) and the lowest drug release was with a cationic emulsifier 
(cetrimide). The saturation concentration of DMU212 in topical bases was also studied to 
determine whether the drug was released from a suspension or a solution system: 
Table 33. DINIU212 saturation concentration in topical bases (n=3). 
SATURATION APPEARANCE UNDER THE 
TOPICAL FORMULATION 
CONCENTRATION (% w/w) MICROSCOPE 
TOM 0.25 Even dispersion 
TOP2 0.25 Strand-like 
TOM 0.50 Droplets 
TON 0.25 Droplets 
TOP5 0.25 Droplets 
TOP6 0.25 Droplets 
The release rate of DMU212 measured in all in vitro studies was from 1% w/v DMU212 
topical formulations. Therefore, the drug release observed was from the drug suspended in 
a base rather than in a solution, since the saturation concentration for all the bases was 
0.25% w/W apart from TOP3 which was 0.5% w/w. Finally, the emulsion type of the 
creams was also determined to check the product integrity. The anionic, cationic and non- 
ionic o/W creams (TOP3-5) were observed as clear globules on a blue background, since 
methylene blue is hydrophilic and water is the continuous phase. The w/o cream (TOP6) 
was observed as blue globules (water) on a clear background. 
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4.4 Discussion 
The release rate of DMU212 fi-om topical formulations was initially determined using 
either aqueous media such as pH 7.4 phosphate buffer and 1% w/v SLS, or organic media 
such as ethanol/water in equal concentrations (Figures 49-50). However, no release was 
observed from TOP3 in any of the aqueous media. This is primarily because of the poor 
aqueous solubility of DMU212 (1.34 ± 0.22 pg/ml, in water) coupled with its high partition 
coefficient (log P of 2.93), which does not thermodynamically favour its release/partition 
from a lipophilic topical vehicle into an aqueous dissolution media. Use of organic media 
such as ethanol/water in a 50: 50 ratio does increase the drug release rate significantly (0.14 
± O. OIPg/cM 2 min) compared to aqueous media (p<0.05), and small amounts of DMU212 
were detected in the dissolution medium (36.47 ± 3.84pglcm 2 over 4 hours). However, this 
quantity is too small to detect any significant differences between the topical formulations. 
Therefore, other organic solvents were evaluated for use as the dissolution medium. 
The saturation conccntration of DMU212 was detennined in organic solvcnt mixturcs of 
ethanol/water/IPM using a ternary phase diagram (Figure 52). Among the different 
solvents evaluated, a mixture consisting of ethanol/water/IPM in a ratio of 30: 0: 70 resulted 
in the highest saturation concentration (2530.24 ± 45.25 ýtglmQ, however, use of this 
media for numerous drug release studies would be expensive. Therefore, a mixture 
consisting of ethanol/water/IPM in a ratio of 80: 10: 10 was chosen as the dissolution 
medium, because firstly a saturation concentration of 1591.14 ± 61.91 pg/mL was obtained 
with this system, secondly this was the only mixture where all 3 solvents were used and 
thirdly previous topical studies with corticosteroids by Shah et al [198] used a similar 
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combination of ethanol/water/IPM in a ratio of 85: 5: 10. The saturation concentration 
measured in this medium was also 300 times the maximum drug concentration measured in 
the drug release studies at 5.27 ± 0.09 pg/mL, therefore, sink conditions were maintained 
since the total drug dissolved in the dissolution medium did not exceed 10% of the drug 
saturation concentration. 
To further maximise the sensitivity of the test conditions the optimum rotary speed was 
determined with ethanol/water/IPM in a ratio of 80: 10: 10 and TOP3 (Figures 53-54). 
Generally an increase in agitation induces a decrease in thickness of the diffusion boundary 
layer at the membrane-receptor interface, as well as providing better mixing to prevent the 
development of static areas where localised drug concentrations may arise. A total of 
124.81 ± 17.64,209.67 ± 3.51,204.03 ± 3.38,214.21 ± 16.14,206.10 ± 17.51 and 198.26 ± 
8.88pg/cm2 was released using stirring speeds of 25,50,75,100,150 and 200 rpm, 
respectively. At a rotor speed of 25 rpm the lowest drug release rate of 0.53 ± 
0.07pg/CM2Min was observed, since the boundary layers at the membrane-receptor 
interface were stagnant and thick, thereby, providing additional resistance to drug diffusion 
from the donor (p<0.05). However from 50 to 200 rpm the drug release rate (Figure 54) 
and total amount of drug released were not significantly different (p>0.05), thereby 
illustrating the ruggedness and reproducibility of the in vitro test system used. At a rotor 
speed of 50 rpm the drug release rate was 0.84 -± 0.01 pg/cm 
2 min, this speed is 
recommended by BP standards for the paddle-over disk method for semisolid formulations 
and was therefore implemented in the in vitro set-up. 
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Release as a function of membrane selection was studied to implement the use of a 
membrane which does not affect drug release, but simply acts as an inert support, therefore, 
ensuring that drug release is dependent on the formulation only (Figures 55-56). A total of 
43.81 : 1: 4.78 and 209.67 ± 3.5 1 ýtg/CM2 was released using silicone and cellulose acetate 
membranes respectively (p<0.05). The slower drug release of 0.19 ± 0.02ý1g/CM2min, 
observed with the silicone membranes was probably due to the increased thickness of the 
membrane at 300gM compared to cellulose acetate at 44ýtm, with which the drug release 
rate was 4 times faster at 0.84 ± 0.0 1 pgIcni 2 min. Silicone membranes are also hydrophobic 
in nature, which may affect the diffusion coefficient of the drug [186], whereas cellulose 
acetate membranes are hydrophilic with hydrophobic properties imparted from pre- 
treatment with IPM, therein more closely reflecting the nature of skin and providing 
justification for use [208]. 
In order to ensure that the drug release characteristics observed were a function of the 
formulation only and that the membrane was not rate-limiting a 1% W/v DMU212 solution 
in DMSO was tested in the in vitro set-up (Figure 57). The experiment was terminated 
after 60 minutes since the maximum possible absorbance on the UV spectrophotometer was 
observed. The total drug release observed was 1095.81 ± 99.22pg/cm2,5 times greater 
than the maximum drug release observed from TOM at 209.67 ± 3.51ltg1cm2 (p<0.05). 
The drug release rate at 14.46 ± I. I Opg/CM2 min was again 17 times higher than for TOP3. 
These results indicate that DMU212 does not adsorb onto the cellulose acetate membrane 
and that the release is governed almost entirely by the formulation itself. 
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Based on these studies the optimal release method determined was with dissolution 
medium of ethanol/water/IPM in a ratio of 80: 10: 10, using an agitation speed of 50 rpm 
and a cellulose acetate support membrane. This release method was used to compare the 
release rate of DMU212 from a lipophilic/anhydrous absorption ointment (TOPI), 
hydrophilic/anhydrous washable ointment (TOP2), anionic o/W cream (TOP3), cationic o/w 
cream (TOP4), non-ionic o/W cream (TOP5) and w/o cream (TOP6) (Figures 58-59). A 
total of 0.62 ± 0.58,10.66 ± 1.33,209.67 ± 3.51,109.68 :b 19.5,136.09 ± 9.89 and 
12.17 ± 3.94pg/CM2 was released using TOPI, TOP2, TOP3, TON, TOP5 and TOP6 
respectively (p<0.05). 
The solubility of DMU212 in the topical vehicles can help to explain the different drug 
release rates. Although, the maximum release is obtained when the drug is saturated (i. e. 
suspended) in the topical vehicle [186,1911, only the dissolved drug can diffuse through 
the membrane. Therefore, it was important to determine the saturation concentration of 
DMU212 in the topical vehicles to detemaine its effect on drug release: 
Table 34. DINIU212 saturation concentration In and average drug release rate from the topical vehicles 
(n=3). 
TOPICAL 
SATURATION AVERAGE RELEASE RATE OF 
FORMULATION 
CONCENTRATION DMU212 FROM DIFFERENT 
(% W/W) BASES (ptg/cm2min) 
TOPI 0.25 0.33 ± 0.17 
TOP2 0.25 1.05 0.65 
TON 0.50 17.93 0.33 
TON 0.25 11.23 1.69 
TOP5 0.25 13.4510.75 
TOP6 0.25 1.16 ± 0.14 
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The drug release observed was from the drug suspended in a base rather than in a solution, 
since the saturation concentration for all the bases was 0.25% w/w apart from TOM which 
was 0.5% w/w. TOM exhibited the greatest solubilizing capacity for DMU212, probably 
due to the presence of SLS in the formulation which can solubilize the drug. Furthermore, 
the optimal release of DMU212 was also from TOP3, suggesting that the release of 
DMU212 is dependent on the concentration of dissolved drug in the topical vehicles. 
Considering the microstructure of the topical vehicles also helps to explain the different 
drug release rates. TOP3,4 and 5 are o/w creams, which have a similar microstructure. 
They can have a complex structure such as a 4-phase system consisting of a hydrophilic gel 
phase, a lipophilic gel phase, an aqueous bulk phase and an internal dispersed lipophilic 
phase [207]. Since, DMU212 is a HPOphilic drug thermodynamically its release would be 
favoured from this hydrophilic base. The poor solubility of the drug in the external 
aqueous environment would lead to fewer drug-vehicle interactions thereby pushing the 
equilibrium towards the drug partitioning out of the vehicle. TOP6 is a w/o cream, where 
water droplets are dispersed throughout a continuous oily phase. The internal water phase 
has less of an affinity for the drug and has no significant influence on the drug diffusion 
and solubility. Tberefore, the activity in the external phase drives the diffusion, however, 
the increased drug-vehicle interactions in the external phase negate the high 
thermodynamic activity require for drug partitioning, leading to a lower drug release rate. 
TOP2 is a hydrophilic/anhydrous washable ointment, consisting of cetostearyl alcohol and 
SLS which form a three-dimensional network to immobilise the liquid and white soft 
parafflin. 71be solubilization of the drug may occur inside emulsifying cetostearyl alcohol 
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[207]. TOPI is a hydrophobic/absorption ointment consisting mainly of white soft 
paraffin, in which the wool fat alcohols are partly suspended and partly dissolved. In this 
vehicle the wool fat alcohol acts as a Iyotropic solubilizing agent [207]. The lower 
thermodynamic activity and therefore slower release rate of DMU212 from both ointments 
is because of the high affinity between the drug and the lipophilic vehicle, which hinders 
partition of the drug from the vehicle to the dissolution medium. Overall the release rate of 
DMU212 was much higher from hydrophilic vehicles incorporating water (TOP3-5), 
compared to lipophilic vehicles (TOP6) containing water, which had little effect on the 
drug release rate compared to the anhydrous bases (TOP 1-2). The drug release from TON 
(209.67 ± 3.5 1 pglcm2) was about 300 times higher compared with release from TOP 1 (0.62 
± 0.58 pg/cm 2) and about 20 times higher compared with TOP2 (10.66 ± 1.33 pg/CM2) and 
TOP6 (12.17 ± 3.94pg/CM2). 
Taking into consideration that TOP3,4 and 5 probably have a similar microstructure and 
the same formulae apart from the emulsifier the differences in total drug released varied 
greatly (Figure 62) (p<0.05). TOM contained the anionic emulsifying agent SLS, TON 
contained the cationic emulsifying agent cetrimide and TOP5 contained the non-ionic 
emulsifying agent tween 60. The highest drug release was with TOM (209.67 -+ 3.51 
ýtg/CM2), followed by TOP5 (136.09: L 9.895gg/cm 2) and the lowest drug release was with 
TON (109.68 ± 19.5gg/cm2). The difference in drug release between TOP3 and TOM is 
almost double showing the greater solubilizing capacity of SLS for DMU212. 
All of the dissolution data were initially plotted according to cumulative amount of drug 
release per unit area vs. time. The plots showed that the cumulative amount of drug 
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released varied in direct proportion with time. Therefore, the release was governed by 
Fick's first law of diffusion (Equation 4.1), where all of the drug release profiles followed 
zero-order kinetics (Figures 49-50 and 53-59), suggesting that the drug release was 
controlled by the membrane. The dissolution data were also plotted according to 
cumulative amount of drug release per unit area vs. the square root of time (Figures 60-61). 
The cumulative amounts of drug released did not vary in direct proportion to the square 
root of time, but were manifest as curves. Therefore, Higuchi's laws (Equation 4.2-4.3) 
were not applicable, suggesting that drug release into the dissolution medium was not 
controlled by the formulation [209). Regardless of the model used to plot the data the rank 
order for the formulations remained unchanged (Figures 58-61). Overall, a TOM > TOP5 
> TON > TOP6 > TOP2 > TOP I rank order was set for release of DMU212 from the 
topical vehicles, based on the total drug released and the release rate of the drug measured 
from the vehicles. 
On the whole, a robust in vitro release test was developed using a modified BP paddle- 
over-disk dissolution method [175] with an in-house release cell, dissolution medium of 
ethanol/water/IPM in a ratio of 80: 10: 10, agitation speed of 50 rpm and a cellulose acetate 
support membrane at 32"C. Formulation screening studies showed the optimum drug 
release of DMU212 to be from an anionic o/W cream. 
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5.1 Introduction 
Development of a universal CYPlBI pharmacophore model that unites known 
chernotherapeutics, CDDG anticancer drugs, natural anticancer compounds and inhibitors 
is advantageous for the design of next generation anticancer prodrugs and may provide a 
better understanding for prodrug mechanism of action. 
5.1.1 CYPIB]pharmacophore construction 
Most studies attempting the construction of pharmacophores use molecular 
modelling/protein sequence homology. Molecular modelling is only functional if the three- 
dimensional crystal structure of the target enzyme is known through X-ray crystallography. 
Once the crystal structure is known, protein sequences with strong sequence homology to 
that of the target protein are compared and aligned onto the crystal structure using computer 
simulations to build a structural model. However, the quality of the model is dependent 
upon the resolved X-ray structure and sequence comparison and alignment quality. 
Early attempts to build CYP models were based on the X-ray crystal structure of P450cam. 
originating from Pseudomonas putida [40]. However, models based on P450cam. are 
unreliable since there is only 15-20% sequence homology with mammalian CYPs leading 
to incorrect sequence alignment with the target protein. Another shortcoming is the 
assumption that the P450carn binding site is identical for all CYPs when actually this is the 
most variable CYP region and specific to each isozyme (210]. A significant step forward in 
the reliability of these models was taken by Williams and colleagues in resolving the crystal 
structure of the first mammalian CYP, rabbit CYP2C5 [211 ]. Consequently, many CYP 
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models were re-modelled using this crystallographic template, due to its increased sequence 
identity to the target protein compared with P450cam. [212]. More recently the availability 
of crystal structures of human CYPs such as CYP2D6 [213], CYP2C8 [214] and CYP3A4 
[215], will likely help to further improve these models [216]. 
The only known CYPIBI model to date, has been developed by Lewis et al [217]. The 
three-dimensional model was based on primary sequence homology with mammalian 
CYP2C5. The relative flatness of the resolved structure led Potter and Tan of the CDDG to 
develop a two-dimensional CYP I B1 model [218]. The model was constructed firstly by 
mapping a range of known anticancer compounds, CDDG prodrugs, flavones, chalcones 
and stilbenes with predefined drug metabolism data. And secondly by mapping a range of 
CDDG inhibitors, whose ability to inhibit CYPIBI was studied using the 7- 
ethoxyresorufin-0-deethylase (EROD) assay. This assay evaluates the ability of CYP 
enzymes to deethylate 7-ethoxyresomfm to form resomfin, which is highly fluorescent and 
can be quantified. Using both these parameters all of the compounds were mapped to 
delineate the CYP IBI pharmacophore model structure. 
The drug molecules were mapped out following two rules: (i) minimal space and (ii) 
mapping the molecules all to one side of the haem to reduce the complexity of the model. 
Both rules wcre based on the assumption that the compound site of metabolism or for 
inhibitors the pyridine ring coordinated to the haem. The minimal space rule involved 
mapping out chalcone compounds as flavanoid conformers to occupy minimal space i. e. in 
the s-trans conformation rather than the s-cis conformation, which is also reported to be the 
more potent chalcone conformation [113]: 
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s-cis confonmtion s-trans conforrmtion 
Figure 63. The chalcone conformations. 
The second rule also utilised the minimal space rule to some degree, where the molecules 
were all mapped out to the left or right of the haem, which is located at the base of the 
pharmacophore. Within the CDDG all compounds studied were mapped to the right of the 
haerw, therefore, the variability of molecular mapping was reduced to result in a less 
complex pharmacophore model. After mapping all of the compounds, the delineated 
CYPIB1 pharmacophore model was shown to contain common areas/hotspots for 
compounds with desirable biological activity. Firstly, two distinct binding pockets i. e. 
horizontal and vertical were identified, where the compounds can bind to the CYPIB1 
active site in a horizontal or vertical binding mode: 
0 
0 
Vertical binding mode Horizontal binding mode 
Figure 64. The horizontal and vertical binding modes of chalcones. 
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Secondly, within the horizontal binding pocket a hydrophobic region was identified, and 
thirdly five hydrogen-bonding residues penetrating into the active site were identified. 
With the discovery of hotspots exclusion zones with common areas of no catalytic 
significance were also defined as *cold spots': 
i 
KEY 
H Hydrogen bonding 
Vertical binding 
residues pocket 
T 
Hydrophobic 
region 
Horizontal 
binding 
pocket 
Fe3+ 
Figure 65. CYPIBI CDDG pharmacophore model [218]. 
The construction of such a pharmacophore model is advantageous for the design of next 
generation prodrugs, by acting as a tool to predict whether a drug candidate will interact 
with a particular CYP isozyme. This could significantly reduce the failure rate in clinical 
trials by identifying potential problems at an early stage of development, to potentially 
reduce the time and money required to bring a new drug to market [216]. This model still 
remains under investigation and continuous refinement as more data is acquired. 
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S. L2 Selection, design and synthesis of CYPIBI activated prodrugs 
The compounds chosen for synthesis and subsequent assay in this study were designed 
from the CYP IBI phannacophore model (Figure 65). The rationale behind the design was 
selective CYPIBI activation as well as use of derivatisable functional groups to enable 
subsequent salt selection and ease of formulation. A series of compounds with a chalcone 
core structure were prepared with a 3,4-methylenedioxy group on the B-ring and an 
imidazole or thiazole substituent on the A-ring. The design of these compounds evolved 
from the CDDG library of novel pyridyl chalcones, where the 3-pyridyl chalcone DMU762 
exhibited one of the most promising anticancer profiles in the MTT in vitro assay. 
T2bIe 35. Summary of DMU762 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
:> 
HUMAN MCF7 MCF7 TUMOUR 
ACTIVATION MDA- 
BREAST WrMOUT WITH MCF10A. SELECTIVE 
FACTOR MB-468 
CELL-LINE TCDD TCDD FACTOR 
IC25 
VALUES 6.0 6.0 1 5.0 0.002 2500 
(4m) 
DMU762 was found to be potently cytotoxic in MDA-MB-468 cancer cells with 
appreciably reduced cytotoxicity in MCFIOA and MCF7 cells with and without TCDD 
induction (Table 35). Both DMU762 and the imidazole and thiazole substituents should 
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theoretically enable salt selection through protonation of the nitrogen to potentially enhance 
the drug physicochemical properties compared to non-ionisable chalcones such as 
DMU135 (Chapter 2). Furthermore, differences in the position of lone pair of electrons on 
the nitrogen will allow the determination of the optimum angle for the nitrogen lone pair of 
electrons to coordinate to the hydrogen bonding residues (Figure 65): 
DMU2145 
0 
0 
> 
0 
DMU2147 
cc N CH3 
DMU2146 
0 
0 
> 
0 
DMU2148 
0 
0 
N, 
> 
0 
s 
DMU2149 
jCH3 
1 
N 
Figure 66. Chemical structures of potential CYPIBI activated prodrugs. 
Chalcones can be readily synthesised by the Claisen-Schmidt aldol condensation reaction 
[219]. This is a base catalysed condensation reaction, which results in the elimination of 
water to yield an ct, p-unsaturated ketone: 
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r-) 0 HO- H 
H H20 
enollsation 
enolate 
0 
Acetophenone 
0 
Lzaldehyde enolate 
OH(-'-ý 
H 
HH 
ýýOH 
OH 
Aldol intermediate 
H2() 
OH- 
Chalcone 
Figure 67. Reaction mechanism for Claisen-Schmidt aldol condensation. 
There first step of the reaction involves proton abstraction, where the acetophenone is 
deprotonated by the base (NaOH) to yield an enolate anion. Secondly, nucleophilic 
addition of the enolate ion to benzaldehyde leads to the formation of an aldol intermediate. 
The final step of the reaction involves dehydration of the aldol intermediate where the 
elimination of a water molecule gives the cc, p-unsaturated chalcone. 
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5.1.3 Selection, design and synthesis of a potentially specific CYPIBI 
prodrug 
The design of the imidazole and thiazole chalcones was based on the CYPIBI 
pharmacophore (Figure 65). These compounds bind to CYPIBI via the vertical binding 
pocket, since the 3,4-methylenedioxy group on the chalcone B-ring co-ordinates to the 
haen-4 as this is the site of metabolism via dealkylation to generate the catechol metabolite. 
As a result these chalcones cannot bind to the CYP IBI active site in the horizontal binding 
mode as this would place the hydrophilic imidazole/thiazole substituted ring in the 
hydrophobic region. The design of a compound in this series, which can bind to both the 
horizontal and vertical binding pockets and the hydrophobic region, could potentially form 
a completely specific CYP IBI activated prodrug with favourable anticancer properties: 
KEY 
H Hydrogen bonding 
Vertical binding residues 
pocket 
Hydrophobic 
N N,, ýý 
region 
I 
++ HYDROGEN BONDIN 
INTERACTION 
Horizontal : 
14- F1 
4--- binding 
pocket 0 
\ 
-0 r 
Figure 68. Mapping of DMU2306 onto the CYPIBI pharmacophore. 
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DMU2306 was synthesised via Claisen-Schmidt condensation of 3,4-methylenedioxy 
acetophenone with Mdazole-2-carboxaldehyde to generate DMU2145. This was followed 
by proton abstraction, where the imidazole ring was deprotonated by the base (2.5M n- 
butyllithium in hexane). Resulting in a resonance stabilised. anion, which underwent a 
nucleophilic substitution reaction with P-chlorophenetole to generate the potentially 
CYP IBI specific anticancer prodrug DMU2306: 
Li 
0 
-0 0> N enolisation Z-' ýNO p, 
lý 
ýo 
, O> 
ý 
/' 0 
DMU2145 
0> 
P-chlorophenetole 
I 
N'.... N.. 
'. '.,,. -... 0 
0 
lzllýý 
DMU2306 
Figure 69. Reaction mechanism for DMU2306. 
5.2 Materials and methods 
Reagents were used as received from Sigma-Aldrich Chemical Company (Dorset, UK) or 
Alfa Aesar (Lancashire, UK). TCDD (2,3,7,8 tetrachlorodibenzo-p-dioxin) was obtained 
from British Greyhound Chromatography (Birkenhead, UK). Silica gel (35-70Vm) and 96- 
well NuncO plates were obtained from Fisher Scientific (Loughborough, UK). Human 
breast cell lines were obtained from the American Type Culture Collection. 
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5.2.1 Analytical methods 
The 1H and 13 C-NMR spectra were recorded on a 40OMHz super-conducting Bruker 
Spectrometer (Karlsruhe, Germany) at 301C. Infrared spectra were recorded in potassium 
bromide disks on a Perkin-Elmer 298 FTIR spectrophotorneter (Massachusetts, USA). 
Mass spectra were recorded on a Finnigan Lasen-nat 2000 MALDI spectrometer (Thermo 
Bioanalysis, Hemel Hempstead, UK). Melting points were determined on a GalIenkamp 
melting point apparatus (Leicestershire, UK). Thin layer chromatography (TLC) was 
performed on aluminiurn sheets pre-coated with silica gel W254 (Merck, Darmstadt, 
Germany) observed under U`V light (450mn) and stained with 2,4-dinitrophenylhydrazine 
(to stain for the carbonyl group). 
5. Z2 Chemical synthesis 
5. ZZI General methodfor synthesis of imidazole and thiazole chalcones 
To an equimolar (eq) quantity of 3,4-methylenedioxyacetophenone (2.00g, 12.18mmol) and 
carboxaldehyde (12-18mmol) in methanol (20mL) was added 20eq of sodium hydroxide 
pellets (9.75g, 243.66mmol). The resulting mixture was stirred at room temperature and 
sequentially monitored by TLC (ethyl acetatelpetroleurn ether/methanol (15: 5: 1) with 3% 
triethylamine) until the reaction was complete. The reaction was quenched with distilled 
water (20mL) and extracted with ethyl acetate (3x5OmL). The combined organic layers 
were washed with saturated brine (50mL), dried with anhydrous magnesium sulphate and 
concentrated under vacuo. The crude product was purified by column chromatography 
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with an isocratic solvent system (ethyl acetate/petroleum ether/methanol (15: 5: 1) with 3% 
triethylamine). 
5. ZZ2 Syn th esis of DMU23 06 
DMU2145 (0.20g, 0.83mmol) was dissolved in dry dimethylforrnamide (lOmL) under 
nitrogen and the solution coole&to -200C. A solution of 2.5M n-butyllithium in hexane 
(0.1 8mL, 0.45mmol) was added slowly and the reaction mixture was stirred for 20 minutes. 
A solution of P-chlorophenetole (43.83g, 279.90mmol) in dry dimethylformamide (IOmL) 
was added. The resulting mixture was stirred at room temperature and sequentially 
monitored by TLC (ethyl acetate/petroleum ether/methanol (15: 5: 1) with 3% triethylamine) 
until the reaction was complete. The reaction was quenched with distilled water (20mQ 
and extracted with ethyl acetate (3x5OmL). The combined organic layers were washed 
with saturated brine (50mL), dried with anhydrous magnesium sulphate, and concentrated 
under vacuo. The crude product was purified by column chromatography with an isocratic 
solvent system (ethyl acetate/petroleum ether/methanol (3: 7: 1) with 3% triethylamine). 
S. Z3 MTT in vitro cyto toxicity assay 
See Section 3.2.6. 
5.3 Results 
A total of 6 imidazole and thiazole prodrugs were synthesised. They were chemically 
evaluated using the techniques described in Section 5.2.1 and their chernical structures, 
physical characteristics and yields are described below: 
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5.3.1 Chemical analysis of imidazole and thiazole chalcones 
1-(3,4-Methylenedioxyphenyl)-3-(IH-2-iniidazolyl)-prop-2-en-1 -one (DMU2145) 
0 
Yellow solid, yield (1.07g, 36%); mp. 220*C; mass spectrum (MALDI) m/z 243.61 (M+ 
1); IR specmm umax (KBr)/crif 1 3225 (N-H), 1653 (C=O); 1 H-NMR (DMSO) 8 6.10 (s, 
2H), 7.10 (d, IH, J=17Hz), 7.40 (s, IH), 7.45 (m, 2H), 7.70 (d, IH, J=17Hz), 7.80 (s, IH), 
7.85 (s, IH), 12.80 (s, IH); 13 C-NMR (DMSO) 6 102.28,107.66,108.35,121.41,124.33, 
130.35,131.41,132.31,143.73,147.84,148.03,152.03,186.76. 
1-(3,4-Methylenedioxyphenyl)-3-(IH4-iniidazolyl)-prop-2-en-I -one (DMU2146) 
&jix> 
Yellow solid, yield (0.67g, 23%); mp. 180*C; mass spectrum (MALDI) m/z 243.93 (M+ + 
1); IR spectrum umax (KBr)lcnf 13182 (N-H), 1648 (C=O); 'H-NMR (DMSO) 8 6.15 (s, 
2H), 7.05 (d, 1H, J=14Hz), 7.50 (s, IH), 7.63 (d, 3H), 7.70 (d, IH, J=13Hz), 7.85 (s, IH), 
12.50 (s, 1H); 13 C-NMR (DMSO) 8 102.14,107.66,108.24,117.98,124.46,132.81, 
134.45,138.16,142.81,148.13,148.73,151.38,187.02. 
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1-(3,4-Methylenedioxyphenyl)-3-(5-methyl-IH-4-imidazolyl)-prop-2-en-1 -one 
(DMU2147) 
CH3 
0 
> 0 
Yellow solid, yield (0.66g, 21%); m. p. 207*C; mass spectrum (MALDI) m/z 257.21 (M+ + 
1); IR spectrum Umax (KBr)/crrf 1 3196 (N-H), 1647 (C=O); 'H-NMR (DMSO) 5 2.55 (s, 
3H), 6.25 (s, 2H), 7.15 (d, IH, J=12Hz), 7.65 (s, IH), 7.75 (d, IH), 7.85 (d, IH, J=14Hz), 
7.90 (m, IH), 7.95 (d, IH), 12.40 (s, IH); 13 C-NMR (DMSO) 8 102.14,107.66,108.24, 
117.98,124.46,132.81,134.45,138.16,142.81,148.13,147.92,151.15,186.60. 
1-(3,4-Methylenedioxyphenyl)-3-(2-thiazolyl)-prop-2-en-l-one (DMU2148) 
0 
Lcrzo> 
Pale orange solid, yield (1.13g, 49%); mp. 143"C; mass spectrum (MALDI) m/z 261.24 
(M+); IR spectrum umax (KBr)/cnfl 1655 (C=O); 'H-NMR (CDC13) 8 6.05 (s, 2H), 6.90 
(d, 1H, J=1511z), 7.45 (d, IH), 7.55 (d, IH), 7.70 (d, IH, J=17Hz), 7.85 (s, 2H), 7.95 (s, 
IH); 13 C-NMR (CDC13)5 10 1.80,107.79,108.33,121.64,124.46,125.11,132.08,134.33, 
144.83,148.12,151.76,164.01,187.18. 
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1-(3,4-Methylenediox)-phenyl)-3-(l-methyl-2-imidazolyl)-prop-2-en-l-one (DMU2149) 
j3 
1 
N 
Yellow solid, yield (1.80g, 77%); m. p. 147C; mass spect-um (MALDI) m/z 257.70 (M+ + 
1); IR spectnmi umax (KBr)/cm7l 1652 (C=O); 'H-NMR (CDC13) 8 3.80 (s, 3H), 6.05 (s, 
2H), 6.60 (d, IH), 7.00 (s, IH), 7.20 (s, 111), 7.58 (d, IH), 7.65 (d, 1H, J=14Hz), 7.75 (m, 
IH), 7.95 (d, IH, J=14Hz); 13C-NMR (CDC13) 8 32.96,101.91,107.90,108.23,123.14, 
123.86,125.03,127.03,130.32,132.55,143.80,148.33,151.93,187.25. 
5.3.2 Chemical analysis ofDMU2306 
1-(3,4-Methylenedioxyphenyl)-3-1(2-phenoxy-ethyl)-2-imidazolyll-prop-2-en-l-one 
(DMU2306) 
N N-.. 
Pale yellow solid, yield (0.06g, 20%); mp. 174*C; mass spectrum (NIALDI) m/z 363.20 
(m' + 1); IR spectrum umax (KBr)/cm-1 1663 (C=O); 'H-NMR (CDC13) 8 4.20 (t, 2H), 
4.60 (t, 2H), 6.00 (s, 2H), 6.80 (d, 1H), 6.85 (t, 2H), 6.90 (d, IH), 7.20 (t, 3H), 7.40 (s, IH), 
7.55 (d, IH), 7.75 (d, IH), 7.85 (d, IH, J=14Hz), 7.95 (d, IH, J=14Hz); 13 C-NMR (CDC13) 
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6 44.62,64.34,99.27,105.43,105.76,111.66,111.68,118.60,122.41,123.24,125.50, 
126.78,126.98,127.08,127.84,142.84,145.57,149.28,155.20,155.33,193.60. 
5.3.3 Biological evaluation of imidazole and thiazole chalcones 
All synthesised compounds were biologically evaluated with the in vitro NITT assay using 
the CDDG in-house breast cell panel of MCF7, MDA-MB-468 and MCFIOA: 
125 
--w- MCF7 TCDD 
DMU2145 
too- I"' IC50=26 4M 
MCF7 
75- DMU2145 
IC50=29 pM 
H0 
50 0 
25 NI,, 
O> 
0Q control 10' 10' 10 2 10.1 10,101 102 
concentration (ILM) 
Figure 70. Cytotoxicity profile of DMU2145 in MCF7 with and without TCDD induction. 
125- 
468 DML12145 
100- 
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1 OA DMU2145 
75- lC50=28 gM 
50- 
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01, 
control 10' 10-1 10-1 1 101 102 
concontration (pM) 
Figure 71. CýIotoxicitv profile of DMU2145 in MDA-MB468 and MCF10A cell lines. 
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Figure 72. Cytotoxicity profile of DMU2146 in MCF7 with and without TCDD induction. 
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Figure 73. Cytotoxicity profile of DMU2146 in MDA-MB468 and MCFIOA cell lines. 
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Figure 74. Cytotoxicity profile of DMU2147 in MCF7 with and without TCDD induction. 
Asma Patel 
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Figure 75. Cytotoxicity profile of DMU2147 in MDA-MB-468 and MCF10A cell lines. 
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Figure 76. Cytotoxicity profile of DMU2148 in MCF7 with and without TCDD induction. 
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Figure 77. CytotoxicitY profile of DMU2148 in MDA-MB468 and MCFIOA cell lines. 
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Figure 78. Cytotoxicity profile of DMU2149 in MCF7 with and without TCDD induction. 
125- 
E 100- r 
--0-468 DMU2149 
IC50=2.4 pM 
44 75- 1 OA DMU2149 F 
IC5o= 11.5 gM '79 50- 0 
9Hý 0 
0 
25- 
0- 
control 10' 10-3 10-2 10-1 100 101 1w 
concentration (I&M) 
Figure 79. Cytotoxicity profile of DMU2149 in MDA-MB-468 and MCF10A cell lines. 
Table 36. Biological evaluation of a series of imidazole and thiazole chalcones. 
DRUG 
MCF7 
IC50 
(PM 
MCF7 TCDD 
INDUCED 
Icso (ý, M) 
ACTIVATION 
FACTOR 
MCFIOA 
IC50 GLM) 
MI)A- 
MB-468 
IC50 ([tM) 
TUMOUR 
SELECTIVE 
FACTOR 
D LJ2145 29 26 1.1 28 6.2 4.5 
DMU2146 19 17 1.1 20 20 1 
DMU2147 45 45 1 >50 >50 1 
DMU2148 1.84 0.83 2.2 5.5 1.3 4.2 
DMU2149 9.8 6.5 1.5 11.5 2.4 4.8 
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None of the imidazole and thiazole chalcones showed activation in the MCF7 assay. 
However, a small amount of bioactivation was observed for DMU2145 and DMU2149 in 
MDA-MB-468 cells compared to MCFIOA cells suggesting selective CYPIBI 
bioactivation. 
5.3.4 Biological evaluation of DMU2306 
DMU2306 exhibited no activation in MCF7 cells, however, slight bioactivation was 
observed in MDA-MB-468 cells compared to MCF10A cells: 
125- 
MCF7 TCDD 
100- 
DMU2306 
E IC50=20 pM 
75- MCF7 DMU2306 IC50=20 pM 
50- N, N,, ý 0 
25- 
0 
0- 
1 control 104 10-3 10-2 10-1 too 
0 
101 1V 
concentration (gM) 
Figure 80. Cytotoxicity profile of DMU2306 in MCF7 with and without TCDD induction. 
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a 25- 
00 
0- 0) II-,, 
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\-O 
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Figure 81. Cytotoxicity profile of DM U2306 in M DA-M B468 and MCFI OA cell lines. 
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Table 37. Biological evaluation of DMU2306. 
MCF7 
MCF7 
DRUG IC50 
TCDD 
(AM 
MUCED 
MCFIOA 
ACTIVATION 
MDA- 
TUMOUR 
MB468 
SELECTIVE 
IC50 
FACTOR 
icso 
FACTOR 
(PM 
icso (AM) (9m 
DAW2306 20 20 1 19 8 2.4 
5.4 Discussion 
Five imidazole/thiazole prodrugs were synthesised successfully using Claisen-Schmidt 
condensation, with good yield. The highest yields were obtained for DMU2149 (77%) and 
DMU2148 (49%) and the lowest were with DMU2147 (210/6), DMU2146 (23%) and 
DMU2145 (36%). These values correlate with the overall reaction times required for the 
individual reactions to proceed to completion where reactions that proceeded the fastest 
gave compounds in the highest yield. Both DMU2149 and DMU2148 reaction times were 
4 hours, whereas the DMU2145 and DMU2146 reactions proceeded within 24 hours. The 
slowest reaction at 28 hours and consequently the lowest yield were both observed for 
DMU2147. All of the compounds were afforded as yellow solids. The highest melting 
points were observed for DMU2145 (220'C), DMU2147 (207'C) and DMU2146 (180'C). 
The lowest melting points were observed with DMU2148 (143"C) and DMU2149 (147'C). 
All of the synthesised chalcones were analysed by 1H-NMR, 13 C-NMR and infrared 
spectroscopy. The 1H-NMR spectra confmned the enone structure of the chalcones with a 
set of doublet peaks between 5 6.90-7.95, with a coupling constant J between 12-17Hz, 
thereby confmning the trans double bond in the chalcone structure. The presence of the 
3,4-methylenedioxy group was confirmed by a characteristic singlet peak observed between 
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8 6.00-6.25 and the NH groups in DMU2145, DMU2146 and DMU2147 were confirmed 
with broad peaks between 8 12.40-12.60. The 13 C-NMR spectra showed a characteristic 
carbonyl peak between 8 187.25-186.60. Infrared spectroscopy also demonstrated the 
characteristic carbonyl peaks between 1647-1655crn7l and characteristic NH peaks between 
3225-3182 cm". Mass spectroscopy of the chalcones showed that the desired compounds 
were synthesised as they all showed M' or M++1 peaks. 
DMU2306 was synthesised. successfully by deprotonation of DNW2145 followed by 
nucleophilic substitution with 0-chlorophenetole, the overall reaction proceeded fairly 
slowly with a reaction time of 45 hours. The product was synthesised in a 20% yield as a 
pale yellow solid with a melting point of 1470C. 'H-NMR spectra confirmed the enone 
structure of the chalcone with a set of doublet peaks between 8 7.85-7.95, with a coupling 
constant J of 14Hz, thereby confirming the trans double bond in the chalcone structure. 
The presence of the 3,4-methylenedioxy group was confirmed by a characteristic singlet 
peak observed at 8 6.00. The 
13 C-NMR spectra showed a characteristic carbonyl peak at 8 
193.60; infrared spectroscopy also demonstrated the characteristic carbonyl peak at 
1652ciTf 1- Mass spectroscopy of the compound showed that the desired compound was 
synthesised with an M++l peak. 
The rationale for selective CYP IBI prodrug bioactivation was substantiated to some degree 
as none of the prodrugs exhibited any discernible activation in MCF7 cells with or without 
CYPIAI induction. However, in MDA-MB-468 cells DMU2145 and DMU2149 showed 
enhanced cytotoxicity towards turnour cells 5-fold compared to MCF 1 OA non-turnour cells. 
But, the tumour selectivity factor was reduced compared to DMU762, which has a 2,500- 
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fold selectivity factor at IC25 suggesting that the 3-pyridyl substituent in the 'A' ring 
instigates superior biological activity compared to the 2-imidazole substituent. 
The other imidazole prodrugs DMU2146 and DMU2147 were non-toxic in all breast cell- 
lines at pharmacologically acceptable dosages. Comparison of these 4-imidazole prodrugs 
to the 2-imidazole versions (DMU2145 and DMU2149) led to the generation of a structure 
activity relationship (SAR). Where, the translocation of nitrogen from 2 to 4-imidazole 
resulted in elimination of CYPIBI mediated tumour cytotoxicity. Mapping DMU2145 
onto the pharmacophore may explain this; alignment of the prodrug to the hotspots shows 
that the lone pair of electrons on the nitrogen form hydrogen-bonding associations with one 
of the hydrogen-bonding residues. Translocation of the nitrogen to the 4 position in 
DMU2146 changes the alignment to eradicate this hydrogen-bonding association: 
Vertical binding 
pocket 
H 
KEY 
H= Hydrogen bonding 
residues 
HYDROGEN BONDING 
i 
4k INTERACTION 
Hydrophobic 
region 
I Horizontal 
binding 
pocket 
Figure 82. DM U2145 mapping to show hydrogen-bonding interaction associated with 2-imidazoles. 
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Figure 83. DM U2146 mapping to show no hydrogen-bonding interaction associated with 4-imidazoles. 
For DMU2147 although the methyl group at the C2 position is electron donating, the 
electron-density is much lower than nitrogen. Therefore the ]one pair of electrons is 
donated to the nitrogen in the imidazole heterocycle and is no longer available for 
hydrogen-bonding. The thiazole prodrug DMU2148 also showed a 4.2-fold enhancement 
in cytotoxicity towards tumour cells. However, the sulphur at the C2 position in DMU2148 
does not have an available lone pair of electrons to form hydrogen-bonding associations. 
Therefore, the bioactivation may be due to the increased lipophilicity incurred on the drug 
from the sulphur group, which could improve transport across the cell membrane. Overall, 
in MDA-MB-468 cells DMU2149 showed enhanced cytotoxicity towards tumour cells 4.8- 
fold compared to MCF I OA non-tumour cells, whereas DMU2145 had a CYP IBI activation 
factor of 4.5. The slight enhancement in cytotoxicity for DMU2149 could be due to the 
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extra methyl group attached to the nitrogen in the imidazole heterocycle, which may 
enhance the drug lipophilicity. 
The discovery of 2-imidazole CYPIBI selectivity led to the development of DMU2306, a 
potentially selective CYPIBI activated prodrug which satisfies most hotspots in the 
CYPIBI pharmacophore (Figure 68). DMU2145 and DMU2149 alone exhibit 5-fold 
CYPIBI turnour selectivity, therefore with the attachment of an extra aromatic group to 
locate in the hydrophobic region of CYP IB1, the cytotoxicity should theoretically improve. 
However, introduction of the aromatic group in DMU2306 actually halved the bioactivation 
in comparison with DMU2145 and DMU2149, with a 2-fold CYPlBI turnour selectivity 
factor (Figure 81). Mapping of DMU2145, DMU2149 and DMU2306 onto the 
pharmacophore may explain this: 
Vertical binding 
pocket 
H 
: 
DMU2145 OMU2149 
KEY 
H= Hydrogen bonding 
residues 
HYDROGEN 
BONDING 
IKIT=DAf'Tif%kl 
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----------- 
Z416&MI, 
Figure 84. Mapping of DMU2145, DMU2149 and DMU2306 onto the CYPIBI pharmacophore. 
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The mapping shows the importance of the hydrogen bonding interaction near the upper part 
of the hydrophobic region for CYP IBI bioactivation. In fact this interaction is even more 
important than satisfying the hydrophobic region, as was shown with DNIU2306. 
However, manipulation of either DMU2145 or DMU2149 such that the lone pair of 
electrons on the imidazole nitrogen is still available for hydrogen-bonding associations, 
whilst also satisfying the hydrophobic region may result in a more potent compound. An 
example of such a compound may be DMU2149 with a hydrophobic aromatic group 
attached to the carbon-2 atom of the enone structure as described by DucId et al [ 113]. 
Overall, optimum bioactivity was shown with the 2-imidazole prodrug DMU2149 and 
since rationale behind the design of these compounds was selective CYPIBI activation as 
well as use of derivatisable fimctional groups to enable subsequent salt selection, 
DMU2149 will undergo salt screening studies (Chapter 6). 
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6.1 Introduction 
Rarely do NCEs possess the desired physicochemical properties such as solubility, 
dissolution rate, stability and hygroscopicity to enable formulation for a therapeutic effect. 
If the NCE contains ionisable functional groups, salt form selection can be considered to 
optimise these properties, consequently it is frequently an essential component of the 
preformulation process (220]. 
Salt selection as a means of improving solubility and bioavailability is considered when 
drug solubility is less than I mg/mL. The salt usually renders the parent compound ionised 
in water i. e. water-soluble and therefore suitable for pharmacoldnetic studies using 
parenteral formulations [221]. Salt synthesis involves reaction between an acid and a base 
where proton transfer or neutralisation occurs, the strength of the components determines 
the probability of salt formation. 43% of FDA approved weakly basic drugs are marketed 
as hydrochlorides and 63% of weakly acidic drugs are marketed as sodium salts [222]. 
The salt forming species are often chosen based on the acidity/basicity of the NCE. For a 
basic compound studying the pH-solubility relationship can indicate whether it will exist as 
the free base or form a salt under certain pH conditions [221]. The pH-solubility profile of 
a basic drug can be expressed as two independent curves where the point of intersection is 
described as the pH of maximum solubility (pH,,,,,,, ) [223]. This relationship can be 
explained by Equations 6.1 and 6.2 [221,224]: 
pH > pH.,, : ST = [BH'] + [B], = [B], I+) (6.1) 
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pH < pH.. 
ST = [BH'I, + (B] = [BH']., I+ 
Ka 
(6.2) 
[H30+1 
Where ST is the total saturation solubility of the drug at any given pH, [B] and [BH] are 
concentrations of free and protonated species of the base, respectively and the subscript s 
represents a saturated species. Each of these equations represents an independent curve in 
the pH-solubility profile for a monobasic drug: 
Figure 85. Schematic representation of the pH-solubility profile of a monobasic drug, showing that the 
solubilities of the base and salt can be expressed by two Independent curves corresponding to two 
Independent equations [221). 
There are two key regions in the pH-solubility profile described above, salt formation will 
only occur if the pH of the aqueous solution of basic drug is adjusted below its pH,,., and 
if the pH of the saturated salt solution is raised above this level the salt will be reconverted 
to the free base. Therefore, the counter-ion chosen for salt selection must be suitable to 
achieve pH conditions below the pH., for a basic compound the pKa of the chosen 
conjugate acid should be lower than the parent compound. The most common criterion for 
selection of counter-ions was proposed by Tong et al (224], who recommended that, for the 
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preparation of salts of a basic drug, the pKa of the conjugate acid should be at least two pH 
units lower than the pKa of the drug. Empirical selection can also be used as described by 
Gould [225) in the preparation of salts from planar, high melting point aromatic sulfonic or 
hydrocarboxylic acids which yielded high melting crystalline salts, whereas flexible 
aliphatic acids yielded oils. However, in general no guidelines exist for salt selection 
during drug development, literature range is limited and selection is normally based on 
experience. Within the scope of this thesis, salt screening studies were conducted for the 
anticancer prodrugs DMUS90 and DMU2149. The salt screening method used in this study 
was a three-tiered approach, with progression to the next stage resulting from failure of the 
previous stage i. e. (i) inorganic mineral acids, (ii) organic aliphatic and olefinic acids and 
(iii) organic aromatic acids. 
6.1.1 DMU590: A morpholinoprodrug 
The clinical potential of the novel trans-stilbene prodrug DMU212 has led to the evolution 
of a library of novel CDDG prodrugs with the core DMU212 molecular skeleton. The 
cytotoxicity of these compounds was screened in the MTT in vitro assay, where the cis- 
stilbene analogue of DMU212 - DMU590 exhibited optimum anticancer activity. 
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Table 38. Summary of DMU590 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
1 
meo ', 
o 
1 
meo OMe 
Oý'ýN 
HUMAN MCF7 MCF7 TUMOUR 
ACTIVATION MDA- 
BREAST WIMOUT WITH 
FACTOR 
MCF10A 
MB-468 
SELECTIVE 
CELL-LINE TCDD TCDD FACTOR 
IC50 
VALUES 0.7 0.08 8.6 so 0.01 5000 
(RM) 
DMU590 was found to be potently cytotoxic in MDA-MB-468 cancer cells with 
appreciably reduced cytotoxicity in MCFIOA and MCF7 cells with and without TCDD 
induction (Table 38). DMU590 was a more potent anticancer prodrug than DMU212, with 
CYP IB I -activation factors of 5000 and 4300 respectively. This improvement in 
cytotoxicity may correspond to the increased likeness in structure between DMU590 and 
the antimitotic stilbene CA-4, which would theoretically increase its antimitotic activity 
(Figure 13). Furthermore, the morpholine, substituent on DNW590 should theoretically 
improve the solubility and also enable salt selection through protonation of the nitrogen to 
enhance the drug physicochemical properties compared to DMU212. 
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6.1.2 DMU2149: An imidazoleprodrug 
A library of imidazole/thiazole, chalcones were prepared to enable salt selection of a 
specific CYP IBI activated prodrug (Chapter 5). The compounds were designed from the 
CDDG designated CYP IBI pharmacophore model (Figure 65) and the core structure of the 
3-pyridyl chalcone DMU762. The cytotoxicity of these compounds was screened in the 
MTT in vitro assay, where the 2-in-ýidazole chalcone DMU2149 exhibited optimum 
anticancer activit)r 
Table 39. Summ2ry of DMU2149 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
0 
CH3 NZ 0 
c 
1 
N> 
z0 
N 
HUMAN MCF7 MCF7 TUMOUR 
ACTIVATION MDA- 
BREAST WITHOUT WITH MCF10A. SELECTIVE 
FACTOR MB-468 
CELL-LINE TCDD TCDD FACTOR 
icso 
VALUES 8 8 1 11.5 2.4 4.8 
(vM) 
DMU2149 was specifically bioactivated in MDA-MB-468 cells, with no activation 
observed in MCF7 cells with or without CYP induction. Moreover, protonation of the 
nitrogen in the imidazole heterocycle can facilitate its salt selection to enhance the drug 
physicochenlical properties compared to DMU762- Although DMU2149 is significantly 
less active compared to all of the other lead CDDG prodrugs, it was synthesised 
specifically within this thesis to enable salt selection. Within the scope of this thesis salt 
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selection studies were conducted for both DMU590 and DMU2149. The aqueous solubility 
of the salts was determined to consider the feasibility for ftirther development and the salts 
with the lowest solubility were eliminated. A comprehensive physicochemical and 
biological analysis of the selected salts was conducted using pH-solubility profiles, DSC, 
SEM and the MTr assay. High-throughput analytical quantification methods were also 
developed for pKa determination of DMU590 and DMU2149 using a UV plate reader. The 
novel technique was corroborated using conventional compounds (indomethacin) and a 
conventional assay (UV spectrophotometer). 
6.2 Materials and methods 
Reagents were used as received from Sigrna-Aldrich Chemical Company (Dorset, UK) or 
Alfa Aesar (Lancashire, UK). TCDD (2,3,7,8 tetrachlorodibenzo-p-dioxin) was obtained 
from British Greyhound Chromatography (Birkenhead, UK). 96-well Nunc(& plates were 
obtained from Fisher Scientific (Loughborough, UK). Human breast cell lines were 
obtained from the American Type Culture Collection and DMU590 was supplied by T. Ijaz 
of the CDDG- 
6.2.1 Salipreparation 
The general salt formation procedure was to prepare an equimolar quantity of prodrug and 
salt forming species i. e. acid in an appropriate solvent (ethanol, methanol, acetone, 
acetonitrile, 2-propanol, toluene, ethyl acetate or dichloromethane) and allow the mixture to 
react/stir for a defmed time to allow crystallization. If this did not occur within a 
reasonable time further techniques were used to initiate crystallization e. g. cooling the 
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n-dxture, evaporation of solvent and addition of anti-solvents e. g. diethyl ether and hexane 
to decrease solubility [221,226]. The following acids were employed for attempted 
DMU590 and DMU2149 salt formation: 
Table 40. Acids used In attempting DMU590 and DMU2149 salt selection. *pKa values obtained from 
[221]. 
ACID DMU590 
pKa(s) ACID DMU2149 SALT? TYPE SALP 
Yellow solid HCI Mineral, 
-6.0 No formed in 70% Hydrochloric Acid inorganic 
(0.08g) yield 
White solid 
1.96, Yellow solid H3PO4 ý&neral, formed in 
7.12, formed in 65% 
Phosphoric Acid inorganic 84% (0.52g) 
12.32 (0.09g) yield 
yield 
Yellow solid H2S04 Nfineral, -3.0, No formed in 87% 
Sulphuric Acid inorganic 1.92 
(0.12g) yield 
r COOH 
3.13, 
HO-C-COOH Organic, 
4.76, No No 
aliphatic 
COOH 6.40 
Citric Acid 
Hoocý'-ýYCOOH 
Organic, 
2.19, 
NH2 4.1) P% 
aliphatic 5 
No No 
9.67 
L-Glutarnic Acid 
COOH 
HOOC 
OH 
Organic, 3.46, 
No No 
aliphatic 5.10 
(-)-L-Malic Acid 
De Monýort UniversitY 175 
Salt Selection Studies oflonisable Prodrugs Asma Patel 
Yellow solid CH3S03H Organic, 
-1.20 No formed in 80% Methanesulphonic Acid aliphatic (0.11g) yield 
COOH Pale yellow solid I Organic, 1.27, 
L; Uurl No formed in 67% 
aliphatic 4.27 
Oxalic Acid (0.09g) yield 
"3C Organic, 
4.90 No No 
Stearic Acid aliphatic 
HOOC"""ý 
COOH Organic, 4.21, 
No No 
aliphatic 5.64 
Succinic Acid 
T OOH 
-OH H Yellow solid T Organic, 3.02, 
HO- H No formed in 54% T 
aliphatic 4.36 
COOH (0.09g) yield 
L-Tartaric Acid 
COOH H 
Yellow solid 
( 
I 
Organic, 3.03, 
No formed in 55% 
HOOC H olefinic 4.38 
(0.08g) yield 
Furnaric Acid 
H: ýCOOH 
I I Organic, 1.92, 
Yellow solid 
H COOH olefinic 6.23 
No formed in 75% 
(0.11g) yield 
Maleic Acid 
H3 Cý-ýý', 
-, -, -, ^, -`cooH Organic, 4.0 No No 
olefinic 
Oleic Acid 
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COOH 
Organic, 
4.30 No No 
aromatic 
NHCOCH3 
4-acetamidobenzoic acid 
a 117: zt COOH 
Orgamc, 
It" 3.50 No No OCOCH3 
aromatic 
Acetyl Salicylic Acid 
0 
OH Organic, 
4.19 No No 
e 
aromatic 
Benzoic Acid 
HO COOH Yellow solid Organic, 
aromatic 
2.93 No formed in 30% 
Gentisic Acid 
(0.02g) yield 
N COOH Organic, 
1 3.55 No No H aromatic 
Hippuric Acid 
H OH 
HOOC COOH 
Organic, 2.51, 
aromatic 3.10 
No No 
Pamoic Acid 
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,,,, 
CH2COOH 
Organic, 
4.28 No No 
aromatic 
Phenyl Acetic Acid 
0 
NH Organic, 
1.80 No No 
S02 aromatic 
Saccharin 
k'AOH Organic, 2.97, 
No No 
aromatic 13.82 
Salicylic Acid 
a OOH 
, 
cu 
S03H 
Organic, 
Yellow solid Cr 
aromatic 
0.70 No formed in 43% 
Bcnzenesulphonic Acid 
(0.07g) yield 
S03H 
Organic, 
0.17 No No 
aromatic 
Naphthalene-2-sulfonic Acid 
S03H 
Organic, 
Yellow solid 
H3C 
aromatic 
1.34 No formed in 69% 
para-Toluenesulfonic Acid 
(0.12g) yield 
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6. Z2 Determination of solubility 
See Section 2.2.1. 
6. ZZ1 Detennination of thepH-solubilityprofile 
The buffer systems used for the pH-solubility profile were lOmM acetate with pH range 
24, lOmM phosphate with pH range 4-8 and lOmM glycine with pI4 range 8-12. 
Depending on the initial pH, either IM NaOH or HCI was used to adjust the pH measured 
using a SevenEaSyTm benchtop pH meter (Mettler-Toledo Inc., Ohio, USA). The saturation 
concentration in these buffer systems was determined by the shake-flask method. 
6. ZZ2 Detennination of thepKa 
The measurement of the pH-solubility profiles was also used to detennine the pKa of the 
ionisable compounds. The equations used for pKa detennination for the acids and bases 
respectively were as follows [227]: 
pH=pK. + log 
S-SO 
(6.3) 
( 
so 
) 
pH = pK,, - log(S - 
So 
(6.4) ( so 
) 
Where So is the solubility of the unionised form of the drug in water and S is the observed 
solubility of the drug at different pH values. Plots of pH versus log [(S - SO)y SO) were 
constructed and the intercept on the pH axis was taken as the pKa value. 
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6. Z3 Differential scanning calorimetry 
See Section 2.2.3. 
6.2.4 Scanning electron microscopy 
See Section 2.2.4. 
6.2 5 MTT in vitro cytotoxicity assay 
See Section 3.2.6. 
6.3 Results 
6.3.1 Determination of solubility andpKa 
6.3.1.1 Determination of DMU590 solubility andpKa 
The aqueous solubility of DMU590 was 120 times higher compared with DMU212 and the 
solubility values measured on the UV plate reader and spectrophotometer were the same: 
Table 41. Average solubility of DMU590 In water measured at 221 20C. 
AVERAGE SOLUBILITY OF 
AVERAGE SOLUBILITY OF 
SOLVENT DMU590 MEASURED ON THE UV 
DMU590 MEASURED ON THE UV 
PLATE READER (mghnL) (n=3) 
SPECTROPHOTONIETER (mghnL) 
(n--3) 
Water 0.120: k 0.004 0.120 ± 0.009 
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Table 42. Solubility of DMU590 in different buffers measured at 22± 21C. 
pH 
AVERAGE SOLUBILITY OF DMU590 
NMASURED ON THE UV PLATE 
READER (mg/mL) (n=3) 
AVERAGE SOLUBILITY OF DMU590 
MEASURED ON THE LTV 
SPECTROPHOTOMETER (mg/mL) (n=3) 
2.0 0.678 ± 0.062 0.635 ± 0.073 
3.0 0.648 ± 0.059 0.626 ± 0.026 
4.0 0.568 ± 0.021 0.572 ± 0.016 
5.0 0.716 ± 0.060 0.754 + 0.005 
5.5 0.642 ± 0.104 0.622 ± 0.132 
6.0 0.297 ± 0.014 0.293± 0.009 
6.5 0.203 ± 0.008 0.206 ± 0.002 
7.0 0.150 ± 0.005 0.158 ± 0.007 
8.0 0.103 ± 0.009 0.093 ± 0.004 
9.0 0.108 ± 0.018 0.098 ± 0.007 
10.0 0.107 ± 0.009 0.106 ± 0.003 
11.0 0.130 ± 0.014 0.129 ± 0.025 
12.0 0.137 ± 0.016 0.124 ± 0.011 
1.0 
0.8 
0.6 
o 0.4 
0.2 
0.0 
4 UVPR 
--§F- uvs 
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 
pH 
Figure 86. pH solubility profile for DMU590 measured on the UV plate reader and spectrophotometer 
at 22± 20C (n=3). 
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The pH-solubility profile of DMU590 showed the free base to be most soluble at low pH 
values bemeen pH 2-5.5. Above pH 5.5 the solubility began to drop off. The pKa of 
DMU590 was also deten-nined from the pH-solubility profile: 
Figure 87. pKa for D. NIU590 measured on the UV plate reader at 22± 20C (n=3). 
1.0 
0.5 
0.0 
-0.5 
-1.0 
pH 
Figure 88. pKa for DMU590 measured on the UV spectrophotometer at 22± 20C (n=3). 
The pKa of DMU590 calculated using both its pH-solubility profile and aqueous solubility 
was 6.23 from the UV plate reader and 6.29 from the UV spectrophotometer. 
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6.3. L2 Detemination ofDMU2149 solubility andpKa 
The aqueous solubility of DMU2149 was measured at 0.073 mg/mL on the UV plate reader 
and 0.085 mg/mL on the UV spectrophotometer: 
Table 43. Average solubility of DINIU2149 In water measured at 22: k 20C 
AVERAGE SOLUBILITY OF 
AVERAGE SOLUBILITY OF 
DMU2149 NEASURED ON THE UV 
SOLVENT DMU2149 MEASURED ON THE UV 
PLATE READER (mg/mL) (n=3) 
SPECTROPHOTOMETER. (mg/mL) 
(n=3) 
Water 0.073 ± 0.004 0.085± 0.001 
Table 44. Solubility of DINIU2149 In different buffers measured at 22± 21C 
SOLUBILITY OF DMU2149 SOLUBILITY OF DMU2149 
pH MFASURED ON THE UV PLATE MEASURED ON THE uv 
READER(mg/mL) SPECTROPHOTOMIETER (mg/mL) 
2.00 3.731 3.697 
3.00 0.826 0.879 
3.25 0.602 0.671 
3.50 OA78 0.486 
3.75 0.289 0.338 
4.00 0.227 0.241 
5.00 0.186 0.194 
7.00 0.143 0.147 
9.00 0.168 0.165 
11.00 0.156 0.152 
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Figure 39. pH solubility profile for D. %l U2149 measured on the UV plate reader and spectrophotometer 
at 22* 20C. 
The pl-l-solubility profile of DMU2149 again showed the free base to be most soluble at 
low pH values. in particular at pH 2 above which the solubility began to steadily decrease. 
The pKa of DMU2149 was also determined from the pl-l-solubility profile: 
20 
1.6 
12 
0 
08 
0.4 
0,0 
15 
-#UVPR 
N UVS 
Figure 90. pKa for DM U2149 measured on the UV plate reader and spectrophotometer at 22± 20C. 
The pKa of DM. U2149 calculated using both its pH-solubility profile and aqueous 
solubilit. -y was 4.53 from the UV plate reader and 4.40 from the UV spectrophotometer. 
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6-3. L3 Detennination of indomethacin solubility 
The pH-solubility profile of indomethacin was determined to validate use of the UV plate 
reader for solubility and pKa measurements. The aqueous solubility of indomethacin 
determined on both the UV spectrophotometer and plate reader corresponded well with that 
stated in literature of 0.015 mg/mL [163], thereby confirming the usefulness of the high- 
throughput method: 
Table 45. Average solubility of Indomethacin in water measured at 22+ 20C. 
AVERAGE SOLUBILITY AVERAGE SOLUBILITY MMASURED 
SOLVENT MEASURED ON TBE UV PLATE ON TBE UV SPECTROPHOTOMIETER 
READER (mg/mL) (n--3) (mg/mL) (n--3) 
Water 0.010: L- 0.001 0.010± 0.001 
Table 46. Solubility of Indomethacin In different buffers measured at 22: h 20C. 
AVERAGE SOLUBILITY MEASURED AVERAGE SOLUBILITY MEASURED 
pH ON THE UV PLATE READER (mg/mL) ON THE UV SPECTROpHoTOMETER 
(n=3) (mg/rnL) (n=3) 
2.00 0.003: k 0.004 0.006: t 0.003 
4.00 0.004-+ 0.001 0.005 d: 0.001 
4.50 0.004±- 0.001 0.003 -f- 0.0001 
5.00 0.0 11 :k0.00 1 0.010 ± 0.0001 
5.50 0.0 18 0.00 1 0.0 18 :k0.0004 
6.00 0.093 0.004 0.093 ± 0.005 
6.25 0.126: k 0.004 0.124 * 0.004 
6.50 0.173 * 0.005 0.172 ± 0.003 
6.75 0.235: E 0.005 0.231 :t0.004 
7.00 0.408 ± 0.009 0.372 A: 0.013 
7.50 0.614: k 0.069 0.589: L- 0.050 
8.00 0.655 ± 0.034 0.641 ± 0.019 
9.00 0.704 ± 0.008 0.643 ± 0.019 
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Figure 91. pH solubility proffle for indomethacin measured on the UV plate reader and 
spectrophotometer at 22± 21C (n=3). 
The pH-solubility profile of indomethacin showed the free acid to be most soluble at high 
pH values between pH 6-9. Below pH 6 the solubility began to drop off The pKa of 
indomethacin was also determined from the pH-solubility profile: 
2.0 
1.6 
* Samplel 
M Sample2 
A Sample3 
1.2 
0.8 
5.5 6.0 6.5 
pH 
7.0 7.5 8.0 
Figure 92. pKa for indomethacin measured on the UV plate reader at 22-+ 20C (n=3). 
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Figure 93. pKa for indometbacin measured on the UV spectrophotometer at 22: k 2*C (n=3). 
The pKa of indomethacin calculated using both its pH-solubility profile and aqueous 
solubility was 4.43 from the UV plate reader and 4.37 from the UV spectrophotometer. 
These values compare favourably with the value of 4.5 stated in literature [228], thereby 
justifying the use of the UV plate reader for pKa measurement. 
6.3.2 DMU590 salt selection 
Phosphoric acid was the only acid from the range of salt selecting species screened (Table 
40) to form a salt for DMU590. Therefore, a comprehensive physicochemical analysis of 
DMU590 phosphate was not conducted within this study, since sample quantities were very 
limited. ne physicochernical and biological properties of DMU590 phosphate measured 
in this study were the solubility, DSC, SEM and cytotoxicIty. 
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6.3. ZI Detennination of solubility 
Solubility deenninations of DMU590 phosphate in water showed the salt to be 1 0,000-fold 
more soluble than DMU590 alone: 
Table 47. Average aqueous solubility of DMU590 phosphate measured at 221: 20C.. 
AVERAGE SOLUBILITY 
AVERAGE SOLUBILITY 
MEASURED ON THE LTV 
SALT NEASURED ON THE UV 
SPECTROPHOTOMETER 
PLATE READER (mghnL) (n=2) 
(mg/niL) (n=2) 
DMU590 Phosphate 1013.89 ± 77.48 986.96 +- 108.09 
6.3. Z2 Differen tial scan n ing calo rim etry 
DSC measurements for DMU590 showed the drug to exist in an amorphous form, with no 
melting point endotherms. However, DMU590 phosphate was crystalline, but there were 
no polymorphs, solvates and impurities, since a single endotherm peak was detected: 
Table 48. DSC of DMUS90 and Its salts - Initial beating from -100-30ooC at 400OC/min. 
NIELTING POINT 
Ts 
ENDOTHERM 
DRUG 
ONSET 
THALF DELTA ONSET PEAK 
DELTA 
TEMIP (*Q 
EXTRAPOLATED Cp TEND TEND 
H (J/9) 
(11c) wicc) ("C) (cc) 
DMU590 -15.88 -11.65 0.30 
DMUS90 
165-12 171.38 91.96 
Phosphate 
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Figure 94. DSC thermogram for DMU590. 
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Figure 95. DSC thermogram for DMU590 phosphate. 
Immediately after the initial scan the samples were rapidly cooled and reheated to 
determine if any recrystallization was apparent. The second DSC scan for both compounds 
did not show immediate recrystallization: 
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Table 49. DSC of DM U590 and its salts Ammediate re-heat from -1 00-300'C at 400'C/min. 
MELTING POINT ENDOTHERM/ 
Tg RE-CRYSTALLIZATION 
EXOTHERM 
DRUG 
ONSET T. HALF DELTA 
ONSET PEAK DELTA 
TENIEP EXTRAPOLATED CP 
TEMP ('C) TEMP ('C) H (J/g) 
(0c) (0c) (J/g*'C) 
DMU590 -12.76 -6.50 0.34 
DMU590 
111.57 135.75 0.72 
Phosphate 
6.3. Z3 Scanning electron microscopy 
SEM imaging of DMU590 phosphate showed the crystals to exist as agglomerated plates: 
Table 50. SEM imaging of DMU590 phosphate. 
CRYSTAL 
DRUG SEM IMAGE 
SHAPE 
DMU590 Triclinic, 
Phosphate plates 
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6.3.2.4 Biological evaluation of DMU590 salts 
The biological activity of DMU590 and DMU590 phosphate was evaluated with the MTT 
assay using the CDDG in-house breast cell panel of MCF7, MDA-MB-468 and MCF I OA: 
125 
1 OA DMU590 
IC50=5OpM 
E 100- 
468 DMLJ590 
75- IC50=0-01AM 
10A DMLJ590 
Phosphate 50- 
IC50>5OgM 
25- 468 DMU590 
Phosphate 
IC50=0.74pM 
0-- 1,.., 14 
control 10 ' 10" 10-' 10' too 16' 102 
concentration (IAM) 
Figure 96. Cytotoxicity profile of DMU590 and DMU590 phosphate in MDA-MB468 and MCFIOA cell 
lines. 
125- 
MCF7 DMLJ590 
E 100- 
r-50=0.74M 
MCF7 
DML)590 TCDD 
75- lCso=O. O8gM 
MCF7 DML)590 
50- 
phosphate 
C50=5.3gM 
25- 
MCF7 DMU590 
phosphate TCDD 
0- 11 IC50=0.07gM 
control 
10' 10" 10' 16' to. 101 10ý 
concentration (pM) 
Figure 97. Cytotoxicitv profile of DMU590 and DMU590 phosphate in MCF7 with and without TCDD 
induction. 
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Table 51. Biological evaluation of DINIU590 and the corresponding phosphate salt. 
MCF7 MDA- 
MCF7 MCF10A TUMOUR 
TCDD ACTIVATION MEB468 
DRUG IC50 IC50 SELECTIVE 
MUCED FACTOR icso 
(9w (PNi) FACTOR 
Icso (RNI) (AD 
DNIU590 0.7 0.08 8.6 50 0.01 5000 
DMU590 
phosphate 
5.3 0.07 75.7 >50 0.74 67.6 
DMU590 phosphate appeared to enhance the CYPIAI induced cytotoxicity approximately 
9-fold more than DMUS90 in MCF7 cells, whereas CYPIB1-mediated cytotoxicity 
demonstrated a 75-fold decrease in salt potency compared to the parent compound. 
6.3.3 DMU2149 salt selection 
The crystalline salts formed during salt screening studies for DMU2149 were the mesylate, 
phosphate, hydrochloride, sulphate, tartarate, besylate, oxalate, tosylate, maleate, fimiarate 
and gentisate. The aqueous solubility of these salts was firstly measured to eliminate salts 
with the lowest solubility. A comprehensive physicochemical and biological analysis of 
the optimum salts was then conducted using pH-solubility profiles, DSC, SEM and the 
MTT assay. 
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6.3.3.1 Determination of solubility 
The best DMU2149 salt forms in terms of aqueous solubility were the mesylate, phosphate, 
hydrochloride and sulphatc respectively, and as such a comprehensive preformulation study 
was conducted for each of them: 
Table 52. Average aqueous solubility of DMU2149 salts measured at 22-+ 211C. 
AVERAGE SOLUBILITY 
AVERAGE SOLUBILITY 
MMASURED ON THE LTV 
SALT MEASURED ON THE UV PLATE 
SPECTROPHOTOMETER. (mg/mL) 
READER (mg/mL) (n--2) 
(n--2) 
Mesylate 27.740 ± 0.068 27.794 ± 2.226 
Phosphate 18.547 =1: 0.471 19.475 ± 0.071 
Hydrochloride 16.044 ± 0.258 17.011 ± 0.486 
Sulphate 15.094 ± 0.589 13.355± 0.628 
Tartarate 9.747± 0.699 10.302 ± 0.600 
Besylate 8.883 ± 0.069 9.126 ± 0.226 
Oxalate 6.010 ± 1.750 5.676 ± 1.700 
Tosylate 2.647 ± 0.305 3.308 ± 0.015 
Maleate 1.066± 0.059 1.132 ± 0.117 
Funurate 0.908 ± 0.161 0.883 ± 0.169 
Gentisate 0.301 ± 0.023 0.293 ± 0.022 
To further evaluate the DMU2149 salt forms with the highest aqueous solubility, their pH- 
solubility profiles were determined: 
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Table 53. Solubility of DMU2149 salts in different buffers measured at 22-+ 20C. 
SOLUBILITY SOLUBILITY 
MEASURED ON THE MEASURED ON THE UV 
SALT pH 
UV PLATE READER SPECTROPHOTOMETER 
(mg/mL) (mg/mL) 
Mesylate 2 32.435 31.657 
Mesylate 4 24.042 23.559 
Mesylate 7 4.120 4.100 
Mesylate 10 1.597 1.554 
Mesylate 12 0.156 0.175 
Hydrochloride 2 12.836 12.794 
Hydrochloride 4 4.870 4.943 
Hydrochloride 7 7.647 7.631 
Hydrochloride 10 2.323 2.149 
Hydrochloride 12 0.104 0.124 
Phosphate 2 12.728 13.418 
Phosphate 4 12.705 12.525 
Phosphate 7 11.389 11.232 
Phosphate lu (). J. ) b 5.4SU 
Phosphate 12 0.261 0.282 
Sulphate 2 14.395 15.581 
Sulphate 4 13.844 13.871 
Sulphate 7 17.554 17.856 
Sulphate 10 12.312 13.284 
Sulphate 12 0.133 0.156 
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Figure 98. pH solubility profiles for DNIL'2149 salts measured on the UV plate reader at 22: 1: 20C. 
40,0 
X0 
20.0 
100 
0 Mesylate 
-IF- Hydrochloride 
Phosphate 
Sulphate 
0.0 =19 I 
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 
PH 
Figure ". pH solubility profiles for DMU2149 salts measured on the UV spectrophotometer at 22± 
20C. 
The pH-solubility profile of DMU2149 salts showed the salts to be most soluble at low pH 
values between pH 2-4 where the mesylate had the highest solubility at pH 2. DMU2149 
sulphate had the highest solubility over a wide pH range of 2- 10. 
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6.3.3.2 Differential scanning calorimetry 
Asnia Patel 
DSC measurements for DMU2149 and its salts did not show the presence of polymorphs, 
solvates and impurities, since all DSC scans exhibited a single endothenn peak, except for 
DMU2149 phosphate which exhibited two endotherin peaks: 
T2ble 54. DSC of DMU2149 and its salts -initial heating from-] 00-3000C at 400OC/min. 
DRUG ONSET 
TEMPERATURE ( 
MELTING POINT ENDOTHERM 
PEAK 
"C) TEMPERATURE ('C) 
ENTHALPY OF 
FUSION AH (J/g) 
DMU2149 157.60 163.06 102.58 
DMU2149 
257.74 264.50 160.96 
Mesylate 
DMU2149 
247.46 277.30 7.97 
Hydrochloride 
DMU2149 41.80 52.30 2.30 
Phosphate 197.69 204.25 91.71 
DMU2149 
227.27 233.01 101.88 
Sulphate 
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Immediately after the initial scan the samples were rapidly cooled and reheated to 
detennine if recrystallization was apparent. The second DSC scan for all compounds 
showed no immediate recrystallization: 
Table 55. DSC of D. NIU2149 and Its salts Arnmediate re-heat from -100-300*C at 400*Ctmin. 
T9 
DRUG 
THALF 
ONSET TEMP (C) EXTRAPOLATED DELTA Cp (Jld*C) 
(1, C) 
DMU2149 20.37 25.87 0.55 
DMU2149 Mesylate 76.39 81.69 0.37 
DMU2149 Hydrochloride 99.57 125.00 0.67 
DMU2149 Phosphate 126.75 144.68 0.85 
DMU2149 Sulphate 115.43 126.74 0.50 
6.3.3.3 Scanning electron microscopy 
SEM imaging of DMU2149 showed the crystals to exist as large columnar crystals, the 
mesylate had smaller needle shaped crystals, the hydrochloride existed as agglomerated 
plate crystals, the phosphate existed as agglomerated blade crystals with a central focus 
expanding outwards in flower shaped formation and the sulphate existed as agglomerated 
needle crystals: 
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Table 56. SEM imaging of DMU2149 and its salts. 
CRYSTAL 
DRUG 
SHAPE 
SEM IMAGE 
DMU2149 
Orthorhombic. 
columnar 
DMU2149 Orthorhombic, 
Mesylate Needles 
C 
: 4i j 
I 
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DMU2149 
Triclinic, 
Hydrochloride 
Agglomerated 
plates 
Triclinic, 
DNM2149 
Phosphate 
Agglomerated 
blades 
Triclinic, 
DMU2149 
Agglomerated 
Sulphate 
rods 
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6.3.3.4 Biological evaluation of DMU2149 salts 
The biological activity of DMU2149 and its salts was evaluated with the NITT assay using 
the CDDG in-house breast cell panel of MCF7, MDA-MB-468 and MCFIOA: 
'125 1 OA DMU2149 
IC50=1 1.5 PM 
100- 
--40--468 DMLJ2149 
44 
lC50=2-4 pM 
0 
44 75- 
1 OA OMU2149 
50- rnesylate 
lC50=10-5 AM 
25- 468 DMLJ2149 
mesylate 
lC50=1.8 jM 
Control 10 ý 10-3 10.2 10-1 100 10,102 
concentration (; LM) 
Figure 101. Cytotoxicity profile of DMU2149 and DMU2149 mesylate in MDA-MB-468 and MCFIOA 
cell lines. 
150- MCF7 
DMU2149 
IC50=8 AM 
too- 
MCF7 TC DID 
DMU2149 
X IC5o=8 pM 
- MCF7 
SO 
DMU2149 rnesylate, 
lC50=8 pM 
- MCF7 TCDD 
DMU2149 mesylate 
0 IC50=8 PM 
Control 104 10-3 10-2 10-1 100 101 102 
concentration (ILM) 
Figure 102. C-*1otoxicity profile of DMU2149 and DMU2149 mesylate in MCF7 with and without 
TCDD induction. 
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125- 
10A DMU2149 
1 ()0 - IM ic50=1 1 ý5 gm 
468 DMLJ2149 
1C50=2.4 pM 
1 OA DMU2149. HCI 
X lc50=1 1 gm 
25 468 DMU2149. HCI 
OL 
C50=2.4 pM 
cod. b 101 lo-, 10-1 10-1 101 10' io, 
concentration (pm) 
Figure 103. C-. lotoxidty profile of DMU2149 and DMU2149 hydrochloride in MDA-MB468 and 
MCFIOA cell lines. 
ISO! MCF7 
DMU2149 
IC50=8 AM 
100- 
MCF7 TCDD 
44 DMU2149 
C50=8 Am 
MCF7 
50- DMU2149. Frl IC50=8 pm 
MCF7 
DMU2149. HCI 
0- 1 IC50=8 pM 
oontrN 10' 10 ' 10 , 10 ' 10,1(), 102 
concentration (pM) 
Figure 104. C-tioloxicity profile of DNIL'2149 and DMU2149 hydrochloride in MCF7 with and without 
TCDD induction. 
125- 1 OA DMU2149 
IC50=1 15 AM 
too- I- 1 468 DMU2149 
44 75- 
IC50=2.4 AM 
;F-1 OA DMU2149 
$01 phosphate 
'C50=11 AM 
25 468 DMU2149 
phosphate 
IC50=2.4 AM 0 
control 10- 10; 
ýV' 
10' 10,10,10, 
conc*ntration (ILM) 
Figure 105. C%1010YLiCit% profile of DMU2149 and DMU2149 phosphate in MDA-MB468 and MCFIOA 
cell lines. 
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MCF7 
150- DMU2149 
IC50=8 gm 
MCF7 TCDD 
100- DMU2149 
IC50=8 gm 
MCF7 
DML)2149 
50 phosphate 
IC5o=8 gM 
MCF7TCDD 
DMU2149 
pho phat s 
02o 10' 1 control 10 10,1 0 1112 00 iCSO =8 PM 
concentration (pM) 
Figure 106. CýIotoxicity profile of DMU2149 and DMU2149 phosphate in MCF7 with and without 
TCDD induction. 
125- 10A DMU2149 
IC50=11.5 AM 
100- 
468 DMU2149 
75- 
IC50=2.4 pM 
1 OA DMU2149 
so- sulphate 
IC50=1 1.5 AM 
25- 468 DMU2149 
sulphate 
IC50=2.4 pM 0 
Con " 10 ý 10 3 10-2 10-1 100 101 102 
concentration (pM) 
Figure 107. Cytotoxicity profile of DMU2149 and DMU2149 sulphate in MDA-MB-468 and MCFIOA 
cell lines. 
150- MCF7 
DMU2149 
IC50=8pm 
MCF7 TCOD 
100- DMU2149 
ICSO=8pm 
MCF7 
DMU2149 sulphate 50L 
IC50=8pm 
- MCF7 TCDD 
DMU2149 sulphate 
0 IC50=8pm 
control 10' 10' 10' 10' 100 101 102 
concentration (ILM) 
Figure lo8. Cytotoxicity profile of DMU2149 and DMU2149 sulphate in MCF7 with and without 
TCDD incluction. 
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Table 57. Biological evalu2tion of DMU2149 and Its salts. 
MCF7 MCF7 MCF10A 
MDA- TUMOUR 
DRUG IC" 
TCDD ACTIVATION icso MB-468 SELECTIVE 
(P. No INDUCED FACTOR (gNo 
IC50 
FACTOR IC50 (gNl) (9" 
DMU2149 8 8 1 11.5 2.4 4.8 
DMU2149 9 8 1 10.5 1.8 5.8 Mesylate 
DMU2149 
Hydrochlo 8 8 1 11 2.4 4.6 
ride 
DMU2149 881 11 2.4 4.6 Phosphate 
DMU2149 881 11.5 2.4 4.8 Sulphate 
The DMU2149 salts did not enhance the cytotoxicity of DMU2149 in MCF7 cells both 
induced and non-induced. Sin-fflar results were found in MDA-MB-468 cells except for 
DMU2149 mesylate which demonstrated a slight increase in potency compared to 
DMU2149. 
6.4 Discussion 
6.4.1 DMU590 salt selection 
The aqueous solubility of DMU590 measured at 0.120 mWmL on both the UV plate reader 
and spectrophotometer was 120 times better compared with DMU212. The increased 
hydrophilicity of DMU590 may be attributed to the presence of the morpholine substituent, 
which counteracts the lipophilic nature of the methyl substituents. The pH-solubility 
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profile of DMU590 (Figure 86) showed the drug to be most soluble at low pH values 
between pH 2-5.5, with the highest solubility observed at pH 2. Above pH 5.5 the 
solubility of DMU590 decreased. Using the aqueous solubility, the pl-l-solubility profile 
and Equation 6.4 the pKa of DMU590 was determined at 6.23 ± 0.05 on the UV plate 
reader (Figure 87) and 6.29 ± 0.02 on the UV spectrophotometer (Figure 88), thereby 
confirming the basic nature of the compound. 
The solubility and pKa values determined on the UV plate reader were comparable to those 
determined on the UV spectrophotometer with maximum difference between the two 
techniques being approximately 10%. In a further test of this methods validity the aqueous 
solubility of indomethacin determined by both the UV plate reader and spectrophotometer 
was 0.010 mg/mL and correlated well with that stated in literature of 0.015 mg/mL [163). 
Furthermore, the pKa of indomethacin measured at 4.43 ± 0.08 on the UV plate reader 
(Figure 92) and 4.37 d: 0.01 on the UV spectrophotomctcr (Figure 93) also correlated well 
with that stated in literature of 4.5 (228]. Overall, these results indicate that the 96-well 
automated UV plate reader can be successfully implemented for high-throughput, 
rniniaturised and valid solubility and pKa quantification. 
Initial salt screening studies with DMUS90 using strong inorganic mineral acids (Table 40) 
were unsuccessful on the whole, generally resulting in the formation of an amorphous 
mass. However, reaction with phosphoric acid did yield a white crystalline salt. 
Theoretically, reaction with hydrochloric and sulphuric acid should have also resulted in 
salt formation, since the pKa of these conjugate acids are 2 pH units lower than DMU590- 
The pKa of phosphoric acid at 1.96 is higher than for hydrochloric acid at -6.0 and 
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sulphuric acid at -3.0, therefore making it a weaker acid, which may have enabled its salt 
selection with DMUS90. This may be because the double bond in the DMU590 structure 
may be highly sensitive to strong acids and could readily undergo protonation causing 
isomerisation to the trans isomer leading to degradation: 
As such the next salt screening screen consisted of organic aliphatic and olefmic acids; 
however, salt formation was fi-uitlcss, corroborating Gould who suggested that aliphatic 
acid conjugation often yielded oils, which would be unsuitable because of the practical 
difficulties associated in working with oils [225]. Gould explained that planar symmetry of 
the anion was important for the maintenance of high crystal lattice forces, so the next 
screening consisted of organic aromatic acids. Theoretically, aromatic acids should yield 
crystalline salts because of 7r-electron sharing between benzene rings in the anions and 
DMU590, which could lead to stacking of the molecules to form a better crystalline 
structure. However, in this instance this theory was unsubstantiated as salt crystallization 
was unsuccessful. 
De Montfort UniversitY 205 
Figure 109. Isomerisation of DMU590 resulting from salt selection with strong acids. 
Sall Selection Studies oflonisable Prodrugs Asma Patel 
The phosphate was the only salt formed in salt screening studies with DMU590. 
Physicochemical and biological evaluation of DMU590 phosphate involved measurement 
of the aqueous solubility, DSC, SEM and cytotoxicity. The aqueous solubility of DMU590 
phosphate was 10,000-fold higher than for DMU590 alone (Table 47). DSC measurements 
for DMU590 showed the drug to exist in an amorphous fon-n, the onset of a glass transition 
temperature (Tg) was observed at -15.880C, with a ACP of 0.30 J/g. 'C. DSC measurements 
for DMU590 phosphate did not show the presence of polymorphs, solvates and impurities, 
since a endotherm peak was detected with an onset temperature of 165.120C and AH of 
81.96 Mg. These values correlate with the overall crystallinity of the two compounds 
DMU590 exists as a highly viscous oil, with no crystalline form, whereas, DMU590 
phosphate exists as a crystalline solid. Immediately after the initial scan the samples were 
rapidly cooled and reheated to determine if any recrystallization was apparent and 
subsequently to determine the solid-state stability of the prodrugs. In the second DSC scan 
for DMU590 a Tg was again observed at -12.760C, with a ACp of 0.34 J/g. IC. For 
DMU590 phosphate the melting point endotherm. was absent and the onset of a glass 
transition temperature (Td was observed at 11 1.57'C, suggesting that the solid was in an 
amorphous state and no immediate re-crystallization was apparent. 
SEM imaging of DMU590 was not attempted, since it has no crystalline structure to 
evaluate. SEM imaging of DNIUS90 phosphate showed the crystal system was triclinic 
with small agglomerates of plate shaped crystals. The exact particle size of DMU590 
phosphate is difficult to assess as the aggregates have both loosely and tightly bound 
particles [1621. However, the overall particle size is relatively small at <2OpM, offering a 
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large surface area: volume ratio for dissolution, which may explain its relatively high 
aqucous solubility. 
The biological data of DMU590 compared to DMU590 phosphate showed a significant 
reduction in CYPIBI induced cytotoxicity i. e. a 75-fold decrease in turnour selectivity 
factor. However, DMU590 phosphate still enhanced cytotoxicity towards tumour cells 68- 
fold compared to MCFIOA normal cells and so a therapeutic window still exists for 
preclinical evaluation. However, in the MCF-7 cell-line there was a 9-fold increase in 
activation factor compared to the parent compound and an in vitro therapeutic window of 
76-fold. 
Overall, DMU590 salt screening studies yielded a single crystalline salt, where phosphoric 
acid was used as the conjugate acid. DMU590 phosphate was I 0,000-fold more soluble in 
water compared with DMU590. DMU590 phosphate was also more thermodynamically 
stable as a crystalline compound compared with DMU590, which exists as a highly viscous 
oil. DMU590 phosphate also exhibited a lower CYPlBl-activation factor compared with 
DMU590- The physicochemical properties of DMU590 and DMU590 phosphate have 
been evaluated and the core findings are summarised in Table 58. A novel high-throughput 
screening method using a 96-well automated UV plate reader has also been successfully 
implemented and validated for pKa quantification. 
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Table 58. Comparison of some of the physicochemical properties of DMU590 and its salt. 
DRUG 
PROP 
DMU590 DMU590 Phosphate 
Activation Factor 
Tuinour Selective Factor 
9 76 
5000 68 
Appearance Pale yellow oil White, crystalline 
Molecular Weight 399 497 
Melting Point (C) - 165.12 
Enthalpy of fusion AH (J/g) - 81.96 
Glass Transition Temperature (*C) -15.88 - 
Heat Capacity Increment ACp 
0.30 
uldoc) 
Crystal System Triclinic, blades 
Polymorphism No evidence of polymorphs No evidence of polyrnorphs 
Aqueous solubility (mg/mL) 0.120 ± 0.009 986.963: h 108.094 
pKa 6.29: L 0.02 
6.4.2 DMU2149 salt selection 
The aqueous solubility of DMU2149 (Table 43), was much improved compared with the 
lipophilic chalcone DMU135; which may be attributed to the presence of the imidazole 
substituent in the chalcone backbone. The pH-solubility profile of DMU2149 (Figure 89) 
showed the drug to be most soluble at low pH values between pH 2-4, with the highest 
solubility observed at pH 2 (Table 44). Above pH 4 the solubility of DMU2149 decreased. 
Using the aqueous solubility, the pH-solubility profile and Equation 6.4 the pKa of 
DMU2149 was determined at 4.53 on the UV plate reader and 4.40 on the UV 
spectrophotometer (Figure 90), thereby confmning the basic nature of the compound. 
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Initial salt screening studies with DMU2149 using strong inorganic mineral acids (Table 
40) yielded the phosphate, sulphate and hydrochloride salts, since the pKa of the respective 
conjugate acids were 2 pH units lower than DMU2149. The second salt-forming group 
using organic aliphatic and olefinic acids yielded the fumarate, maleate, mesylate, oxalate 
and tartarate salts. The conjugate acids used for these salts had pKa values lower than that 
of DMU2149, moreover, the aliphatic and olefinic conjugate acids used which did not yield 
salts had pKa values higher than of DMU2149. The final salt-forming group using organic 
aromatic acids yielded the besylate, tosylate and gentisate salts. The conjugate acids used 
for these salts also had pKa values lower than that of DMU2149. The aqueous solubility of 
all these salts was firstly measured to eliminate salts with the lowest solubility. 
Overall, all of the salts had better aqueous solubility than DMU2149 alone (Table 52). The 
salt with the lowest aqueous solubility was the gentisate. The highest solubilities were 
observed with the mesylate, phosphate, hydrochloride and sulphate respectively, all of 
which were formed from strong low molecular weight conjugate acids. Detennination of 
the pH-solubility profile for these salts may provide an indication of the salt behaviour in 
vivo as well as providing valuable information for intravenous and oral formulations. The 
pH-solubility profile of the DMU2149 salts (Figures 98-99) showed all of the salts to be 
more soluble at low pH values between pH 2-4, where the highest solubilities were 
observed at pH 2. DMU2149 sulphate was the most soluble salt over a wide pH range of 2- 
10, followed by DMU2149 phosphate. The highest solubility at pH 2 was observed with 
DMU2149 mesylate. At pH 7 the highest solubility was with DMU2149 sulphate, followed 
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by DMU2149 phosphate. The lowest solubility at pH 7 was with the DMU2149 mesylate, 
followed by DMU2149 hydrochloride. 
DSC measurements for DMU2149 and it salts except for the phosphate did not show the 
presence of polymorphs, solvates and impurities, since all thermograms showed a single 
endotherm peak (Figure 100). DMU2149 had an onset temperature of 157.601C with a AH 
of 102.58 J/g, DMU2149 mesylate had an onset temperature of 257.74'C with a AH of 
160.96 J/g, DMU2149 hydrochloride had an onset temperature of 247.460C with a AH of 
7.97 J/g and DMU2149 sulphate had an onset temperature of 227.270C with a AH of 
101.88 J/g. The DSC trace for DMU2149 phosphate exhibited two melting point 
endotherms with onset temperatures of 41.80 and 197.69T and AH values of 2.30 and 
91.71 J/g respectively, suggesting the presence of solvates, polymorphs or hydrates. 
However, the broad nature of the endotherm suggests that presence of a solvate, since 
polymorphic variants generally exhibit sharper peaks. This theory is supported by the peak 
temperature at which this endotherm was observed i. e. 52.301C, which coincides with the 
boiling point of the solvent used for phosphate salt selection i. e. acetone, which has a 
boiling point of 56.30C. 
immediately after the initial scan the samples were rapidly cooled and reheated to 
determine if recrystallization was apparent and subsequently to determine the solid-state 
stability of the prodrugs. In the second DSC scan the melting point endothen-n for 
DMU2149, DMU2149 mesylate, DMU2149 hydrochloride, DMU2149 sulphate and 
DMU2149 phosphate was absent and the Tg's were observed at 20.37,76.39,99.57,126-75 
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and 115.431C respectively, suggesting that the crystals were in an amorphous state and no 
immediate recrystallization was apparent. 
SEM imaging of DMU2149 showed the crystal system was orthorhombic with large 
columnar crystals that have a relatively large particle size of >200ýM and a relatively small 
surface area: volume ratio. The mesylate had an orthorhombic crystal system with needle 
crystals, a small surface area and particle size of <10ýN. The hydrochloride had a triclinic 
crystal system with agglomerated plate crystals and a small particle size of <lOpM. The 
phosphate had a triclinic crystal system with agglomerated blade crystals with a central 
focus expanding outwards in flower shaped formation and a particle size of <30gM. 
Finally, the sulphate had a triclinic crystal system with agglomerated rod crystals and a 
particle size of <30ýM- 
DMU2149 alone had the lowest aqueous solubility corresponding to the largest crystal 
shapes, with little surface area available for dissolution. DMU2149 mesylate has the 
optimum solubility correlating with the crystals which exist as individualised crystals 
offering a large surface area for dissolution. The next most soluble salt was the phosphate 
salt, which has flower shaped plate like crystals with a large surface area. The 
hydrochloride salt was the next most soluble with a crystal-aggregate existence offering 
little surface area to aid dissolution. The lowest salt solubility was observed with the 
sulphate which has a highly aggregated rod shaped crystal formation, with the lowest 
surface area available for dissolution. 
The biological data of DMU2149 compared to DMU2149 salts was fairly similar, with no 
sigrlifIcant enhancement in CYP induced cytotoxicity. The greatest enhancement in turnour 
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selectivity was observed with DMU2149 mesylate, which had a 5.8 fold tumour selective 
factor compared to 4.8-fold with DMU2149. 
Overall, DMU2149 salt screening studies yielded eleven crystalline salts, the mesylate, 
phosphate, hydrochloride, sulphate, tartarate, bcsylate, oxalate, tosylate, maleate, famarate 
and gentisate. Initially the aqueous solubility of the salts was determined to consider the 
feasibility for further development and the salts with the lowest solubility were eliminated. 
The optimum salt forms in terms of aqueous solubility were the mesylate, phosphate, 
hydrochloride and sulphate respectively. A preformulation study was conducted on each of 
these salts so as to select a salt with optimum physicochemical and biological properties. 
Table 59 lists the physicochemical properties of these salts and DMU2149. All the salts 
showed a better pH-solubility profile than DMU2149, the sulphate and phosphate being the 
best, with optimum buffering capacity. The mesylate and hydrochloride salts had a lower 
buffering capacity and thus were discarded for further studies. DSC measurements showed 
none of the salts to exhibit polymorphic variants apart from DMU2149 phosphate, which 
was found to exist in more than one form and thus was discarded for future studies. None 
of the salts significantly altered the biological activity of DMU2149. SEM imaging of the 
salts showed all of the salts to have a relatively small particle size, however, the mesylate 
salt had needle shaped crystals which may result in poor powder flow properties [221], 
providing a further reason for its elimination. On the basis of these results DMU2149 
sulphate is recommended for further development. 
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Table 59. Comparison of some of the physicochemical properties of DMU2149 and Its salts. 
DRUG 
DMU2149 DMU2149 DMU2149 DMU2149 DMU2149 Mesylate, Phosphate Hydrochloride Sulphate 
Activation Factor I I 1 1 1 
Tumour 
Selective Factor 4.8 5.8 4.6 4.6 4.6 
Appearance Yellow, Yellow, Yellow, Yellow, Yellow, 
crystalline crystalline crystalline crystalline crystalline 
Molecular 
Weight 256 352 354 293 354 
Melting Point 157.60 257.74 41.80 247 46 227 27 (OC) 197.69 . . 
Enthalpy of 102.58 160.96 2.30 7 97 101 88 fusion AH (J/g) 91.71 . . 
Orthorhomb Orthorhomb Triclinic, Triclinic, Triclinic, Crystal System ic, columnar ic, needles aggregated aggregated aggregated blades plates rods 
No evidence No evidence At least two No evidence of 
No evidence 
Polymorphism of of fornis 
polymorphs of polymorphs polymorphs detected polymorphs 
Aqueous 0.085 ± 27.794 18.547 15.094 
solubility 0.001 2.226 0.471 16.044 0.258 0.589 (mgImL) 
pKa 4.40 --- 
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7.1 Introduction 
A potential problem with using chalcone prodrugs such as DMU135 is their high 
lipophilicity and poor aqueous solubility, which presents problems during drug 
formulation. Moreover, the lack of derivatisable functional groups, does not allow 
manipulation of the drug physicochernical properties as a salt form. One possible strategy 
to overcome these problems is to incorporate the chalcone functionality into a nitrogen 
containing heterocycle, to form pyridone or pyridine anticancer prodrugs: 
ýINH 
A Pyridone 
B Chalcone 
A B Pyridine 
Figure 110. Mapping of pyridones and pyridines onto the chalcone structure. 
This strategy should theoretically improve drug solubility and enable salt selection through 
protonation of the nitrogen to enhance the drug physicochemical properties compared to 
chalcones, whilst simultaneously retaining their anticancer properties. The chalcone 
stability should also improve with an increase in rigidity of the heterocyclic structure, 
thereby, avoiding the tendency for chalcones to undergo retro-aldol condensation reactions. 
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7.1.1 Discovery of a novelpyridoneprodrug 
A library of pyridone prodrugs had been previously prepared by S. Lodhi of the CDDG, to 
develop compounds with favourable physicochemical and biological properties compared 
with chalcones. The cytotoxicity of these coMPounds was screened in the MTT in vitro 
assay, where the pyridone DMU949 with a 3,4-methylenedioxy substituent on the A-ring 
and a 3,4-dimethoxy functionality on B-fing, exhibited one of the optimum anticancer 
profiles: 
Table 60. Summary of DMU949 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
0T '%-- -oMe 
\- o 
HUMAN MCF7 MCF7 ACTIVATION MDA- TUMOUR 
BREAST WITHOUT WITH FACTOR 
MCF10A, MB- SELECTIVE 
CELL-LINE TCDD TCDD 468 FACTOR 
, 
IC50 
VALUES 100 100 1 >100 0.04 2500 
- 
(pm) 
DMU949 was found to potently inhibit the growth of MDA-MB468 cancer cells, 
compared to MCFIOA and MCF7 cells with and without TCDD induction. The structural 
similarity between DMU949 and GTP (Figure 110) has led the CDDG to hypothesise that 
the activated catechol metabolite of the prodrug may function as a GTP competitive 
inhibitor: 
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NH 
OMe 
DMU949 catechol metabolite 
HO OMe 
OH I 
N 
</ NH 
Guanosine triphosphate (GTP) 
(PO3-)3"*- 
00 
N- NH 2 
HO OH 
Figure 111. Mapping of DMU949 onto GTP. 
GTP is an essential component in the cell signalling cascade (Figure 2), controlling the 
activity of membrane bound G-proteins such as Ras. Ras proteins that are oncogenically 
mutated do not attain a stabilised GTP transition state, and therefore fail to hydrolyse their 
GTP-bound form to a regulated, inactive GDP-bound form [229], resulting in uncontrolled 
cell proliferation and cancer [1]. The structural similarities between pyridones and GTP, 
suggests that they may be able to occupy the GTP binding site of G-proteins to prevent this 
unregulated cell proliferation. 
Although DMU949 has an excellent cytotoxicity profile, the tautomeric nature of the drug 
may present potential problems during drug development. The predominant tautomer in 
solid state is the 2-pyridone (tautomer 1); however, the hydrogen bond to the nitrogen is 
also suitable to move to the oxygen to give a second tautomer as 2-hydroxypyridine 
(tautomer 2) [230]: 
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0 OH 
NH N 
Ar, Ar2 Ar, Ar2 
Tautomer I Tautomer 2 
H*X- OH + X. H 
HZ 
"ýN 
I, X- 
Ar, 10! 5ý Ar2 
Figure 112. The tautomeric forms of DMU949. 
Unfortunately, the tautomeric nature of the drug does not allow for salt selection. This is 
because the predominant tautomer (2-pyridone) is already protonated at the nitrogen and to 
further protonate the oxygen would require a much stronger acid, which would not form 
usefid salts. Two strategies were undertaken to overcome this problem, firstly derivatives 
of DMU949 were designed in a double-prodrug strategy and secondly the pyridone prodrug 
was synthesised as its pyridine counterpart, which would enable salt selection. 
A promising means of optiniising the properties of prodrugs and overcoming drawbacks 
such as solubility, lipophilicity and stability involves the double-prodrug concept (pro- 
prodrugs) [231]. Therefore, it should be possible to overcome the salt selection problems 
of DMU949 by derivatising it in such manner that a handle is provided for salt synthesis. 
Salt selection of the pro-prodrug should improve the delivery of DMU949, since 
theoretically the handle would be enzymatically cleaved systemically in vivo to release the 
prodrug DMU949, which would then be specifically bioactivated in tumours by CYP IBI. 
Within the scope of this thesis DMU2297 and DMU2298 were designed as analogues of 
DMU949: 
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Figure 113. Chemical structures of potential pro-prodrugs of DMU949. 
7. L 1.1 Synthesis ofDMU229 7 
DMU2297 was prepared according to the protocol described by Top et al [232]. The pro- 
prodrug was synthesised by deprotonation. of DMU949 using sodium hydride to generate 
the enolate ion, which was then alkylated. with 2-dimethylaminoethyl chloride 
hydrochloride in a nucleophilic substitution reaction to generate DMU2297: 
0 H *e 0-- 
N, 
H IN 
OMe OMe a 
OMe 0 OMe 
\ýO DMU949 
C1 0 0, ^, ýNW2 Me2N 
2-Dimethylainino N IN 
ethyl chloride OMe Nzý OMe hydrochloride 
o OMe 0 OMe 
I \-O \-O DMU2297 I 
Figure 114. Reaction mechanism for DMU2297. 
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ZL1.2 Synthesis ofDMU2298 
DMU2298 was prepared according to the protocol described by Tyvorskii et al [233]. The 
pro-prodrug was synthesised by proton abstraction, where DNW949 was deprotonated by 
the base (potassium carbonate) to yield an enolate ion. Finally, the 0" anion in the enolate 
attacked the electron deficient carbon in the 2-bromoacetamide in a nucleophilic 
substitution reaction to generate DMU2298: 
B 
0 0. 
NH IN 
ome OMe 
0 OMe 0 ome 
\_O DMU949 
UB 
t o- 0-, -r 
NH 2 H2N 
0 2-Bromoacetaniide N 
ome 
N 
ome 
0 ome 0 ome 
ý_o \-() DMU2298 
Figure 115. Reaction mechanism for DMU2298. 
7.1.2 Discovery of a novelpyridineprodrug 
A library of pyridine prodrugs had also been previously prepared by S. Lodhi of the CDDG 
to overcome the tautomeric nature of pyridones and to enable salt selection of a potent 
anticancer prodrug. The cytotoxicity of these compounds was screened in the MTT in vitro 
assay, where the pyridine version of DMU949 - DMU982 exhibited one of the optimum 
anticancer profiles: 
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Table 61. Summary of DMU982 in vitro cytotoxicity data. Data provided by P. Butler of the CDDG. 
0 
HUMAN MCF7 MCF7 
ACTIVATION MDA- TUMOUR 
BREAST WITHOUT WITH MCF10A M[B- SELECTIVE FACTOR 
CELL-LINE TCDD TCDD 468 FACTOR 
IC5o VALUES 
0.09 0.06 1.5 30 0.01 3000 6LM) 
DMU982 was found to be potently cytotoxic in MDA-MB-468 cancer cells with 
appreciably reduced cytotoxicity in MCF10A and MCF7 cells with and without TCDD 
induction. Moreover, the pyridine heterocycle of DMU982 should theoretically improve 
the solubility and also enable salt selection through protonation of the nitrogen to enhance 
the drug physicochemical properties compared to DMU949. 
In this study the following physicochemical properties of the prodrugs DMU949 and 
DMU982 were determined; solubility, pH-solubility profile, pKa, partition coefficient, pH- 
partition coefficient profile, SEM and DSC. Salt selection studies were also conducted for 
DMU982. The aqueous solubility of the salts was performed to consider the feasibility for 
further development and the salts with the lowest solubility were eliminated. A 
comprehensive physicochernical and biological analysis of the selected salts was conducted 
using pH-solubility profiles, DSC, SEM and the MTT assay. Analogues of DMU949 were 
also synthesised in a double-prodrug strategy and metabolic evaluation of the analogues 
was undertaken to determine if the double-prodrug strategy was successful. 
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7.2 Materials and methods 
Reagents were used as received from Sigma-Aldrich Chemical Company (Dorset, UK) or 
Alfa Aesar (Lancashire, UK). TCDD (2,3,7,8 tetrachlorodibenzo-p-dioxin) was obtained 
from British Greyhound Chromatography (Birkenhead, UK). General analytical grade 
ethanol, IPA, DMSO, HPLC grade water and 96-well NuncS plates were obtained from 
Fisher Scientific (Loughborough, UK). Pooled human liver microsomes (20mg 
microsonial protein/mL, 410pmol total CYP/mg protein), human recombinant CYPs 
(CYPIAI and IBI) expressed in baculovirus-infected insect cells with co-expression of 
human NADPH-CYP reductase (SupersomeSTM) and wild-type baculovirus-infected insect 
cell microsomes (control n-krosomes) were obtained from Gentest Corporation (Woburn, 
USA). HPLC analytical columns were supplied by Phenomenex (Cheshire, UK). Human 
breast cell lines were obtained from the American Type Culture Collection. Anticancer 
prodrugs DMU949 and DMU982 were supplied by K. Ruparelia and S. Lodhi of the 
CDDG. 
7.2.1 Synthesis ofDMU949 derivatives 
7.2.1.1 Syn th esis of DMU22 97 
Sodium hydride in oil (0.34g, 8.54mmol) was washed 3 times with anhydrous petroleum 
ether under nitrogen to remove the oil phase. DMU949 (1.00g, 2.85mmol) in anhydrous 
tetrahydrofaran (30mL) was added slowly. After the reaction mixture had been stirTed for 
20 minutes, anhydrous dimethylformamide (3OmL) was added, followed by 2- 
dimethylaminoethyl chloride hydrochloride (0.41g, 2.85mmol). The resulting mixture was 
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stirred at reflux temperature and sequentially monitored by TLC (ethyl acetate/petroleum 
ether/methanol (5: 5: 1) with 3% triethylamine) until the reaction was complete. The 
reaction was quenched with distilled water (60mL) and extracted with ethyl acetate 
(3x5OmL). The combined organic layers were washed with saturated brine (5OmL), dried 
with anhydrous magnesium sulphate and concentrated under vacuo. The crude product was 
purified by column chromatography with an isocratic solvent system (ethyl 
acetate/petroleum etherlmethanol (5: 5: 1) with 3% triethylamine). 
ZZL2 Synthesis of DMU2298 
DMU949 (0.10g, 0.28mmol) was dissolved in dry dimethy1formamide (5mL) under 
nitrogen. 2-Bromoacetamide (0.04g, 0.28mmol), potassium carbonate (0.01g, 0.71mmol) 
and sodium iodide (0.001g, 0.007mmol) were added to the mixture. The resulting mixture 
was stirred at 50-60'C and sequentially monitored by TLC (dichloromethane with 3% 
ethanol) until the reaction was complete. The reaction was quenched with distilled water 
(20mL) and extracted with dichloromethane (3x5OmL). The combined organic layers were 
washed with saturated brine (5OmL), dried with anhydrous magnesium sulphate and 
concentrated under vacuo. The crude product was purified by column chromatography 
with an eluent of dichloromethane and an increasing gradient of ethanol (34%). 
7.2.2 Metabolism ofDMU949 derivatives 
7.2. Zl Buffer preparations 
All buffers were prepared using the following reagents: HPLC grade water, hydrochloric 
acid (HCI), sodium hydroxide (NaOH), potassium phosphate (KH2P04), disodium 
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hydrogen orthophosphate (Na2HP04), magnesium chloride (MgC12.6H20) and 
P-nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH). 
Sodium/potassium phosphate buffer (100mM) was prepared by the addition of 8.375g of 
Na2HP04 and KH2PO4 to 900mL of HPLC grade water. Depending on the initial pH, 
either IM NaOH or HCl was used to adjust the pH to 7.4, measured using a SevenEasyTM 
benchtop pH meter (Mettler-Toledo Inc., Ohio, USA). The buffer volume was adjusted to 
IL and the pH re-checked and adjusted if necessary. A solution of 15mm magnesium 
chloride was prepared by the addition of 30.75g Of MgC12.6H20 to IL of distilled water, 
The 15mM stock solution was diluted appropriately to give a 5MM M902 solution. A 
solution of NADPH (5mM) was prepared immediately before each experiment. NADPH 
(1-3mg) was weighed out into an eppendorf tube and an appropriate volume of HPLC grade 
water was added to give a final concentration of 5mM. The solution was stored on ice until 
required. 
7. ZZ2 Authentic standardpreparation 
The authentic standards DMU2297 and DMU2298 were dissolved in DMSO to provide 
10mM stock solutions. Serial dilutions of the stock solutions were prepared to give 
concentrations of 100,10,5 and 2pM as required. Standard solutions were stored at 41C 
until required. The purity of the solutions was assessed by BPLC analysis prior to 
experiments, where the highest measurable concentration for DMU2297 was 5gM and for 
DMU2298 was 2pM using the lowest gain setting on the fluorescence detector, and as such 
these concentrations were used for compound incubations. 
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7. ZZ3 HPL C analytical m eth odfor DMU949 defivatives 
Separation of DMU2297 and DMU2298 and their potential metabolites was achieved using 
the following analytical method: Phenomenex Synergi Max-RP (250x4.6nun) analytical 
column at 40'C. The mobile phase (flow rate of ImL/min) consisted of 80% solvent A 
(water) and 20% of solvent B (acetonitrile). On sample analysis a gradient was initiated 
with solvent B rising to 80% over 15 minutes. Solvent B was held at 80% for 3 minutes 
before returning to the initial conditions. A re-equilibration time of 6 minutes was allowed 
between each sample analysis. The DMU949 derivatives and their potential metabolites 
were detected by fluorescence using an excitation wavelength of 337nm and an emission 
wavelength of 420nm. Analysis was conducted on a PerkinElmer (Massachusetts, USA) 
analytical system consisting of a Series 200 autosampler and pump coupled with a FP-1520 
fluorescence detector (Jasco, Essex, UK), DG-4400 in-line degasser (Phenomenex, 
Cheshire, UK) and a column heater-chiller (Jones Chromatography, California, USA). 
Analytical data was collected on TotalChrom HPLC software (PerkinElmer). 
7.2.2.4 Quantification ofDMU949 derivatives 
Ile DMU949 derivatives were quantified in incubate samples by preparation of the 
appropriate calibration curves. Denatured, pooled microsomes (0.1 mg/mL) were spiked 
with appropriate volumes of DMU2297 (5gM) or DMU2298 (2gm) in DMSO, to give final 
concentrations of each in the ranges of 0.5-5gM and 0.2-2gM respectively. Calibration 
standards were treated in an identical manner to incubate samples (Section 7.2.2.5) prior to 
HPLC analysis and all calibration curves were linear in the concentration ranges used with 
correlation coefficients Of ý-"0-995- 
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7. ZZ 5 Microsomal incubations and sample preparations 
Compounds were incubated with CYPlAl, CYPIBI, control microsomes and pooled 
human liver microsomes (PHLM) under the following conditions: DMU2297 (5PM) or 
DMU2298 (2pM), CYP and control SupersomesTm (20pmol/mL), PHLM 
(164prnol/mL), NADPH (0.5MM), MgC12 (0.5mM) and sodium/potassium phosphate 
buffer (20mM, pH 7.4) at 37'C in a humidified incubator. Samples (10ORL) were taken at 
5 minute intervals between 0 and 25 minutes after the enzymatic reaction was initiated by 
the addition of the enzyme. The reactions were terminated by addition of an equal volume 
of ice-cold acetonitrile. Following centrifugation (3500 rpm, 15 minutes, 4'Q aliquots 
(100 pL) of the supernatants were analysed by HPLC. Control incubations were prepared 
by exclusion of either the compound, NADPH, enzyme or through using non-CYP 
expressing CTRL Supersomegm. All samples were prepared in triplicate. 
7. ZZ6 Co-elution studies 
To confmn the identity of the metabolites co-elution studies were performed. Incubations 
were prepared as previously described (Section 7.2.2.5). Samples were either analysed 
directly after centrifugation or if metabolism was observed samples were spiked with a 0.05 
or 0.5gM solution of authentic DMU949 prior to analysis. If any of the metabolites 
produced corresponded to DNW949, an increase in peak area for that particular metabolite 
should have been observed. 
7.2.3 Determination ofsolubility 
See Section 2.2.1. 
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7.23.1 Detennination of the pH-solubilityprofile 
See Section 6.2.2.1. 
Z23.2 Detennination of thepKa 
See Section 6.2.2.2. 
Z2.4 Determination oflog P 
See Section 2.2.2. 
7.2 4.1 D eterin in a do n of th e pH-log Pp roftle 
The buffer systems used for the pH-log P profile were I OmM acetate with pH range 1.75-4, 
I OmM phosphate with pH range 4-8 and IOmM glycine with pH range 8-12 (Section 3.2.1). 
The log P in these buffers was determined by the shake-flask method (Section 2.2.2). 
7.2.5 Differential scanning calorimetry 
See Section 2.2.3. 
7.2.6 Scanning electron microscopy 
See Section 2.2.4. 
7.2.7 Salipreparation for DMU982 
See Section 6.2.1. 
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7.3 Results 
7.3.1 Chemical analysis of DMU949 derivatives 
A total of two DMU949 derivatives were synthesised. They were chemically evaluated 
using the techniques described in Section 5.2.1 and their chemical structures, physical 
characteristics and yields are described below: 
2-[4-(3,4-Methylenedioxyphenyl)-6-(3', 4'-dimethoxyphenyl)-2-pyridyloxyll- 
dimethylaniinoethyl (DMU2297) 
OMe 
OMe 
White solid, yield (0.05g, 4%); m. p. 129C; mass spectrum (MALDI) M/z 432.20 (M+ + 1); 
IR spectrum umax (KBr)/Cm" 1607 (0-CH3), 1506 (N-C); 'H-NMR (CD30D) 8 2.40 (s, 
6H), 2.80 (ý 2H), 3.90 (s, 3H), 3.95 (s, 3H), 4.55 (t, 2H), 6.00 (s, 2H), 6.80 (s, IH), 6.90 (d, 
IH), 7.05 (d, IH), 7.25 (d, 2H), 7.50 (s, 1H), 7.70(d, IH), 7.75 (s, 1H); 13 C-NMR (CD30D) 
8 45.71,45.83,56.40,56.50,59.10,64.04,102.85,106.71,108.25,109.61,111.54,111.78, 
112.60,120.83,122.08,133.36,133.88,149.86,149.96,150.43,151.49,153.19,156.10, 
165.14. 
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2-[4-(3,4-Methylenedioxyphenyl)-6-(3', 4'-dimethoxyphenyl)-2-pyridyloxyll-acetamide 
(DMU2298) 
OMe 
ome 
White solid, yield (0.09g, 80%); m. p. 188"C; mass spectrum (MALDI) m/z 408.40 (M+ 
1); IR spech= umax (KBr)/Cnf 13367 and 3182 (N-H), 1670 (C=O), 1607 (0-CH3); 'H- 
NMR (DMSO) 5 3.90 (s, 3H), 4.00 (s, 3H), 5.00 (s, 2H), 5.60 (s, 1H), 6.00 (s, 2H), 6.40 (s, 
I H), 6.85 (s, I H), 6.90 (s, I H), 6.95 (d, I H), 7.20 (t 2H), 7.50 (s, I H), 7.60 (d, I H), 7.70 (s, 
1H); 13 C-NMR (DMSO) 8 55.72,55.79,64.13,101.57,105.44,107.44,108.88,110.38, 
110.70,111.76,119.55,121.29,131.04,131.69,148.23,148.38,148.96,149.99,151.19, 
154.02,162.73,170.76. 
7.3.2 Metabolism of DMU949 derivatives 
The in vitro metabolism of DMU2297 and DMU2298 by PHLM and control microsomes 
was investigated using HPLC, to determine whether the double-prodrugs were systemically 
cleaved to DMU949. The metabolism by CYP IAI and CYP IBI was also investigated: 
7.3.2.1 Metabolism ofDMU2297 
DMU2297 was not metabolised by CYPIB1, control microsomes or PHLM, however, 
disappearance of the parent compound was observed with CYPlAl: 
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Figure 116. Time profile incubation of DMU2297 with CYPIAI, CYPIB1, control and PHLM (n=3). 
To ensure that the CYP IAI -mediated disappearance of DMU2297 was metabolism and not 
non-enzymatic degradation of the compound in the incubate; the stability of DMU2297 was 
assessed under the incubation conditions. Incubations of the compound without enzyme 
and incubations of the compound with CYP IAI were undertaken, both in the presence and 
absence of NADPH: 
50 
40 
:cW 
30 
0 2.0- 
1.0- 
0.0 - 
0 
CYPlAl + 
NADPH 
--G-CYPlAl - 
NADPH 
A No Enzyme 
+ NADPH 
No Enzyme 
- NADPH 
Figure 117. Time profile incubation of DMU2297 with CYP1A1 ± NADPH and no enzyme ± NADPH 
(n=3). 
0 CYP1A1 
CYP1 131 
PHILM 
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Non-enzymatic metabolism of DMU2297 was not observed, with the concentration of drug 
remaining constant throughout the incubation period both in the presence and absence of 
NADPH. This indicates that DMU2297 is stable under the incubation conditions and also 
that NADPH has no affect on the stability of the compounds. No metabolism was observed 
when CYPIAI was incubated without NADPH, with the drug concentration remaining 
constant throughout the incubation period. Metabolism of DMU2297 by CYP IAI resulted 
in the formation of two metabolite peaks. Co-elution of the metabolites with authentic 
standards of DMU949 (0.05 and 0.5ýiM) were conducted to establish whether DMU2297 
was re-converted to DMU949: 
DMU2297 
DMU949 DMU2297 + CYP1A1 at tO 
DMU2297 + CYP1A1 at t25 
DMU2297 + CYPIA1 at t25 
spiked with 0.05pM DMU949 
DMU2297 + CYP1A1 at t25 
spiked with 0.5pM DMU949 
Metabolites 
DMt 
L* 
............... 
16 is 20 22 24 
Figure 118. Metabolism of DM U2297 with CYPI Al (n=3). 
The results showed that although DMU2297 was metabolised, the metabolite peak at 
retention time 12.3 was not DMU949, as the DMU949 spike had a retention time of 12.5. 
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The similarity in retention times for DMU949 and the metabolite suggest that the 
metabolite produced by CYP IAI is structurally very similar to DMU949. 
7.3. Z2 Metabolism of DMU2298 
The metabolism of DMU2298 by CYPIAI, CYPIBI, PHLM and control ri-&rosomes was 
also investigated: 
5.0 
40 
30 - 
ýýCYPýW 
M CYP1B1 
20 - 7- 
PHLM 
Control 
10 
00 
05 10 15 20 25 30 
Time (mins) 
Figure 119. Tinveprofile incubation of DMU2298 with CYPlA1, CYPIB1, control and PHLM (n=3). 
DMU2298 was not metabolised by any of the investigated enzymes, with no concomitant 
compound disappearance or detection of metabolite peaks. Therefore, DMU2298 was not 
metabolised back to DMU949. 
7.3.3 Solubility and pKa determination 
Both DMU949 and DMU982 are slightly soluble in water; however, they were more 
soluble in organic solvents such as PEG 400 and NMP. Overall, DMU982 was more 
soluble in all solvents compared to DMU949: 
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Table 62. Avcr2ge solubility of DMU949 In various solvents measured at 22±20C 
AVERAGE SOLUBILITY OF AVERAGE SOLUBILITY OF 
DMU949 MEASURED ON DMU949 MEASURED ON THE 
SOLVENT 
THE UV PLATE READER UV SPECTROPHOTOMETER 
(mg/mL) (n7-3) (mg/mL) (n=3) 
Water 0.003 ± 0.001 0.003 ± 0.0004 
10% v/v aqueous ethanol 0.002 ± 0.001 0.002 ± 0.001 
Isopropyl alcohol 0.030: E 0.004 0.030 ± 0.003 
N-Methyl Pyrrolidone 8.26110.348 8.094 ± 0.272 
Glycerol 0.043 ± 0.011 0.042 ± 0.009 
Propylene Glycol 0.192 ± 0.013 0.194 ± 0.005 
Polyethylene Glycol 400 0.549 ± 0.030 0.567 ± 0.037 
Table 63. Average solubility of DNIU982 in various solvents measured at 22 1 20C 
AVERAGE SOLUBILITY OF AVERAGE SOLUBILITY OF 
DMU982 MEASURED ON DMU982 MEASURED ON THE 
SOLVENT 
THE UV PLATE READER UV SPECTROPHOTOMETER 
(mg/mL) (n=3) (mg/mL) (n--3) 
Water 0.001 ± 0.001 0.001 ± 0.0004 
10% v/v aqueous ethanol 0.002 ± 0.001 0.00 1±0.00 1 
isopropyl alcohol 0.174 ± 0.011 0.179 ± 0.011 
N-Methyl Pyrrolidone 93.146: h 1.909 86.183 ± 5.766 
Glycerol 0.03110.005 0.028 ± 0.002 
Propylene Glycol 0.421-± 0.044 0.434 ± 0.004 
Polyethylene Glycol 400 17.176 ± 2.080 18.024 ± 1.031 
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The pH-solubility profile of DMU949 was also deten-nined, over a pH range of 2-12: 
Table 64. Solubilitv of DNI L'949 in different buffers measured at 22 ± 21C 
AVERAGE SOLUBILITY OF DW949 AVERAGE SOLUBILITY OF DMU949 
pH MEASURED ON THE UV PLATE MEASURED ON THE LTV 
READER (mg/mL) (n=3) SPECTROPHOTOMETER (mg/mL) (n=3) 
2 0.002 ± 0.0002 0.003 ± 0.0003 
4 0.003 ± 0.0003 0.003 ± 0.0004 
7 0.001 ± 0.0002 0.001 ± 0.0001 
8 0.001 ± 0.0001 0.001 ± 0.0005 
9 0.001 0.0005 0.001 ± 0.0007 
11 0.002 0.0009 0.001 ± 0.0001 
10 0.001 ± 0.0002 0.001 ± 0.0001 
12 0.002 ± 0.0003 0.002 ± 0.0005 
0.020- 
2 
E 
0.015 
ý0 
0.010 6 UVPR 
uvs 
0.005 
.2 
Co 0.000 -, ý7%ý 
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 
pH 
Figure 120. pH solubility profile for DMU949 measured on the UV plate reader and spectrophotometer 
at 22 ± 21C. (n=3). 
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The pH-solubility profile of DMU949 showed that the drug solubility does not significantly 
change with pH, thereby indicating that DMU949 is a non-ionisable compound. The pH- 
solubility profile of DMU982 was also determined over a pH-range of 2-11: 
Table 65. Solubilitý of DNI U982 in different buffers measured at 22 ± 20C 
pH 
AVERAGE SOLUBILITY OF DNfU982 
MEASURED ON THE UV PLATE 
READER (mg/mL) (n=3) 
AVERAGE SOLUBILITY OF DNIU982 
MLEASURED ON THE UV 
SPECTROPHOTOMETER (mg/mL) (n=3) 
2.00 0.175 ± 0.006 0.170 ± 0.005 
3.00 0.045 ± 0.009 0.046 ± 0.008 
3.25 0.014 ± 0.002 0.014 ± 0.001 
3.50 0.005 0.0002 0.005 0.0002 
3.75 0.006 0.001 0.006 0.001 
4.00 0.002 0.000 0.002 0.0001 
5.00 0.002 0.001 0.002 0.0002 
6.00 0.001 0.001 0.001 0.0003 
7.00 0.001 0.0002 0.001 0.0002 
8.00 0.002 0.001 0.002 0.001 
11.00 0.002: j- 0.0001 0.002 0.0001 
0.20- 
:7 
E 
7b 
E 01 
0.10 -I 
005 - 
0.00 
0.0 
UVPR 
uvs 
Figure 121. pH solubility profile for DMU982 measured on the UV plate reader and spectrophotometer 
at 22 * 20C. (n=3). 
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The pH-solubility profile of DMU982 showed the free base to be most soluble at low pH 
values between pH 2-4. Above pH 4 the solubility began to drop off. The pKa of 
DMU982 was also determined from the pH-solubility profile: 
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Figure 122. pKa for DNIU982 measured on the UV plate reader measured at 22 ± 21C (n=3). 
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Figure 123. pKa for DMU982 measured on the UV spectrophotometer measured at 22 ± 2*C (n=3). 
The pKa of DMU982 calculated using both its pl-l-solubility profile and aqueous solubility 
was 3.73 from the UV plate reader and 3.77 from the UV spectrophotometer. 
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7.3.4 Log P determination 
Log P experimental values detennined suggest that DMU982 is a more favourable 
candidate for preclinical evaluation than DMU949, which has a higher log P value and 
therefore is more lipophilic, presenting greater barriers to formulation and drug aqueous 
solubility. 
Table 66. Concentration of DMU949 In different phases and log P, measured on UV 
spectrophotometer. 
WAN CONCENTRATION OF NEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(jig/mL) (n--6) (gg/mL) (n=6) 
1 0.05 106.52 3.30 
2 0.03 105.38 3.49 
3 0.11 100.31 2.95 
MEAN log P 3.25: 1: 0.28 
Table 67. Concentration of DMU982 in different phases and log P, measured on UV 
spectrophotometer. 
NEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SANTLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(gg/niL) (n=6) (gg/mL) (n=6) 
0.24 96.76 2.61 
2 0.28 95.89 2.53 
3 0.40 95.89 2.38 
MEAN log P 2.51 ± 0.12 
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7.3.4.1 Fluorescentplate reader method 
The log P values for DMU949 and DMU982 deterniined on the fluorescent plate reader 
were comparable with those determined on the UV spectrophotometer, thereby confuming 
the usefulness of the high-throughput method: 
Table 68. Concentration of DTNIU949 In different phases and log P, measured on the fluorescent plate 
reader. 
MEAN CONCENTRATION OF MEAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE LogP 
(jig/mL) (n--6) (jig/niL) (n=6) 
1 0.06 95.48 3.17 
2 0.04 92.01 3.33 
0.08 85.65 3.05 
MEANIogP 3.18=1-0.14 
Table 69. Concentration of DMU982 In different phases and log P, measured on the fluorescent plate 
reader. 
NEAN CONCENTRATION OF WAN CONCENTRATION OF 
SAMPLE DRUG IN WATER PHASE DRUG IN OCTANOL PHASE Log P 
(gghnL) (n---6) (gghnL) (n7-6) 
1 0.14 85.65 2.78 
0.35 87.29 2.40 
3 0.26 88.61 2.54 
MEAN log P 2.57 ± 0.20 
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7.3.4.2 Determ imadon of the pH-Iog P profile 
T"he pH-log P profile of D. MU982 showed that between pH 4.75-8.75 the log P was 
maintained at the level detennained with water as the aqueous phase. Below pH 4.75 
partitioning into the octanol phase decreased: 
Table 70. Log P of DM U982 in different buffers. 
A%*ERAGE log P OF DMU982 AVERAGE log P OF DM`U982 
pH MEASURED ON THE FLUORESCENT MEASURED ON THE UV 
PLATE READER (mg/mL) (n=3) SPECTROPHOTOMETER (mg/mL) (n=3) 
1.75 0.81± 0.05 0.60 ± 0.01 
2.75 1.72 * 0.04 1.70 ± 0.01 
3.75 2.13 * 0.08 2.20 ± 0.06 
4.75 2.42 * 0.12 2.44 ± 0.08 
5.75 2.52 * 0.17 2.38 ± 0.05 
6.75 2.37* 0.06 2.48 :ý0.12 
8.75 2.24: t 0.07 2.32 ± 0.11 
30 - 
20 - 
-I 
20 40 6.0 8.0 10.0 
0ý0 -ý-- 
OV 
--0-- FPR 
--a- UVS 
I PH I 
Figure 124. pH-I*g P prome for DMU982 In the octanol-buffer system measured on the fluorescent 
plate reader and 0' spect rophotometer. 
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7.3.5 Differential scanning calorimetry 
DSC measurements for DMU982 did not show the presence of polymorphs, solvates and 
impurities. since all prodrug scans exhibited a single endotherm peak. DMU949 exhibited 
two endothenn peaks: 
Table 71. DSC of DNIU949 and DMU982 - initial heating from -100-3000C at 400'C/min. 
MELTING POINT 
Tg 
ENDOTHERM 
DRUG ONSET T, HALF DELTA ONSET PEAK 
DELTA 
TEMP EXTRAPOLATED Cp TEMP TENT 
H (J/g) 
(1, C) (1, C) (J/g""C) (0c) (0c) 
DMU949 
152.06 180.20 10.66 
254.51 267.01 108.79 
DMU982 167.20 176.65 77.33 
1364 Peak = 267.01 IC 
130 
, 2' 
110 
Area = 248.045 mJ 
Detta H= 108.7917 J/g 
Onset= 254 51 T 
so - 
70 - Area = 24 298 mJ 
Peak = 180 20 T 
Detta H 10.6570 J/g 
so - 
Onset 152. T 
so 
39-97 
. 5303 
so 100 150 200 250 296. 
Tomomattra (IC' 
Figure 125. DSC thernwgram for DMU949. 
40 
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Immediately after the initial scan the samples were rapidly cooled and reheated to 
determine if any recrystallization was apparent. The second DSC scan for both compounds 
showed some recrystallization: 
Table 72. DSC of DMU949 and DNIU982 -4mmediate re-heat from -lW3000C at 400'C/min 
MELTING POINT EXOTHERM 
Tg RECRYSTALLIZATION 
ENDOTHERM 
DRUG 
ONSET T, HALF DELTA ONSET PEAK 
DELTA 
TEMP EXTRAPOLATED CP TEMP TEMP 
( 0c) (11c) (J/g*'C) 
H (J/g) 
(0c) (0c) 
DMU949 - - - 261.09 271.89 107.10 
94.69 110.86 -57.25 DMU982 21-99 30.13 0.47 160.48 170.48 64.66 
241 
Figure 126. DSC thermogram for D. **ILVISZ. 
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7.3.6 Scanning electron microscopy 
SEM imaging of DMU949 showed the crystals to exist as large compact agglomerated 
rods, whereas DMU982 had non-agglomerated blade shaped crystals: 
Table 73. SEM imaging of DMU949 and DMU982. 
DRUG 
CRYSTAL 
SEM IMAGE 
SHAPE 
Triclinic, 
DMU949 Agglomerated 
rods 
Orthorhombic, 
DMU982 
Blades 
WIN 
A 
t 
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7.3.7 Salt selection 
The crystalline salts formed during salt selection for DMU982 were the sulphate, maleate, 
phosphate, hydrochloride, mesylate, tartarate, oxalate, besylate, tosylate and saccharinate. 
The aqueous solubility of these salts was firstly measured to eliminate salts with the lowest 
solubility. A comprehensive physicochen-dcal and biological analysis of the optimum salts 
was then conducted using pH-solubility profiles, DSC, SEM and the MTT assay. 
7.3.7.1 Detennination of solubility 
The DMU982 salt forms with the highest aqueous solubility were the sulphate, maleate, 
phosphate and hydrochloride respectively, and as such a comprehensive prcformulation 
study was conducted for each of them: 
Table 74. Average aqueous solubility of DMU982 salts measured at 22: h 20C 
AVERAGE SOLUBILITY AVERAGE SOLUBILITY 
SALT M[EASURED ON THE UV PLATE 
MEASURED ON THE UV 
READER (mg/mL) (n--3) SPECTROPHOTOMEETER (mg/mL) 
(n--3) 
Sulphate 0.210: E 0.002 0.202: k 0.001 
Maleate 0.184 ± 0.001 0.184 ± 0.005 
Phosphate 0.083 + 0.002 0.087 ± 0.001 
Hydrochloride 0.061 * 0.001 0.065 10.0004 
Mesylate 0.039 -h 0.004 0.045: 1: 0.002 
Tartarate 0.019 0.001 0.021 ± 0.002 
Oxalate 0.015 0.0003 0.015 ± 0.0001 
Besylatc 0.014. + 0.003 0.014 ± 0.002 
Tosylate 0.007 ± 0.001 0.006 ± 0.0002 
Saccharinate 0.006 + 0.002 0.006 ± 0.0004 
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To further investigate the best salt form for future studies the pH-solubility profiles of these 
salt forms was determined: 
Table 75. Solubility of DMU982 salts in different buffers measured at 221 20C 
SALT pH 
AVERAGE SOLUBELITY 
MEASURED ON THE UV 
PLATE READER (mg/mL) (n=3) 
AVERAGE SOLUBILITY 
NEASURED ON THE UV 
SPECTROPHOTONETER 
(mg/mL) (n=3) 
Sulphate 2 0. IS 5 :L0.007 0.160 ± 0.004 
Sulphate 4 0.076: 1: 0.001 0.080 0.001 
Sulphate 7 0.014 ± 0.0001 0.016 0.0001 
Sulphate 10 0.002± 0,0001 0.002 0.001 
Sulphate 12 0.004± 0.001 0.004 0.001 
Maleate 2 0.219 ± 0.001 0.223 0.000 1 
Maleate 4 0.006 ± 0.001 0.009 0.0004 
Maleate 7 0.007 ± 0.002 0.005 0.0001 
Maleate 10 0.002 0.0001 0.002± 0.001 
Maleate 12 0.006 0.001 0.006± 0.001 
Phosphate 2 0.138 0.001 0.143 ± 0.001 
Phosphate 4 0.038 0.002 0.043 ± 0.001 
Phosphate 7 0.003 0.0001 0.003 ± 0.0001 
Phosphate 10 0.001 ± 0.0002 0.001 ± 0.0001 
Phosphate 12 0.006 ± 0.0003 0.004: b 0.001 
Hydrochloride 2 0.115J: 0.001 0.122 ± 0.001 
Hydrochloride 4 0.009± 0.001 0.020 ± 0.002 
Hydrochloride 7 0.002 0.001 0.001 ± 0.001 
Hydrochloride 10 0.001 0.0001 0.001 0.0002 
Hydrochloride 12 0.003 0.0002 0.003 0.0002 
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Figure 127. pH solubility profiles for DMU982 salts measured on the UV plate reader at 22 ± 20C (n=3). 
0.3 
76 
.20.2 1 
0 Maleate 
Hydrochloride *a 
0.1 Phosphate 
Sulphate 
0.0 
0.0 5.0 10.0 15.0 
pH 
Figure 128. pH solubility profiles for DMU982 salts measured on the UV spectrophotometer at 22 
20C (n=3). 
DMU982 sulphate had the highest solubility over a wide pH range of 2-10. The highest 
solubility at pH 2 was observed with DMU982 maleate and at pH 7 the highest solubility 
was with DMU982 sulphate. 
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7.3.7.2 Differential scanning calorimetry 
DSC measurements for DMU982 maleate did not show the presence of polymorphs, 
solvates and impurities, since all prodrug scans exhibited a single endotherm peak. 
DMU982 phosphate and hydrochloride exhibited two endotherin peaks, whereas DMU982 
sulphate exhibited three endotherm peaks: 
Table 76. DSC of DNIU982 salts - initial beating from -100-300*C at 400'C/min. 
NMLTING POINT 
Ts 
ENDOTHERM 
DRUG ONSET THALF DELTA ONSET PEAK 
DELTA 
TENT EXTRAPOLATED Cp TENT TEMP 
* H (J/g) (0c) (0c) (Jlg oc) (1, C) (0c) 
129.66 153.69 22.79 
DMU982 172.58 183.82 4.79 
Sulphate 247.89 272.00 98.31 
DMU982 106.97 115.98 0.82 138.78 150.01 20.32 
Maleate 
DMU982 231.76 243.79 19.55 
Phosphate 261.43 273.58 59.10 
DMU982 175.25 186.46 17.61 
Hydrochloridc 278.78 285.61 50.89 
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Immediately after the initial scan the samples were rapidly cooled and reheated to 
determine if any recrystallization was apparent. The second DSC scan for all compounds 
showed no immediate recrystallization: 
Table 77. DSC of DMU982 salts -immediate re-heat from -100-300*C at 400'C/min. 
Tg 
DRUG igritu-x 
ONSET TEMP (OC) EXTRAPOLATED DELTA Cp (J/g*'C) 
(0c) 
DMU982 Sulphate 95.10 111.27 0.76 
DMU982 Maleate 23.92 33.63 0.58 
DMU982 Phosphate 66.55 103.60 0.10 
75.44 86.08 0.62 
DMU982 Hydrochloride 169.00 186.73 0.87 
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7.3.7.3 Scanning electron microscopy 
SEM imaging of DMU982 sulphate showed agglomerated rod and plate shaped crystals, 
the maleate had agglomerated fibrous crystals, the phosphate had agglomerated rod crystals 
and the hydrochloride existed as agglomerated needle and fibrous crystals: 
Table 78. SEM imaging of DMU982 salts. 
CRYSTAL 
DRUG 
SHAPE 
Trichnic. 
DMU982 Agglomerated 
Sulphate rods and 
plates 
Trichnic. 
DMU982 
Agglomerated 
Maleate 
fibrous 
SEM IMAGE 
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tW 
Ilk 
f 00 4F, 
V, 
It 
- 
Inclinic 
DMU982 
Agglomerated tp- 1ý ft'. 
Phosphate 
rods 
1k 
At 
I richilic. 
DMU982 Agglomerated 
Hydrochloride needles and 
tibrow, 
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7.3.7.4 Biological evaluation ofDMU982 salts 
The biological activity of DMU982 and its salts was evaluated with the NITT assay using 
the CDDG in-house breast cell panel of MCF7, MDA-MB-468 and MCFIOA: 
125- 
1 OA DMU982 
100- Ik 
'C50=30 pM 
--41--468 DMU982 
75- 
lC50=0-01 ýLM 
1 OA DML)982 
sulphate 50- 
'C50ý> 100 9M 
25- 468 DMU982 
sulphate 
0- 
'C50=0.35 pM 
control 104 10-3 10"2 10-1 100 10' 102 
concentration (pM) 
Figure 130. Cylotoxicity profile of DMU982 and DMU982 sulphate in MDA-MB468 and MCFIOA cell 
lines. 
125- -9- MCF7 
DMU982 
E too- 
IC50=0.09 AM 
MCF7TCDD 
75- DMU982 
;F 'C50=0.06 gM 
MCF7 
so- DMU982 sulphate 
IC50=20 pM 
40 25- MCF7 TCDD 
DMU982 sulphate 
0- lC50=7 pM 
control 10' 10-3 10-2 10-1 100 101 102 
concentration (I&M) 
Figure 131. Cytotoxicity profile of DMU982 and DMU982 sulphate in MCF7 with and without TCDD 
induction. 
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125- 
10A DMU982 
too- Ik 
C50=30 gM 
--0-468 DIVIL)982 
IC50=0.01 PM 75- 
10A DMU982 
50- maleate 
IC50=>100 PM 
25- -1- 468 DMU982 
maleate 
r, 50=0.3 pM 0- 
Control 104 10-3 10-2 10-1 10,10,10, 
concentration (ILM) 
Figure 132. Cytotoxicity profile of DMU982 and DMU982 maleate in MDA-MB468 and MCF10A cell 
lines. 
125 MCF7 
DMU982 
100 0- IC50=0.09 ; Am 
- MCF7 TCDD 
75 DMU982 
IC50=0.06 ýLM 
- MCF7 50 DMU982 maleate 
lcso=ý100 AM 
25- - MCF7 TCDD 
DMU982 maleate 
0-4 lC50=22 AM 
Control 10,10-1 10-2 10-1 10 01 01 102 
concentration (ILM) 
Figure 133. C)Iotoxicitv profile of D%lt'982 and DMU982 maleate in MCF7 with and without TCDD 
Induction. 
151 OA D MU982 
1001 lk 
IC50=30 gM 
1 
468 D MU982 
44 75- 
IC50=0.01 AM 
10A DMU982 
phosphate 
so- r-,, =>100 PM 
25 468 DMU982 
phosphate 
0ý1 
r, 50=0.4 pM 
contrN 10' 101 10-1 10-1 100 10,102 
concentration (pM) 
Figure 134. Cytotoxicity profile of DMU982 and DMU982 phosphate in MDA-MB468 and MCF10A 
cell lines. 
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150 
MCF7 
DMU982 
IC50=0.09 AM 
E --s- MCF7 TCDD 
100- DMU982 
r-,, =0.06 gM 
MCF7 
DMU982 
phosphate 
c5cý=80 PM 
-0- MCF7 TCDD 
DMU982 
50L 
0 phosphate 
oontrol 10ý 10-3 10-2 10-1 100 101 10 C50=9 PM concentratlon (gM) 
Figure 135. Cytotoxicity profile of DMU982 and DMU982 phosphate in MCF7 with and without TCDD 
induction. 
125- 
-46- 1 OA DMU982 
E 100- lC50=30 gM 
0 
-a- 468 DMU982 75- IC50=0.01 PM 
so 10A DMU982. HCI 
C50=58; Am 
25 468 DMU982. HCI 
OL I In 
IC50--0.7 pM 
control 10 10*3 10-2 10-1 10,10,10, 
concentration (pM) 
Figure 136. Cytotoxicity profile of DMU982 and DMU982 hydrochloride in MDA-MB468 and 
MCFIOA cell lines. 
150- MCF7 
DMU982 
'C50ý0 09 PM 
MCF7TCDD 
.H 
100- 11- DMU982 
IC50=0.06 AM 
MCF7 
> FICI 
IC50=>100 PM 
MCF7 
50 
DMU982. HCI 
OL I lC50=10 PM 
control 10-1 10-3 102 10-1 100 101 102 
concentration (; LM) 
Figure 137. Cytotoxicity profile of DMU982 and DMU982 hydrochloride in MCF7 with and without 
TCDD incluction. 
De Montfort University 252 
Formulation Studies ofPyridone and Pyridine Prodrugs Asma Patel 
Table 79. Biological evaluation of DMU982 and its salts. 
MCF7 MCF7 MCF10A 
MDA- TUMOUR 
DRUG 
TCDD ACTIVATION 'C50 IC50 
UB-468 SELECTIVE INDUCED FACTOR (AM) IC50 FACTOR IC50 (PM (ým 
DMU982 0.09 0.06 2 30 0.01 3000 
DMU982 20 7 >100 0.35 286 Sulphate 
DMU982 >100 22 5 >100 0.3 333 Maleate 
DMU982 80 99 >100 0.4 250 
Phosphate 
DMU982 
Hydrochlo >100 10 10 58 0.7 83 
ride 
The DMU982 salts appeared to enhance the CYPlA1 induced cytotoxicity of DMU982 in 
MCF7 cells. Whereas, CYPIBI-mediatcd cytotoxicity demonstrated a decrease in salt 
potency compared to the parent compound. 
7.4 Discussion 
DMU982 exhibited a slightly better solubility profile in all solvents compared with 
DMU949 (Table 62-63), however, both prodrugs exhibited poor aqueous solubility. The 
lipophilicity of these prodrugs stems from the non-ionisable functionalities on the pyridone 
and pyridine backbones, the presence of the lipophilic methyl groups on both prodrugs is 
important for potency-, however, the opposite effect is true for the drug pharmaceutical 
properties [151]. Both prodrugs contain two methyl groups and five hydrogen bond 
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acceptor groups, however, DMU949 also contains a hydrogen bond donor group, which is 
reflected in the relative solubilites as the increased hydrogen bonding capacity of DMU949 
slightly increases its polarity. Optimum solubility for both prodrugs was exhibited in NMP. 
The solubility of DMU949 in NMP was measured at 8.261 -+ 0.348 mg; /m. L on the LTV plate 
reader and 8.094 ± 0.272 mg/mL on the UV spectrophotometer and the solubility of 
DMU982 in NNIP was measured at 93.146 ± 1.909 mg/mL on the UV plate reader and 
86.183. * 5.766 mghnL on the UV spectrophotometer. These results suggest that NMP may 
be the solvcnt/co-solvent of choice for future parenteral formulation and pharmacoldnetic 
studies possibly combined with PEG 400, propylene glycol or IPA, which were the next 
best prodrug solubilizing agents respectively. 
The pH-solubility profile of DMU949 (Figure 120) showed that it is non-ionisable, as the 
solubility did not change dramatically with pH as seen with conventional pH-solubility 
profiles where dramatic increases arc observed when the drug is ionised. The non-ionisable 
nature of the drug could be attributed to the existence of DMU949 as a tautomer, where 
protonation causes the drug or its tautomer to revert to the 1-H-2-hydroxypyridine form of 
DMU949 (Figure 112). The pH-solubility profile of DMU982 (Figure 121) showed the 
drug to be most soluble at low pH values between pH 2-4, with the highest solubility 
measured at pH 2 on both the UV plate reader and spectrophotometer (Table 64), above pH 
4 the solubility of DNIU982 decreased. Using the aqueous solubility, the pl-l-solubility 
profile and Equation 6.4 the pKa of DMU982 was determined at 
3.73 :k0.002 on the UV plate reader (Figure 122) and 3.77 ± 0.09 on the UV 
spectrophotometcr (Figure 123), thereby confirming the basic nature of the compound. 
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Overall, for both DMU949 and DMU982 pH modification did not alter the solubility as 
much as solvent modification, suggesting that co-solvation is the way forward for 
parenteral drug formulation. 
Both DMU949 and DMU982 log P data suggest that the prodrugs are lipophilic, DMU982 
exhibited the more favourable log P compared with DMU949 which is more lipophilic 
presenting greater barriers to drug aqueous solubility and adsorption. The log P of 
DMU949 determined by the UV spectrophotometer was 3.25 ± 0.28, compared to that 
determined on the fluorescent plate reader at 3.18 ± 0.14 and the log P of DMU982 
determined by the UV spectrophotometer was 2.51- ± 0.12, comparable to the value 
determined on the fluorescent plate reader at 2.57 ± 0.20, thereby confirming the usefulness 
of the high-throughput method. The pH-log P profile of DMU982 showed that between pH 
4.75-8.75 the log P was maintained at 2.39 ± 0.12 on the fluorescent plate reader and 2.40 
0.07 on the UV spectrophotometer (average of log P values between pH 4.75-8.75). These 
values are consistent with that determined for the unionised state of the drug using water as 
the aqueous phase. As the pH decreased below pH 4.75, partitioning into the octanol phase 
decreased, reflecting the ionisation of DMU982 in the aqueous phase. The inverse L- 
shaped pH-log P profile correlates well with the pH-solubility profile as do the pKa values 
determined for DMU982, with the log P lowest when the fraction of ionised DMU982 
increases above pH 3.75. 
DSC measurements for DMU982 did not show the presence of polymorphs, solvates and 
impurities, since a single melting point endotherm was detected with an onset temperature 
of 167.2011C and AH of 77.33 J/g. DSC measurements for DMU949 exhibited two melting 
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point endotherms with onset temperatures of 152.06'C and 254.5 PC and AH values of 
10.66 and 108.79 J/g respectively. These values correlate with the overall solubility of the 
two drugs; DMU982 requires less energy to overcome the intermolecular crystal lattice 
forces (i. e. AH) and as such was more soluble in all solvents compared with DMU949. The 
existence of two melting point endothenns for DMU949 is probably due to the 
polymorphic nature of the drug. 
Immediately after the initial scan the samples were rapidly cooled and reheated to 
determine if any recrystallization was apparent and subsequently to determine the solid- 
state stability of the prodrugs. In the second DSC scan only one melting point endothcrm. 
was observed for DMU949 with an onset temperature of 261.091C and AH of 107.10 Fg. 
These values indicate that upon immediate re-heat only one DMU949 polymorphic variant 
had recrystallized, suggesting that this is the more stable polymorph. With DMU982 a Tg 
%, as observed at 21.99*C, however, a recrystallization exotherm was also observed at 
94.69*C %vith a AH of -57.25 J/g, as well as a melting point endothcrm at 160.48'C with a 
AH of 64.66 J/g. This indicates that upon immediate re-heat some DMU982 crystals were 
in an amorphous state, some crystals were in the state of recrystallization, whereas some 
crystals had already recrystallized. The fact that both DMU949 and DMU982 exhibited 
recrystallization suggests that they have good solid-state stability. 
SEM imaging of DMU949 showed the crystals system was triclinic with large compacts of 
agglomerated rods that have particle size of >40gM and a small surface area. DMU982 
crystals were distinct with a particle size of approximately <20ýLM with a larger surface 
area and existed as arthorhombic blade crystals. The degree of agglomeration and the 
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relatively small surface area: volume ratio of DMU949 as opposed to DMU982 could 
account for its poorer solubility profile. The physicochernical properties of DMU949 and 
DMU982 have been evaluated and the core findings are sununarised in Table 80: 
Table 80. Comp2rison of some of the physicochemical properties of DMU949 and DMU982. 
PROPERTY 
DRUG DMU949 DMU982 
Activation Factor I 
Tumour Selective Factor 2500 
Appearance Terracotta, crystalline 
Molecular Weight 367 
Melting Point (T) 152.06 254.51 
Enthalpy of fusion AH (J/g) 
10.66 
108.79 
Crystal System Triclinic, aggregated rods 
Polymorphism 2 polymorphs detected 
Hydrogen Bond Acceptor Groups 5 
Hydrogen Bond Donor Groups I 
Aqueous solubility (mg/mL) 0.003 * 0.0004 
solubility in NMP (mghnL) 8.094 ± 0.272 
1.5 
3000 
Off-white, czystalline 
351 
167.20 
77.33 
Orthorhombic, blades 
No evidence of polymorphs 
5 
0 
0.001: 1: 0.0004 
86.183 ± 5.766 
Log P 3.25 0.28 2.51 ± 0.12 
pKa 3.77 ± 0.09 
Generally, both DMU949 and DMU982 were found to be lipophilic, poorly soluble in 
water and greatly soluble in organic solvents such as NMP. The preformulation study 
conducted suggests that DMU982 has better development prospects compared to DMU982 
with optimum solubility and log P. Although, thermodynamically DMU949 is more stable, 
the prodrug has two tautomers, which make it unsuitable for salt selection, whereas, salt 
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founs of DMU982 can be identified to potentially improve its physicochemical properties. 
Accrued with the cytotoxic data these physicochemical studies buttress the advancement of 
DMU982 to ftniher drug development studies. 
Initial salt screening studies with DMU982 using strong inorganic mineral acids (Table 40) 
yielded the sulphate, phosphate and hydrochloride salts, since the pKa of the respective 
conjugate acids were two pH units lower than DMU982. The second salt-forming group 
using organic aliphatic and olefinic acids yielded the maleate, mesylate, tartarate and 
oxalate salts. The conjugate acids used for these salts had pKa values lower than that of 
DMU982, moreover, the aliphatic and olefinic conjugate acids used which did not yield 
salts had pKa values higher than of DMU982. The final salt-forming group using organic 
aromatic acids yielded the besylate, tosylate and saccharinatc salts. The conjugate acids 
used for these salts also had pKa values lower than that of DMU982. The aqueous 
solubility of all these salts was firstly measured to eliminate salts with the lowest solubility. 
overall, all of the salts had better aqueous solubility than DMU982 alone (Table 74). The 
salt with the lowest aqueous solubility was the saccharinate and the salts with the highest 
aqueous solubilities were the sulphate, maleate, phosphate and hydrochloride respectively, 
all of which were formed from strong low molecular weight conjugate acids. The most 
soluble salt form was 210 times more soluble compared with DMU982. Deten-ninationof 
the pH-solubility profile for these salts may provide an indication of the salt behaviour in 
vivo as well as providing valuable information for intravenous and oral formulations. The 
pH-solubility profile of DMU982 salts (Figures 127-128) showed all of the salts to be more 
soluble at low pH values between pH 2-4; the highest solubilities were observed at pH 2. 
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DMU982 sulphate was soluble over a wider pH range of pH 2-10 compared with the other 
salts (Table 75). The highest solubility at pH 2 was observed with DMU982 maleate. At 
pH 7 the highest solubility was with the DMU982 sulphate, followed by DMU982 maleate. 
The lowest solubility at pH 7 was with the DMU982 phosphate, followed by DMU982 
hydrochloride. 
DSC measurements for DMU982 maleate did not show the presence of polymorphs, 
solvates and impurities, since a single melting point endotherm was observed with an onset 
temperature of 138.78'C and a AH of 20.32 j/g, however, a small Tg was also observed at 
106.97*C with a ACp of 0.82 J/g. "C, suggesting that some of the maleate crystals had 
amorphous character. The DSC traces for DMU982 phosphate, hydrochloride and sulphate 
(Figure 129) showed more than one endotherm, suggesting the presence of solvates, 
polymorphs or hydrates. DSC measurements for DMU982 phosphate exhibited two 
melting point endotherms with onset temperatures of 231.760C and 261.430C and AH 
values of 19.55 and 59.10 J/g respectively. DSC measurements for DMU982 
hydrochloride exhibited two melting point endotherms with onset temperatures of 175.25'C 
and 278.78*C and AH values of 17.61 and 50.89 J/g respectively. DSC measurements 
for 
DMU982 sulphate exhibited three melting point endotherms with onset temperatures of 
129.66,172.58"C and 247.89'C and AH values of 22.79,4.79 and 98.31 J/g respectively. 
Imrnediately after the initial scan the samples were rapidly cooled and reheated to 
determine if any recrystallization was apparent and subsequently to determine the solid- 
state stability of the prodrugs. In the second DSC scan the melting point endotherms for 
the sulphate, malcate and phosphate were absent and the Tg's were observed at 95.10,23.92 
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and 66.55 respectively, DMU982 hydrochloride exhibited two Tg's at 75.44 and 169. OOOC 
suggesting that the crystals were in an amorphous state and no immediate recrystallization 
was apparent. 
SEM imaging of DMU982 salts showed all of them to have a triclinic crystal system. The 
sulphate had agglomerated rod and plate shaped crystals, the maleate had agglomerated 
fibrous crystals, the phosphate existed as agglomerated rod shaped crystals and finally the 
hydrochloride existed as agglomerated needle and fibrous crystals. The particle size of the 
salts is difficult to assess as the aggregates have both loosely and tightly bound particles 
(1621.7be degree of agglomeration and the relatively small surface area of all DMU982 
salts would account for their poor aqueous solubility, compared with DMU590 and 
DMU2149 salts. 
The biological data of DMU982 compared to DMU982 salts showed a significant reduction 
in CYPIBI induced cytotoxicity (Table 79). Of the salts analysed DMU982 maleate 
showed the most useful CYPIBI induced cytotoxicity, with a 333-fold tumour selectivity 
factor, although this was still lower than that seen for the parent compound DMU982 of 
3000-fold. Nonetheless, a therapeutic window is retained. In the MCF-7 cell-line all of the 
salts enhanced the activation factor compared to the parent compound. DMU982 
hydrochloride showed the greatest enhancement in CYPIAI induced cytotoxicity with a 
I 0-fold activation factor compared to 2-fold with DMU982. DMU982 sulphate showed the 
lowest enhancement in CYPIA1 induced cytotoxicity with a Mold activation factor. 
overall, DMU982 salt screening studies yielded ten crystalline salts, the sulphate, maleate, 
phosphate, hydrochloride, mesylate, tartarate, oxalate, besylate, tosylate and saccharinate. 
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Initially the aqueous solubility of the salts was determined to consider the feasibility for 
further development and the salts with the lowest solubility were eliminated. The optimum 
salt forms in terms of aqueous solubility were sulphate, maleate, phosphate and 
hydrochloride respectively. A preformulation study was conducted on each of these salts 
so as to select a salt with optimum physicochemical and biological properties. Table 81 
lists the physicochemical properties of these salts and DMU982. The pH-solubility profiles 
of the sulphate and phosphate were better than DMU982, the sulphate being the best, with 
optimum buffering capacity. DSC measurements showed the sulphate, phosphate and 
hydrochloride to exist in more than one form and thus were discarded from future studies. 
The maleate exhibited no polymorphic variants; however, it did show some amorphous 
character. Biological evaluation of the salts showed the maleate to have the optimum 
CYP I BI -activation factor. Finally, SEM imaging of the salts showed all of the salts to 
have highly agglomerated crystals. On the basis of these results overall DMU982 maleate 
is recommended for further development. 
DeAfontfOrt University 261 
Formulation Studies offWone and Pyridine Prodrugs Asma Patel 
Table 81. Comparison of some of the Physicochemical properties of DMU982 and its salts. 
DRUG 
DMU982 DMU982 DMU982 DW982 DMU982 
PROPE: Y 
ýRTý Sulphate Maleate Phosphate Hydrochloride 
Activation Factor 2 3 5 9 10 
Turnour Selective 
Factor 3000 286 333 250 83 
Appearance 
Off-white, Yellow, Yellow, Yellow, Yellow, 
crystalfine crystalline crystalline crystalline crystalline 
Molecular 
Weight 351 433 451 433 372 
Melting Point 167.20 
129.66 
172.58 138.78 231.76 175.25 0C) 247.89 261.43 278.78 
Enthalpy of 77.33 
22.79 
4.79 20 32 19.55 17.61 fusion AH (J/g) 98.31 . 59.10 50.89 
Glass Transition 
- - 106 97 - - Temperature (*C) . 
Heat Capacity 
Increment ACp 0.82 
(40c) 
Triclimc, Triclinic Triclinic 
Triclinic, 
Crystal System Orthorhomb aggregated , aggregated aggregated 
aggregated 
ic, blades rods and fibrous rods needles and plates fibrous 
No evidence At least 3 No evidence At least 2 At least 2 
Polymorphism of polymorphs of polymorphs polymorphs 
polymorphs detected polyrnorphs detected detected 
Aqueous 0.001 ± 0.202 ± 0.184 ± 0.087: L 0.065 ± 
solubility 0.0004 0.001 0.005 0.001 0.0004 (mg/mL) 
pKa 3.77: k 0.09 ---- 
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DMU2297 and DMU2298 were designed as analogues of the CYPIBI activated prodrug 
DMU949 in a double-prodrug strategy. These prodrugs were designed to enable salt 
selection and to be metabolically activated to DMU949 in vivo. This strategy should 
theoretically overcome the non-ionisable and lipophilic nature of DMU949. Both double- 
prodrugs were synthesised successfully by deprotonation of DMU949 followed by 
nucleophilic substitution with either 2-dimethylaniinoethyl chloride hydrochloride 
(DMU2297) or 2-bromoacetamide (DMU2298). The overall reaction for both compounds 
proceeded fairly slowly with reaction times of 18 (DMU2297) and 26 hours (DMU2298). 
Both compounds were afforded as white solids; DMU2298 was afforded in a good yield 
(80%), whereas DMU2297 was afforded in a very poor yield (4%). The highest melting 
point was observed for DMU2298 (188*C) and the lowest was with DMU2297 (129"C). 
Both compounds were analysed by 'H-NMR, 13 C-NMR and infrared spectroscopy. The 
'H-NMR spectra confirmed the presence of the 3,4-methylenedioxy group by a 
characteristic singlet peak observed at 8 6.00, the methoxy groups were observed between 5 
3.90-4.00 and the NH groups in DMU2298 were confirmed with broad peaks at 5 5.60 and 
8 6.40. The 13C-jqNM spectra also demonstrated the presence of methoxy groups between 
8 55.72-56.50, the NMe2 groups in DMU2297 were observed between 8 45.71-45.83 and 
the spectra for DMU2298 showed a characteristic carbonyl peak at 8 170.76. Infrared 
spectroscopy for both compounds also demonstrated the presence of methoxy group peaks 
at 1607cnf 1. For DMU2297 a characteristic NC stretch was observed at 1506cm7l, and 
for 
DMU2298 a characteristic carbonyl peak was observed at 1670cm7l and NI-I peaks were 
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observed between 3367-3182 cm". Mass spectrometry of the compounds showed that the 
desired compounds were synthesised as they both showed M++l peaks. 
The in vitro metabolism of DMU2297 was assessed by incubation with the CYP I isozymes 
IAI and 1131, PHLM and control microsomes. Apart from CYPIA1, DMU2297 was not 
mctabolised by any of the other investigated enzymes (Figure 116). To ensure that the 
CYPIAI-mediated disappearance of DMU2297 was metabolism and not non-enzymatic 
degradation of the compound in the incubate; the stability of DMU2297 was assessed in the 
incubate. Control incubations prepared by exclusion of NADPH or removal of the active 
enzyme showed DMU2297 was stable under the incubation conditions (Figure 117). 
Furthermore, incubations of CYP IAI without NADPH showed no drug metabolism, which 
indicates that DMU2297 metabolism is CYP-mediated; since NADPH is a necessary co- 
factor in CYP catalyzed reactions [40]. 
CYPIAI catalysed metabolism of DMU2297 resulted in the formation of one primary 
metabolite (M I) at a retention time of 12.3 and a secondary metabolite (M2) at a retention 
time of 10-9. Co-clution studies of MI with DMU949 showed that DMU2297 was not 
metabolised. back to DMU949 (Figure 118), since the metabolite peak did not correlate with 
the DMU949 peak at a retention time of 12.5. The most probable route of metabolism for 
MI is dealkylation of the 3,4-methylenedioxy functionality to generate the catcchol motif 
on the A-ring of DMU2297 (Figure 138), since many similar CDDG prodrugs such as 
DMU135 undergo similar CYPI-mediated metabolism. The structure of the secondary 
metabolite M2 remains unknown. 
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Figure 138. Proposed metabolism of DMU2297. 
Regardless of the metabolic route, DMU2297 was not re-converted to DMU949 by PHLM, 
CYP IAI or CYP IB1. Two metabolites were formed upon incubation with CYP IA1, none 
of which co-eluted with DMU949. In order to evaluate the clinical potential of DMU2297, 
which is beyond the realms of this study, further investigations need to be conducted with 
the metabolites formed. 
The in vitro metabolism of DMU2298 was also assessed by incubation with the CYPI 
isozymes IAI and IBI, PHLM and control microsomes. DMU2298 was not metabolised 
by any of the investigated enzymes (Figure 119) and DMU949 was not detected after drug 
incubations and as such DMU2298 is not a candidate for further pre-clinical evaluation. 
On the whole, the double-prodrug strategy for both DMU2297 and DMU2298 was 
unsuccessful, since the in vitro re-conversion to DMU949 was not observed. 
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With the advent of combinatorial chemistry and high-throughput screening techniques an 
ever increasing number of lead compounds are being identified, however the 
physicochernical properties of these compounds are not necessarily favourable for 
development [122,123]. As a result, the assessment of drug pharmaceutical properties has 
become an increasingly important addition to traditional drug efficacy and toxicity 
measurement, to accelerate drug discovery and development in a time and cost-effective 
manner (234]. This strategy enables the early identification of the attributes and drawbacks 
of lead candidates before they enter the fonnal drug development process. Compounds 
presenting developmental challenges can be identified early and analogues can be evaluated 
to fmd the best candidate for lead nomination [235]. Ultimately lead candidates with both 
potency and desirable pharmaceutical properties will have a better chance of successfully 
completing the clinical programme and becoming therapeutic products to further the quest 
for turnour selective chemotherapy. 
Development of compounds with desirable pharmaceutical properties has featured heavily 
in the evolutionary design of lead CDDG prodrugs (Figure 139). Initially a series of 
stilbene (DMU212) and chalcone (DMU135) anticancer prodrugs was designed based on 
the pharmacophore of estradiol. These prodrugs favoured drug potency whilst 
compromising on drug pharmaceutical properties, with no derivatisable functional groups 
to enable manipulation of physicochernical properties through salt selection. Subsequently 
DMU590 was designed specifically as a morpholino prodrug so that salt forms could be 
formulated with more desirable physicochemical properties compared to DMU212. 
Jonisable chalcones were also designed (DMU762, DMU2145, DMU2146, DMU2147, 
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DMU2148, DMU2149 and DMU2306) with derivatisable fimctional. groups so that salt 
forrns could be formulated with more desirable physicochemical properties compared to 
DMU135. Another strategy used to overcome the lipophilic nature of chalcones was to 
incorporate the chalcone fimctionality into a nitrogen containing heterocycle, to form 
pyridone (DMU949) and pyridine (DMU982) anticancer prodrugs. Analogues of DMU949 
(DMU2297 and DMU298) were also designed to overcome its tautomeric nature so that 
salt forms could be formulated with more desirable physicochernical properties compared 
to DMU949: 
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Figure 139. Evolution of CIDIDG prodrugs. 
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The ultimate aim of the strategies adopted by the CDDG was to design both a potent and 
developable CYPIB1 activated anticancer prodrug. The suitability for development of 
these prodrugs was investigated within the body of this work. 
The 3,4-methylenedioxy chalcone DNM135 was found to be potently cytotoxic in MDA- 
MB-468 and TCDD induced MCF7 cancer cells with appreciably reduced cytotoxicity in 
MCFIOA and naYve MCF7 cells (Table 9). Furthermore, DMU135 acts as a potent broad 
spectrum tyrosine kinase inhibitor [119] and is well tolerated in xenograft models of human 
cancer (MDA-MB-468) in nude mice [141]. In light of these findings the pharmaceutical 
properties of DMU135 was evaluated in Us study. DMU135 is a non-ionisable compound 
which was found to be poorly water soluble and lipophilic. The solubility of DMU135 was 
greatly enhanced by solvent modification, where the optimum solubility was exhibited with 
NMP (>350000% increase in solubility) and PEG 400 (>35000% increase in solubility). 
The results of solvent modification and SEM imaging suggest that the high crystallinity of 
DMU135 more significantly contributes to its poor aqueous solubility than its non-polarity. 
DMU135 was also shown to be thermodynamically stable with no evidence of polyrnorphic 
variants. However, development of DMU135 may be hampered by stability problems 
associated with chalcones, whereby, retro-aldol condensation reactions are possible in 
aqueous environments, as well as photo-isornerization in ambient light conditions from the 
trans to the cis isomer. 
The 0-methylated trans-stilbene DMU212 was found to potently inhibit the growth of 
MDA-MB-469 and TCDD induced MCF7 cancer cells, compared to MCFIOA and naive 
MCF7 cells (Table 8). Furthermore, DMU212 has potent apoptotic activity [135], retards 
&-Moniforl UniversilY 269 
Drug Development and the Questfor Tumour Selective Chemotherapy Asma Patel 
the gastrointestinal adenoma formation in Apcm"* mouse models [138] and is selectively 
bioactivated in human breast tumour clinical samples [103]. The clinical potential for 
DMU212 in turnour selective chemotherapy is being realised with imminent clinical trials 
in USA and as such the phannaceutical properties of DMU212 was evaluated within the 
body of this work. DMU212 is a non-ionisable compound which was found to be poorly 
water soluble and lipophilic. The solubility of DMU212 was greatly enhanced by solvent 
modification, where the optimum solubility was exhibited with NMP (>150000% increase 
in solubility) and PEG 400 (>13000% increase in solubility). The results of solvent 
modification and SEM imaging again suggest that the high crystallinity of DMU212 more 
significantly contributes to its poor aqueous solubility than its non-polarity. DMU212 was 
also shown to be thermodynamically stable with no evidence of polymorphic variants. 
it was also possible to formulate DMU212 in oral and topical preparations. Oral 
formulation studies led to development of a reliable in vitro dissolution method for 
DMU212 hard gelatine capsules using surfactant (SLS) containing dissolution medium at 
37.5"C %Nith physiological relevance to gastrointestinal conditions and an agitation speed of 
100 rpm. The fastest dissolution rate of DMU212 was exhibited with capsules containing a 
drug particle size fraction of <150ýM and sorbitol as the diluent. Topical formulation 
studies led to the development of a robust in vitro release test for DMU212 topical bases 
using a modirted BP paddle-over-disk dissolution method [175] with an in-house release 
ccIl and dissolution meditun of ethanol/water/IPM in a ratio of 80: 10: 10, agitation speed of 
50 rpm and a cellulose acetate support membrane at 320C. The fastest drug release of 
DNIU212 was from an anionic o/w cream. 
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Although, DMU212 is a lipophilic prodrug with no derivatisable functional groups the 
aqueous solubility can be enhanced with solvent modification and additional drug 
permeability measurements may help to further predict its in vivo behaviour. 
Thermodynamically DMU212 was found to be stable; however, fin-thcr studies using 
thermogravimetric and solution stability analysis may help to anticipate any stability issues 
before DINIU212 enters the definitive drug development process. Overall, the lipophilicity 
of DMU212 does not appear to hamper its development as both DMU212 oral and topical 
formulations were identified with good drug release properties. The findings of this study 
indicate that the turnour specific prodrug DMU212 has both potency and desirable 
pharmaceutical properties and may satisfy the quest for turnour selective chemotherapy. 
The morpholine cis-stilbcne DMUS90 was designed as an ionisable analogue of DMU212. 
it was found to be potently cytotoxic in MDA-MB-468 cancer cells with appreciably 
reduced cytotoxicity in MCFIOA and MCF7 cells with and without TCDD induction 
(Table 38), and as such the phannaceutical properties of DMU590 was investigated in this 
study. The aqueous solubility of DMU590 was greatly enhanced compared to DMU212 
(1200/a increase in solubility). Its solubility increased by decreasing the pH below 5.5, 
particularly at pH 2 (500% increase in solubility); therefore, the use of low pH for 
parcritcral. formulations is preferred. Thermodynamic evaluation of DMU590 showed the 
drug to exist in an amorphous fOrrrL Another method used for increasing the drug 
solubility without altering the chemical structure of the drug was salt formation. Salt 
screening studies led to development of a crystalline phosphate salt with solubility higher 
than DMU590 (>80001/o increase in solubility) and a clinically acceptable therapeutic 
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Aindow. Although, DMU590 appears to have good development prospects recent in vivo 
studies have shown that it is not a candidate for further drug development, as a 24 hour 
=sit period is required in situ before the drug can be bioactivated. 
The 3,4-methylenedioxy pyridone DMU949 was found to be potently cytotoxic in MDA- 
MB-468 and TCDD induced MCF7 cancer cells with appreciably reduced cytotoxicity in 
MCF10A and naTive MCF7 cells (Table 60), and as such the pharmaceutical properties of 
DMU949 was investigated in this study. DMU949 is a non-ionisable compound which was 
found to be poorly water soluble and lipophilic. The solubility of DMU949 was greatly 
enhanced by solvent modification, where the optimum solubility was exhibited with NMP 
(>25000/o incrcase in solubility) and PEG 400 (>150% increase in solubility). The results 
of solvent modification and SEM imaging suggest that the high crystallinity of DMU949 
more significantly contributes to its poor aqueous solubility than its non-polarity. 
'Jurmodynamic evaluation of DMU949 showed it to have two polymorphic variants, 
which may present problems during drug development. To overcome the tautomeric nature 
of DMU949 whilst retaining its potency, analogues of the pyridone were designed in a 
double-prodrug strategy. However, metabolic evaluation of these analogues showed that 
the double-prodrug strategy was unsuccessful, since the in vitro re-conversion to DMU949 
was not observed. Overall, the developmental challenges associated with DMU949 
indicate that it is not a candidate for flirther drug development. However, use of the 
double-prodrug strategy for the rational design of other novel analogues may provide an 
opportunity for DMU949 in turnour selective chemotherapy. 
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The 3,4-methylenedioxy pyridine DMU982 was found to be potently cytotoxic in MDA- 
NIB468 and TCDD induced MCF7 cancer cells with appreciably reduced cytotoxicity in 
MCF10A and naTve MCF7 cells (Table 61), and as such the pharmaceutical properties of 
DIMU982 was investigated in this study. DMU982 is an ionisable compound which was 
found to be poorly water soluble and lipophilic. The solubility of DMU982 was greatly 
cnhanced by solvent modification, where the optimum. solubility was exhibited with NMP 
(>90000% increase in solubility) and PEG 400 (>17000% increase in solubility). Its 
solubility increased by decreasing the pH below 4, particularly at pH 2 (175% increase in 
solubility). These results indicate that the use of a low pH for parenteral formulations is 
preferred, with the addition of co-solvents such as NMP and PEG 400. The results of 
sol%, cnt modification and SEM imaging suggest that the high crystallinity of DMU982 more 
significantly contributes to its poor aqueous solubility than its non-polarity. DMU982 was 
also shown to be thermodynamically stable with no evidence of polymorphic variants. 
Another method used for increasing the drug solubility of DMU982 without altering the 
chernical structure of the drug was salt formation. DMU982 salt screening studies yielded 
ten crystalline salts, the sulphate, maleate, phosphate, hydrochloride, mesylate, tartarate, 
oxalate, besylate. tosylate and saccharinate. To aid in the selection of the best salt to 
progress with, the solubility of DMU982 salts was initially evaluated, where the salts with 
the lowest solubility were eliminated. The optimum salt forms in terms of aqueous 
solubility were the sulphate, maleate, phosphate and hydrochloride respectively. A 
prcformulafion study was conducted on each of these salts so as to select a salt with 
optimum physicochernical and biological properties, where the salts were evaluated by 
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solubility, pH-solubility profiles, polymorphism, morphology and cytotoxicity. Based on 
the results of this comparative physicochemical screening, the maleate salt was 
recommended for further development. However, further evaluation by solution stability, 
hygroscopicity, dissolution and thermogravimetry may help to further compare the 
optimum salt forms, to ensure that the optimum salt form is recommended for development. 
Although, DINIU982 is a lipophilic prodrug the aqueous solubility can be enhanced with 
both solvent modification and salt selection and additional drug permeability measurements 
may help to further predict its in vivo behaviour. - Thermodynamically DMU982 was found 
to be stable; however, ftirther studies using thermogravinietric and solution stability 
analysis may help to anticipate any stability issues before DMU982 enters the definitive 
drug development process. The findings of this study indicate that. the turnour specific 
prodrug DMU982 has both potency and desirable pharmaceutical properties and may 
satisfy the quest for turriour selective chemotherapy. 
The development challenges associated with non-ionisable chalcones were also addressed 
in this study %Nith the design of CYP IBI activated ionisable chalcones, based on the CDDG 
CYP IBI pharmacophore model. Overall, a SAR was determined where the 2-imidazole 
position was found to be important for selective CYPIBI bioactivation. resulting from 
confirmation of a necessary hydrogen-bonding interaction near the aromatic 'A' ring 
hydroxylation hotspot (Fig= 85). The 4-imidazole position does not associate with this 
hydrogcn-bonding and thus does not allow CYPlBI bioactivation. Optimum bioactivity 
was observed with the 2-imidaozle prodrug DMU2149. The potency observed with 
DNIU2149 was significantly lower than the other lead prodrugs and as such it is not a 
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candidate for further drug development. However, since the imidazole prodrugs were 
specifically designed to enable salt selection, DMU2149 underwent salt screening and 
preformulation studies. 
The aqueous solubility of DMU2149 was enhanced compared to the non-ionisable chalcone 
DMU135 (73% increase in solubility). Its solubility increased by decreasing the pH below 
4, particularly at pH 2 (>50% increase in solubility); therefore, the use of low pH for 
parcnteral. formulations is preferred. Thermodynamic evaluation of DMU2149 showed the 
drug to be stable with no evidence of polymorphic variants. Another method used for 
increasing the drug solubility of DMU2149 without altering the chemical structure of the 
drug was salt formation. DMU2149 salt screening studies yielded eleven crystalline salts, 
the mesylate, phosphate, hydrochloride, sulphate, tartarate, besylate, oxalate, tosylate, 
maleate, fumarate and gentisate. To aid in the selection of the best salt to progress with, 
DMU2149 salts were initially evaluated by solubility, where the salts with the lowest 
solubility were eliminated. The optimurn salt forms in terms of aqueous solubility were the 
mesylate, phosphate, hydrochloride and sulphate respectively. A preformulation study was 
conducted on each of these salts so as to select a salt with optimum physicochemical and 
biological properties, where the salts were evaluated by solubility, pH-solubility profiles, 
polymorphism, morphology and cytotoxicity. Based on the results of this comparative 
physicochernical screening, the sulphate salt would be recommended for Rather 
development, if DMU2149 were a lead drug candidate. However, further evaluation of 
solution stability, hygroscopicity, dissolution and thermogravimetry may help to further 
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compare the optimum salt forms, to ensure that the optimum salt form is recommended for 
development. 
Another strategy implemented in this study was to reduce attrition rates in the later stages 
of drug development, by accelerating the assessment of drug pharmaceutical properties 
[146]. Where novel miniaturisation of high-throughput analytical technologies were 
implemented in the preformulation and formulation programmes, to identify potential 
physicochernical problems (solubility, pKa, log P and dissolution) at an early drug 
development stage [122,124-127]. 
Several novel applications have been investigated. A high-throughput screening method 
using a 96-well fluorescent plate reader has been successfully implemented and validated 
for log P quantification to improve assay efficiency. 'Novel uses have also been 
successfully implemented and validated for the 96-well UV plate reader firstly in solubility 
and pKa quantification. Secondly, in high-throughput capsule formulation screening, from 
which optimum formulations may be ascertained. The MTT cytotoxicity assay was used as 
a novel application for determination of formulation effects on active drug cytotoxicity and 
Cyp I selectivity. Overall, high-throughput analytical technology can potentially accelerate 
the assessment of pharmaceutical properties. This enables the early identification of lead 
candidates with suboptimal biopharmaceutical properties, thereby reducing attrition rates in 
the later stages of drug development [ 146]. 
Over the past decade the increased understanding of the genomics and molecular pathology 
of cancer [14] has shifted the ethos of cancer drug development from an empirical to a 
mechanism based viewpoint, to potentially provide tumour specific therapy (Table 2). The 
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tumour specific expression of CYPIBI in particular provides the opportunity for turnour 
selective chemotherapy. However, even with the recent advances in combinatorial 
chemistry and high-throughput screening techniques, the quest for tumour selective 
chemotherapy remains relatively unfulfilled. With the sole finus of most drug design being 
potency and selectivity, most chernotherapeutics agents lack the required pharmaceutical 
properties to ensure efficient progress through the drug development pipeline. As a result 
the assessment of drug pharmaceutical properties is becoming increasingly important in the 
identification of lead candidates, which will ultimately have both drug potency and 
desirable pharmaceutical properties. 
The physicochcn-&al properties of a range of novel anticancer prodrugs have been assessed 
within this study and are summarized in Table 82. The findings of this study indicate that 
the CYPIBI activated anticancer prodrugs DMU212 and DMU982 have both potency and 
desirable pharmaceutical properties and may satisfy the quest for tumour selective 
chemotherapy and as such are recommended for further drug development. 
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Table 82. Comparison of physicochemical properties of lead CDDG anticancer prodrugs. 
DRUG 
DMU135 DMU212 DMU590 DMU949 DMU982 
P FR T y :ý !i 
Activation Factor 90 22 9 1 2 
Tumour Selective 380 4300 5000 2500 3000 
Factor 
Appearance 
Pale yellow, Yellow, Pale yellow Terracotta, Off-white, 
crystalline crystalline oil crystalline crystalline 
Molecular Weight 342 300 399 367 351 
Melting Point (*C) 138.27 164.96 - 
152.06 
254.51 167.20 
Enthalpy of fusion 83.79 107.27 10.66 77.33 
AH (J/S) 108.79 
Glass Transition 
- - 88 -15 - - Temperature (*C) . 
Heat Capacity 
Incren ent, &Cp 0.30 
(J/g'*C) 
Orthorhombic, 
I nclinic 
Triclinic, Orthorhombic Crystal System aggregated , columnar aggregated 
, blades blades rods 
Polymorphism 
No evidence No evidence No evidence 2 polymorphs No evidence 
of polymorphs of polymorphs of polymorphs detected of polymorphs 
Hydrogen Bond 6 4 6 6 5 
Acceptor Groups 
Hydrogen Bond 0 0 0 1 0 Donor Groups 
Aqueous solubility 0.001-1 0.001 J: 120± 0 009 0 0.003 =L 0.001 (mg/mL) 0.0001 0.0001 . . 0.0004 0.0004 
Solubility in NIMP 367.569± 152.727 094 0.272 8 
86.183 
(mg/mL) 4.286 1 OA96 . 5.766 
Log P 2.49± 0.01 2.93 0.05 3.25 0.28 2.51 ± 0.12 
pKa - 6.29: k 0.02 3.77 ± 0.09 
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Appendix 
Table 83. Summary of compounds investigated or synthesized In this study. 
Me 
OMe MeO 
OMe 
MeO 
DNW135 
3-Benzo[1,3]dioxol-5-yl-l - 
(3,4,5-trimethoxy-phenyl)- 
propenone 
DNW949 
4-Benzo[1,3]dioxol-5-yl-6- 
(3,4-dimethoxy-phenyl)-IH- 
pyridin-2-one 
«y0'x> DMU2146 
I-Benzo[1,3]dioxol-5-yl-3- 
(3H-imidazol4-yl)-propenone 
DMU212 DMU590 
trans 3,4,5,4'- 4-(2-j2,6-Dimethoxy-4-[2-(4- 
tetramethoxystilbene 
N 
N: ý 
OMe 
0j ! -;: OMe 
\- 0 
DMU982 
4-Benzo[1,3]dioxol-5-yl-2- 
(3,4-dimethoxy-phenyl)- 
pyTidine 
0 
H0 
1 
N> (/ 
ýo 
NY 
CH3 
DMU2147 
methoxy-phenyl)-vinyl]- 
phenoxy)-ethyl)-morpholine 
0 
(Ir0> 
DNW2145 
I-Benzo[1,3]dioxol-5-yl-3- 
(lH-irnidazol-2-yl)-propenone 
0 
N 
/I t" 
10> 
ýo 
CS 
I -Benzo[1,3]dioxol-5-yl-3-(5- 
methyl-3H-imidazol-4-yl)- 
DMU2148 
I-Benzo[1,3]dioxol-5-yl-3- 
thiazole-2-yl-propenone 
propenone 
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j3 
000, 
-ýWe2 
0, -, yNH2 C 'N I 
0,, 
I ; Zý 
I OMe N 1A 
I OMe N 
DMU2149 
I-Benzo[1,3]dioxol-5-yl-3-(I- (2-[4-Benzo[1,3]dioxol-5-yl- 
methyl-IH-imidazol-2-yl)- 6-(3,4-dimethoxy-phenyl)- 
propenone pyridin-2-yloxy]-ethyll- 
dimethyl-amine 
2-[4-Benzo[1,3]dioxol-5-yl-6- 
(3,4-dimethoxy-phenyl)- 
pyridin-2-yloxy]-acetamide 
DMU2306 
I-Benzo[1,3]dioxol-5-yl-3-[I- 
(2-phenoxy-ethyl)-IH- 
inUazol-2-yl)-propenone 
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DMU2298 
